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Sudden cardiac death
Sudden cardiac death (SCD) refers to an unexpected natural death due to a cardiac cause that is 
usually attributed to a very fast heart rhythm caused by an electrical disturbance of the heart.1 
Ventricular tachycardia (VT) refers to an accelerated rhythm of >100 beats per minute in the heart’s 
ventricles. VT often results in a reduced pump function of the heart, which causes symptoms such 
as dizziness, lightheadedness, and heart beat sensations that feel like pounding.2 VT can deteriorate 
into ventricular fibrillation (VF), with quick, chaotic electrical impulses causing the ventricles to 
contract in an asynchronous manner. This leads to insufficient blood flow to vital organs and to 
sudden cardiac arrest, and eventually to SCD if left untreated (Figure 1). SCD may occur in individuals 
with or without preexisting cardiovascular disease, although many have a previous cardiac history, 
and may have experienced an acute myocardial infarction (MI), a cardiac arrest or suffer from severe 
heart failure.2 
Figure 1. Pathophysiology and epidemiology of sudden death from cardiac causes
Reproduced with permission from Huikuri HV, Castellanos A & Myerburg RJ. Sudden death due to cardiac 
arrhythmias. New England Journal of Medicine 2001;345(20):1473-1482. 
© Massachusetts Medical Society.
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 The incidence of SCD varies between countries and depends on the defi nition used, but recent 
prospective studies have shown worldwide annual incidences ranging from 50-100 per 100.000 in 
the general population.3-5 Due to improved primary and secondary prevention, the mortality risk 
due to coronary heart disease (CHD) has declined considerably during the past decades,6,7 while 
mortality rates due to SCD remain high.8,9 Still more than 50% of all CHD deaths are caused by SCD, 
and SCD accounts for 15-20% of all deaths, which emphasizes the importance of adequate measures 
to prevent SCD.1
The implantable cardioverter-defi brillator – a continuously evolving fi eld
In the late 1960s, the development of the implantable cardioverter-defi brillator (ICD) was pioneered 
by Michel Mirowski, as he was frustrated by lack of available treatment options for a close friend who 
had been admitted to hospital with recurrent VTs. He envisaged the implantation of a continuous 
guard of the cardiac rhythm that could deliver defi brillation in the event of VT/VF. After building 
and refi ning experimental models during the 1970s, the fi rst human cardiac electronic device was 
implanted in 1980 in a patient who had suff ered two previous cardiac arrests.10,11 While the ICD at 
fi rst was limited to patients with documented cardiac arrest due to VF and was only implanted in a 
small number of centers, the United States Food and Drug Administration (FDA) approved the use 
of commercial devices in 1985.10 This was the start of a revolutionary treatment for the prevention 
of SCD that has continued to evolve. 
Figure 2. The transvenous implantable cardioverter-defi brillator12
 The ICD is an electronic device that is implanted right under the skin in the pectoral area, where 
it continuously monitors the heart rhythm (Figure 2). Detection of VTs is based on information 
derived from the high-voltage defi brillation lead placed in the right ventricle. Therapies for VTs are 
delivered by this lead as well. In case of a potentially life-threatening tachyarrhythmia, the ICD can 
off er three types of treatment: antitachycardia pacing (ATP), cardioversion (a low energy shock), or 
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defibrillation (a high energy shock up to 800 volts). VTs are usually treated by means of ATP, with 
cardioversion as back-up therapy in case of non-successful ATP. VF on the contrary, is generally 
directly treated with defibrillation.10
 In addition to tachyarrhythmia treatment, a small number of patients are estimated to need 
additional bradycardia pacing (i.e. rhythm control when the heart beats too slow).13 In patients 
suffering from chronic heart failure (CHF), a debilitating disease characterized by symptoms of 
tiredness, shortness of breath and peripheral and/or lung edema due to structural or functional 
abnormality of the heart, an ICD with additional resynchronizing capacities (the cardiac 
resynchronization therapy device or CRT-D) may be indicated.14 CHF affects cardiac conduction 
pathways in approximately 30% of the cases, by causing a delayed depolarization of the ventricles.15 
This can lead to disruption of the regular and simultaneous innervation of the ventricles, which 
may further deteriorate the already impaired ejection fraction of patients with CHF.16 CRT facilitates 
synchronous innervation by simultaneously pacing both ventricles via at least two leads: one in the 
right ventricle and one inserted through the coronary sinus to pace the left ventricle.
 Due to the potentially disabling complications that can result from transvenous leads, an entirely 
subcutaneous ICD system (S-ICD, Figure 3) has recently been developed, which is unlikely to be the 
last development in this continuously evolving field.17 
Figure 3. The subcutaneous  implantable cardioverter-defibrillator 
© 2014 Boston Scientific Corporation or its affiliates. All rights reserved. Used with permission of Boston Scientific 
Corporation. 
 Initially, the ICD was only indicated as a secondary prevention measure in patients who had 
experienced a sudden cardiac arrest. A meta-analysis of three large scale secondary prevention trials 
(the Antiarrhythmics Versus Implantable Defibrillator (AVID) trial, the Cardiac Arrest Study Hamburg 
(CASH) and the Canadian Implantable Defibrillator Study (CIDS)) has shown that the ICD is superior 
in reducing the risk of mortality, with a relative risk reduction of 28% as compared to antiarrhythmic 
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drugs. This improved prognosis was almost entirely attributed to a 50% risk reduction in arrhythmic 
death.18 Throughout the years, however, the indications for ICD therapy have expanded to include 
also primary prevention of SCD. Patients with a primary prevention prophylaxis have not previously 
experienced a sudden cardiac arrest or suffered from symptomatic VTs, but are considered at higher 
risk due to depressed left ventricular function based on ischemic or non-ischemic cardiomyopathy. 
Recently, genetic disorders, such as long QT syndrome or Brugada syndrome, have also been 
included as an indication for a primary prophylactic ICD. The beneficial effect of ICD implantation 
for primary prevention in the reduction of all-cause mortality has been demonstrated in several 
randomized clinical trials (i.e. the Multicenter Automatic Defibrillator Implantation Trial (MADIT) and 
the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)).19,20 Several meta-analyses confirmed 
the reduction in all-cause mortality by ICD implantation compared to optimal medical treatment, 
with mortality reductions up to 26% in patients at high risk of SCD.21-24 
Medical challenges for patients with an ICD
Despite the evident benefits of the ICD in terms of prevention of SCD, ICD patients may face 
several challenges in the phase around implantation and later on. Procedure- and device-related 
complications occur both on the short- and long-term, including pocket infections, hematomas, 
lead dislodgement and lead fractures.25,26 Patients experiencing a lead complication are at risk 
for electrical storm, i.e. multiple recurrences of ventricular arrhythmias over a short period of 
time. In addition, ICD hardware malfunction could lead to inappropriate sensing, with resultant 
inappropriate shocks.25 Next to the challenges of the ICD itself, the underlying heart disease may 
have a considerable impact on patients, with for example reduced ejection fraction negatively 
impacting on daily functioning. Moreover, a substantial number of ICD patients has experienced 
a previous cardiac event, such as myocardial infarction or sudden cardiac arrest, and are currently 
suffering from CHF and other comorbid conditions such as hypertension, peripheral arterial disease, 
diabetes, renal failure and respiratory disease.27 Thus, complications,28 underlying heart disease and 
non-cardiac comorbidities27 all pose patients at increased risk of morbidity and mortality.
  
Psychological functioning of patients with an ICD
After implantation, ICD patients are faced not only with medical challenges, but also have to 
overcome both the stress of possibly having experienced a life-threatening arrhythmia (in case of 
a secondary prevention indication) and get used to the presence of the ICD as well.29 Although 
the majority of patients with an ICD adjusts well to living with the ICD,29,30 emotional distress is 
not uncommon, with a recent review indicating that approximately one in five (i.e. 20%) patients 
experience emotional distress that might affect not only their daily functioning but may also 
increase the risk of morbidity and mortality despite state-of-the-art treatment with an ICD.31,32 This 
prevalence is similar to the prevalence of emotional distress in other cardiac populations31 and 
somewhat higher than the prevalence of emotional distress in the general population.33 Because 
of the unpredictable course of arrhythmias and the uncontrollability of shocks, anxiety plays a 
leading role in ICD patients, with prevalence rates ranging from 13-87% for anxiety, versus 5-41% 
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reported for depression.29,31,34,35 Most likely related to the occurrence of shocks post implantation, 
posttraumatic stress symptoms occur in approximately 10-20% of patients (versus a prevalence of 
8% in the general population).36-38 Notably, patients who experience a sudden cardiac arrest outside 
the hospital setting report an even higher prevalence of posttraumatic stress.39
 Several medical and patient factors have been associated with emotional distress and patient 
well-being in the arrhythmia literature. Among the patient factors, these include personality, pre 
implantation distress, coping and social support.38,40-42 Among the medical factors, the occurrence 
of shocks is often mentioned as primary culprit of emotional distress and poor quality of life,43-45 
although the influence of shocks may depend on the interval between the shock and when distress 
was assessed.46 Patients’ perceptions of the ICD and shocks vary considerably, with some patients 
describing the ICD as a live-saving device, while a smaller group indicates that they would rather 
be without the defibrillator and take their chances with a potentially lethal arrhythmia. There is also 
variability in patients’ pain perception of shocks, although 80% of patients rate the shock-associated 
pain as 3 or higher on a 1 to 5 scale.47 Besides shocks, the underlying heart disease, in particular 
symptomatic heart failure, influences the well-being of patients, possibly playing a more prominent 
role than the ICD itself and the occurrence of shocks.48,49 With ICD patients often using multiple 
medications to control their heart disease, it is important to investigate the relation between cardiac 
medication use and emotional distress. With respect to the use of beta-blockers and statins, results 
within the general cardiac population are mixed, with some studies reporting a positive association 
between beta-blocker50 and statin use51 and the presence of emotional distress, while other studies 
do not find such a relationship52-54 or even report a protective effect.55-57 Importantly, evidence in 
patients with an ICD is lacking. Furthermore, as mentioned previously, ICD patients often suffer 
from multiple comorbid conditions, which may hamper their daily functioning and influence 
psychological well-being. Unfortunately, evidence on the impact of comorbidities on emotional 
distress in ICD patients is absent. In sum, gaps in knowledge exist on the relation between medical 
factors, including complications around and post implantation, the use of medication and the 
presence of comorbid conditions, and emotional distress in ICD patients. These gaps should be 
bridged by future research in order to optimize the care and management of ICD patients in clinical 
practice.
Psychological functioning and clinical outcomes
The importance of psychological factors in heart disease has recently been endorsed in the 
European Guidelines on prevention of cardiovascular disease, with even stronger levels of evidence 
for psychological factors as risk factors for cardiovascular disease than for example the evidence for 
biomarkers or genetic factors.58 Accumulating evidence suggests that psychological factors, such 
as depression, anxiety, mood disturbance, anger and personality, are associated with an increased 
risk of ventricular arrhythmias and mortality.32,59,60 However, whether psychological factors increase 
the risk of worse clinical outcomes in their own right or whether they are risk markers of underlying 
mechanisms or disease severity is not yet known.
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Explaining the link between emotional distress and clinical outcomes
Several bodily systems have been proposed as pathways that may explain the relationship between 
emotional distress and clinical outcomes (i.e. ventricular arrhythmias or mortality). Among these 
are the immune system, the hypothalamic-pituitary-adrenal (HPA) axis, and the autonomic nervous 
system. However, there is a knowledge gap in the arrhythmia literature regarding these potential 
explanatory pathways, with only a few studies investigating autonomic measures in relation to 
psychology and disease. 
The role of the autonomic nervous system in the unhealthy heart
Being part of the peripheral nervous system, the ANS regulates a number of vital unconscious 
processes, including cardiac functioning. The ANS is connected with the heart via sympathetic and 
parasympathetic nerve branches. Activation of sympathetic neurons has a stimulating effect on the 
heart and circulatory system, resulting in increased heart rate, contractility and conduction speed, 
while activation of the parasympathetic neurons has an opposite, inhibiting effect on the heart.61
The autonomic nervous system has an important share in the generation and maintenance of 
ventricular arrhythmias, during which a shift from a sympatho-vagal balance to sympathetically 
dominated innervation is observed.62 Several factors have been proposed as triggering or causal 
factors of ventricular arrhythmias, including a prolonged action potential, alterations in calcium 
homeostasis that account for abnormalities in excitation-contraction coupling, abnormal conduction 
of signals along the heart, the presence of coronary artery disease (CAD), altered neurohumoral 
signaling, including alterations in the adrenergic and renin-angiotensin-aldosterone system (RAAS), 
and genetic predisposition.62,63 
Heart rate variability – a measure of autonomic control
Heart rate variability (HRV) is the oscillation in the time interval between consecutive heart beats 
and is a widely used measure of autonomic control.64,65 HRV can be measured with Holter monitoring 
during which the electrical activity of the heart is monitored and registered. Variation in heart rate 
may be assessed by a number of methods. 
 First, time domain measures can be used. These measures are based on the normal-to-normal 
(NN) intervals, that is all intervals between adjacent QRS complexes resulting from sinus node 
depolarizations.65 Time domain measures include the standard deviation of all normal-to-normal 
(NN) intervals (SDNN) and the HRV triangular index, both reflecting overall variability in heart rate 
(HR), the standard deviation of the average NN interval calculated over 5-minute periods (SDANN), as 
an estimate of long-term components of HRV, the proportion of NN intervals deviating >50 ms from 
the preceding interval (pNN50), and the root mean square of successive differences in NN intervals 
(RMSSD), both specifically reflecting parasympathetic efferent activity to the heart.65,66 Second, 
power spectral analysis using Fast Fourier Transformation reveals frequency domain measures, 
including total spectral power, representing the total variance in HR pattern, high frequency (HF) 
HRV, describing parasympathetic modulation of heart rate, low frequency (LF), representing both 
sympathetic and parasympathetic modulation of the heart, very low frequency (VLF), displaying 
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long-term influences such as hormones, and ultra-low frequency (ULF), another long-term measure 
of HRV.65 Next to these separate measures, the LF/HF ratio is used as an indicator of sympatho-vagal 
balance, although the evidence on the exact meaning of this measure is yet inconclusive.67 Disturbed 
autonomic functioning, expressed by increased sympathetic and decreased parasympathetic 
innervation, is a strong predictor of cardiovascular events,68-70 and in patients with an ICD, abnormal 
HRV patterns have been reported in the minutes before arrhythmia onset.71
 Emotional distress, including symptoms or clinical syndromes of depression, anxiety, and 
posttraumatic stress disorder (PTSD), has been associated with disturbed heart rate variability in 
both people with and without cardiac disease. In the general population, reduced HRV has been 
found in patients with major depressive disorder (MDD) and/or anxiety disorders.72-76 In the cardiac 
population, depression and anxiety are associated with reduced HRV in various subgroups of cardiac 
patients,77-82 although there may be confounding mechanisms, such as use of antidepressants, 
physical activity and fitness, that warrant further examination.74,75,83 Results with respect to PTSD 
are less clear, with some studies in the general population showing a reduced HRV,84,85 while others 
have reported inconsistent results86,87 or even no differences88,89 in HRV between individuals with 
and without PTSD. The relationship between emotional distress and HRV in ICD patients remains 
understudied, with only one study reporting of a reduced parasympathetic modulation of the heart 
in patients with an ICD.90  
The partner of the ICD patient – a neglected companion
In the field of cancer research, a lot of attention has been paid to the well-being of patients’ partners, 
showing that emotional distress in patients and partners is related, and couples tend to react to the 
disease as an emotional system instead of reacting as an individual.91,92 This means that partners 
have an important share in the disease- and recovery process of the patient. However, research 
on this topic in the field of cardiology in general and ICD patients in particular is scarce. Available 
research shows that levels of emotional distress in partners may be as high as in patients.93 Anxiety 
plays an important role in partners, for similar reasons as in ICD patients,93,94 and the type of distress 
(e.g. anxiety versus depression) experienced by patients and partners concurs within the dyad.95 
The role of the partner is not only important from a psychological point of view, but also from a 
clinical perspective. Emotional distress in partners96 and reduced marital quality97 have been 
associated with poorer prognosis in patients with CHD. Thus, although some evidence exists on 
the importance of partners in the psychological and physical recovery process of the patient, it 
remains unknown how emotional distress of ICD patients and their partners correlates over time, 
and whether partners’ levels of emotional distress influence patients’ health status. In addition, no 
research to date has been performed on the association between emotional distress in partners and 
prognosis of patients with an ICD. 
Aims and outline of this dissertation
All studies described in this dissertation have been based on the ‘Mood and personality as 
precipitants of arrhythmia in patients with an Implantable cardioverter-Defibrillator: A prospective 
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Study’ (MIDAS) cohort. A consecutive series of 448 patients implanted with a first-time ICD at the 
Erasmus Medical Center, Rotterdam, the Netherlands and their partners, were enrolled in the study 
between August 2003 and February 2010 and completed questionnaires pre implantation and at 
10 days, 3, 6 and 12 months post implantation. A subset of 82 patients from the MIDAS cohort 
participated in the MIDAS-HRV sub study. This subset of patients was hooked up to a Holter monitor 
at 10 days, 6 and 12 months post to measure 24-hour HRV. In addition to the Holter recordings, 
patients were asked to complete an activity diary in order to register eating, sleeping and activity 
patterns.
 The current dissertation is divided into four parts. Part one discusses the association between 
medical treatment and clinical patient characteristics on the one hand and emotional distress on the 
other hand. In Part two, the interrelationship between emotional distress, the autonomic nervous 
system and prognosis is examined. Part three extends the image of the patient as a single actor to 
a dyadic system of ICD patients and their partners, examining the influence of partner distress on 
patient well-being and prognosis. The aims of Part four were to map out the process of information 
provision around ICD implantation, to evaluate patients’ satisfaction about the information 
provided and to investigate whether information provision and patient satisfaction are associated 
with emotional distress. Furthermore, Part four examines whether proposed psycho-educational 
and psychological care is actually implemented in clinical practice. A schematic representation of 
the studies in this dissertation is presented in Figure 4.
Part one: Medical treatment, clinical characteristics and their association with 
emotional distress
So far, little research has been performed on the association between medical treatment and 
clinical patient characteristics on the one hand and emotional distress on the other hand in ICD 
patients. This part of the dissertation aims to give an overview of the interrelationship between 
medical and emotional status. In Chapter 2, the association between procedure- and device-
related complications around implantation and psychological morbidity during 12 months post 
implantation is investigated. Although the number of complications is decreasing due to improved 
techniques and changes in the programming of the ICD, the occurrence of infections, lead 
dysfunction and inappropriate shocks cannot be fully prevented. 
 The ICD population is very heterogeneous and chronic medical comorbidity is a rule rather 
than an exception. Chapter 3 discusses the relationship between medical comorbidity and both 
emotional distress and health status. Furthermore, as a consequence of comorbidities, ICD patients 
often use multiple types of medication in order to control their heart disease and accompanying 
conditions. Chapters 4 and 5 therefore examine the associations between beta-blocker therapy 
and statin therapy, and emotional distress.
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Part two: In search of a psychophysiological link between emotional distress and 
clinical outcomes: Autonomic nervous system function as a candidate mechanism
It is known that there is a link between emotional distress and clinical outcomes in patients with an 
ICD. However, the pathways that may explain these links received little attention. As one possible 
mechanism, the autonomic nervous system, with HRV as a specific index of autonomic function, 
is highlighted in this part of the dissertation. Chapter 6 reviews the relation between several 
indicators of emotional distress and HRV measures over 24 hours, and during resting activity and 
sleep. In Chapter 7 subsequently, the association between heart rate and mortality in ICD patients 
is investigated.
Part three:  Looking beyond the scope of the patient: The impact of partners of ICD 
patients
Instead of looking at the patient as a single actor solely responsible for his or her emotional status, 
partners should be incorporated in research on psychological functioning and treatment of ICD 
patients. Hence, in Part three, Chapter 8 examines the interrelationship between emotional distress 
of patients and their partners and its influence on patients’ health status. As little is known about 
the prognostic impact of partners’ emotional distress on patients’ survival, this will be examined in 
Chapter 9.
Part four: Inside the consulting room – helping the patient to get back on track
When it comes to medical psychology, scientific research and clinical practice should always be 
intertwined, indissoluble fields. With this fourth part, a further attempt is made to consolidate the 
bridge between research and practice. Since education about treatment with an ICD and what to 
expect, including potential psychological consequences, have been shown to influence patients’ 
adaptation to living with an ICD,98-100 the process of information provision around implantation and 
patients’ satisfaction with this process is evaluated in Chapter 10. The relation between information 
provision, satisfaction and emotional distress in patients is also described in this chapter. Given that 
screening for emotional distress and periodic monitoring of distress in patients with an ICD is not 
yet part of standard clinical practice, there is a need for studies that elucidate whether patients 
receive adequate treatment for their distress and if not what the potential consequences might 
be. Hence, Chapter 11 examines the frequency of psychological treatment in ICD patients and the 
influence of undertreatment of emotional distress on patients’ health status.
The main findings of this dissertation will be discussed in Chapter 12. In this chapter, 
recommendations for future research and clinical practice will be outlined as well.
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Figure 4. Schematic representation of studies in this dissertation. 
Numbers indicate the relating chapters.
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INTRODUCTION 
Despite the unequivocal medical benefits of implantable cardioverter defibrillator (ICD) therapy 
for the prevention of sudden cardiac death,1 there is a risk for procedure- (e.g. infection and 
bleeding) and device-related complications (e.g. inappropriate shocks and lead dysfunction).2 Such 
complications may not only influence morbidity and mortality3,4 but also patient well-being and 
quality of life.2,5 To date, the majority of studies have focused on the separate impact of shocks and 
device advisories on patient well-being rather than procedure- and device-related complications, 
with results being mixed.6,7 
METHODS
Patients and study design
We examined whether procedure- and device-related complications are associated with 
psychological morbidity in a consecutive cohort of ICD patients (N=443; 79% men; mean age=58±12 
years) implanted between August 2003 and May 2010 at the Erasmus Medical Center, Rotterdam, the 
Netherlands, and participating in the Mood and personality as precipitants of arrhythmia in patients 
with an Implantable cardioverter Defibrillator: A prospective Study (MIDAS). 
Measures
Depression, anxiety and ICD concerns
Patients completed the 14-item Hospital Anxiety and Depression Scale (HADS)8 and the 8-item 
ICD Patient Concerns questionnaire (ICDC)9 at baseline, at 3, 6, and 12 months post implantation. 
Information on demographic and clinical characteristics was captured from the patients’ medical 
records or purpose-designed questions. Information on ICD therapy during follow-up was obtained 
by means of device interrogation. 
Statistical analyses
We used a composite of procedure- (i.e. any complication being directly or indirectly caused 
by the implantation procedure and occurring up to 30 days post implantation) and device-
related complications (i.e. an event related to the implanted ICD system, including lead-related 
complications occurring also 30 days post implantation). Inappropriate and appropriate shocks 
were also considered as device-related complications; appropriate shocks were only included if the 
shock was given for a ventricular tachycardia (VT) with a cycle length >250 ms, as these rhythm 
disturbances essentially could have been terminated by antitachycardia pacing. Others have used 
a similar distinction between procedure- and device-related complications.10,11 The association 
between procedure- and device-related complications and psychological morbidity was assessed 
with repeated measures univariable and multivariable analysis of variance using general linear 
mixed modeling analysis, with an unstructured covariance structure. 
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RESULTS
We found no systematic differences on baseline characteristics between patients with and without 
complications (all p>0.05). Of all  patients, 70 (15.8%) experienced a complication, with 3 patients 
experiencing 2 complications during the 12 months follow-up, leading to a total complication rate 
of 73 (16.5%). Of these, 18 patients (4.1%) experienced a procedure-related complication, while 52 
patients (11.7%) experienced a device-related complication (Table 1).




Procedure-related Lead dislodgement 






Device-related Lead dislodgement 
(>30 days post implantation)
7 (1.6%)
Inadequate sensing 2 (0.4%)
Non successful termination of VF 2 (0.4%)
Inappropriate shock 19 (4.3%)
Appropriate shock 22 (4.9%)
Total 52 (11.7%)
Non-device related Pocket infection 2 (0.4%)
Pericarditis 1 (0.2%)
Total 3 (0.7%)
* Results are presented as N (%); 3 patients had more than one event
Abbreviations: N, number; VF, ventricular fibrillation
The course of symptoms of anxiety and depression, and ICD concerns during the 12-month 
follow-up stratified by complications are displayed in Figure 1. In unadjusted analyses, there was 
a significant association between complications and anxiety (estimate (e)=1.15; p=.029) and ICD 
concerns (e=2.28; p=.019), but not with depression (e=0.99; p=.07). There was a significant time 
by complications interaction effect between baseline and 3 months follow-up for anxiety (e=1.41; 
p<.001), depression (e=0.51; p<.001), and ICD concerns (e=3.25; p<.001), indicating that patients 
with complications reported a slower decrease in psychological morbidity than patients without 
complications. In addition, a significant time by complications interaction effect was found 
between 3 and 6 months follow-up for ICD concerns (e=-0.93; p=.039), indicating that patients 
with complications reported a faster decrease in ICD concerns between 3 and 6 months post 
implantation than patients without complications. After adjusting for gender, type of implanted 
ICD, atrial fibrillation, symptomatic heart failure, coronary artery disease, appropriate shocks during 
follow-up with a cycle length <249 ms, and the use of beta-blockers, the associations between 
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complications and anxiety (e=1.15; p=.030) and between complications and ICD concerns (e=2.03; 
p=.038) remained significant. The relationship between complications and depression remained 
non significant (e=0.95; p=.08). 
Figure 1.  Association between a composite of procedure- and device-related complications and psychological 
morbidity at baseline, and at 3, 6 and 12 months post implantation*
* Presented as mean scores
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DISCUSSION
To our knowledge, this is the first study to examine the impact of procedure- and device-related 
complications on psychological morbidity in ICD patients. Previous studies have examined the 
influence of complications on morbidity and mortality3,4 and the separate impacts of shock and 
device advisories on patient well-being rather than procedure- and device-related complications, 
with results being mixed.6,7 In the current study, patients experiencing a procedure- or device-
related complication in the first 12 months post implant reported more anxiety and ICD concerns 
as compared to patients without complications, while no difference was found on depression. 
These analyses were adjusted statistically for a set of a priori determined potential demographic 
and clinical confounders, including appropriate shocks with a cycle length <249 ms. In clinical 
practice, ICD patients experiencing a complication should be monitored for symptoms of anxiety, 
as anxiety not only leads to impairments in quality of life but may also increase the risk of ventricular 
tachyarrhythmias and mortality independent of demographic and clinical risk factors.12 
 The limitations of this study should be acknowledged. Given the short-term follow-up, we do 
not know what the impact might be of complications on patient well-being long-term. Due to a 
complication rate of 15.8%, we were not able to examine whether different types of complications 
may exert a differential influence on outcome, as this would have required a larger sample size.
 In conclusion, our findings show that ICD patients experiencing a procedure- or device-related 
complication in the first 12 months post implant may be at risk for anxiety and ICD concerns, 
while we found no impact on depression. Further studies are warranted that look at the impact of 
complications on patient well-being and psychological morbidity beyond 12 months, focusing on 
the impact of procedure- and device-related complications separately, as inappropriate shocks may 
have a larger influence than procedure-related complications. However, due to the application of 
new programming algorithms, the incidence of inappropriate shocks has decreased substantially, 
warranting large-scale studies to be able to elucidate this relationship, which might best be achieved 
by building in patient-reported assessments in current or new ICD registries.
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ABSTRACT
Background: Comorbidity burden has been linked to survival in patients with an implantable 
cardioverter-defibrillator (ICD), but no study has examined the influence on psychological well-
being and health status. We examined the relationship between comorbidity burden and anxiety, 
depression, and health status in patients with an ICD during the first 12 months post implantation 
using a prospective study design.
Methods: Consecutively implanted ICD patients (N=401; 78% men) completed the Hospital Anxiety 
and Depression Scale (HADS) and the Short Form Health Survey 36 (SF-36) at baseline, 3, 6, and 
12 months post implantation. Data were analyzed using general linear mixed modeling repeated 
measures multivariable analysis of variance.
Results: The mean Charlson Comorbidity Index (CCI) score was 3.5 (±2.4). In adjusted analyses, 
comorbidity burden was significantly associated with depression (p=.003) and the physical health 
status domains of the SF-36 (physical functioning: p<.001; role limitations - physical: p=.023; bodily 
pain: p=.004; and general health: p=.025) but not with anxiety (p=.62) and the mental health status 
domains of the SF-36 (all p>.05). Chronic heart failure, chronic obstructive pulmonary disease 
(COPD), cerebrovascular disease and renal failure were the comorbidities with the most impact on 
depression and physical health status.
Conclusions: Comorbidity burden was a significant predictor of poorer psychological well-being 
and physical health status in ICD patients the first 12 months post implantation. In the care and 
management of ICD patients, it is important to recognize the impact of comorbidity burden on 
patients’ mood and health status, and that adjunctive intervention may be warranted to enhance 
well-being. 
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INTRODUCTION
The implantable cardioverter-defibrillator (ICD) is the first-choice therapy for patients at risk for 
sudden cardiac death due to ventricular arrhythmias.1,2 Despite the effectiveness of ICD therapy 
demonstrated in clinical trials, patients enrolled in clinical trials do not fully reflect ICD patients seen 
in the real-world clinical setting, due to the former being younger and having less comorbidities.3 
The presence of multiple comorbid conditions is associated with a poorer survival.4-6 As a result of 
poorer physical functioning and increased problems in daily life, a higher number of comorbidities 
may also influence patients’ psychological well-being, including symptoms of anxiety and 
depression, and health status.6-8 
 Monitoring psychological status of patients with multiple comorbidities is thus of utmost 
importance, in particular because the variability in clinical presentation and types of comorbidities 
present may hinder the detection of psychological distress.9 To our knowledge, no previous study 
has examined the impact of comorbidities on the well-being and health status of ICD patients but 
rather tend to have focused on the impact of ICD therapy. In addition, as the population of ICD 
patients is very heterogeneous with patients receiving implantation for a wide range of indications, 
the risk of an increased comorbidity burden is high. 
 The purpose of the current study was to examine the association between patients’ pre 
implantation Charlson Comorbidity Index (CCI) score, and anxiety, depression, and health status in 
patients with an ICD during the first 12 months post implantation using a prospective study design. 
METHODS
Patients and study design
Between August 2003 and February 2010, 448 consecutive patients who were implanted with a first-
time ICD in the Erasmus Medical Center, Rotterdam, the Netherlands, were enrolled in the Mood and 
personality as precipitants of arrhythmia in patients with an Implantable cardioverter Defibrillator: 
A prospective Study (MIDAS). Patients with a life-expectancy of <1 year, being on the waiting list 
for heart transplantation, a history of psychiatric illness other than affective/anxiety disorders, or 
insufficient knowledge of the Dutch language were excluded. The study protocol was approved 
by the Medical Ethics Committee of the Erasmus Medical Center, and the study was conducted 
according to the Helsinki Declaration. An ICD nurse provided written and oral information on the 
study prior to ICD implantation. After obtaining written informed consent, patients were asked 
to complete a set of standardized and validated questionnaires at baseline (i.e. one day prior to 
implantation), and at 3, 6 and 12 months post implantation. Information on baseline demographic 
and clinical characteristics was extracted from patients’ medical records and purpose-designed 
questions in the questionnaires. 
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Measures
Comorbidities and the Charlson Comorbidity Index
Information on comorbidities prior to ICD implantation was obtained via chart abstraction from 
the patients’ medical records and laboratory values at baseline. Renal functioning was assessed by 
estimating the baseline glomerular filtration rate (eGFR), according to the abbreviated Modification 
of Diet in Renal Disease (MDRD) Study equation.10 In accordance with practice guidelines, an eGFR 
<60 mL/min/1.73 m2 was considered as impaired renal functioning.11 An abbreviated CCI score was 
composed with the following comorbid conditions: myocardial infarction (MI), congestive heart 
failure, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), diabetes mellitus, 
peripheral vascular disease, renal failure, and any malignancy excluding metastatic tumors.5 In 
order to obtain a  comorbidity index that is in accordance with the original CCI, a weight of 2 was 
assigned to renal failure and any malignancy, and a weight of 1 to the other comorbid conditions.12 
By adding up the values assigned to each comorbid condition, a comorbidity score was calculated 
for each patient. Because age is a risk factor for mortality independent of the presence of comorbid 
conditions and the incidence of comorbidities increased with higher age in our sample, we adjusted 
the score by adding one point to the score for each decade of life over the age of 50 at time of study 
entry, according to the validated combined comorbidity index.5,13 The advantage of this abbreviated 
index is that it reckons with the comorbid disorders most prevalent in and relevant to cardiac 
patients, and that age is included as an additional indicator of health.
Psychological well-being and health status
Symptoms of anxiety and depression were measured at baseline, and at 3, 6 and 12 months follow-up 
using the Hospital Anxiety and Depression Scale (HADS).14 The HADS consists of 7 items measuring 
symptoms of anxiety (HADS-A) and 7 items measuring symptoms of depression (HADS-D), all scored 
on a 4-point Likert scale.14 Scores range from 0 to 3 (total score range of 0-21), with higher scores 
reflecting more symptoms.14 The HADS has good psychometric properties.15 
 The Short Form Health Survey 36 (SF-36) was used to assess patients’ health status at baseline, 
and at 3, 6 and 12 months post implantation.16 The items contribute to 8 subscales: physical 
functioning, role limitations - physical, bodily pain, social functioning, mental health, role limitations 
- emotional, vitality and general health. Scores on the individual subscales range from 0 to 100, 
with higher scores indicating better health status, and a higher score on the bodily pain subscale 
indicating the absence of pain.17 Psychometric properties for the SF-36 are adequate.16
 Type D personality is the combined tendency to experience increased negative affectivity 
and social inhibition. The 14-item Type D scale (DS14), consisting of 7 items measuring negative 
affectivity (i.e. ‘I often feel unhappy’) and 7 items measuring social inhibition (i.e. ‘I am a closed kind of 
person’) was used to assess Type D personality at baseline.18 All items are scored on a 5-point Likert 
scale, ranging from 0 (false) to 4 (true), with a total score ranging from 0 to 28.18 A cut-off score of 
≥10 on both subscales defines individuals with a Type D personality.19 
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Statistical analyses
Repeated measures multivariable analysis of variance (RM-ANOVA) using general linear mixed 
modeling analysis was performed to test the longitudinal association between CCI and psychological 
well-being. This technique uses the data efficiently by also including incomplete cases in analyses. 
As a result of this, bias is limited and statistical power is preserved. Intra class correlations, a measure 
of score dependencies within patients, were computed for anxiety, depression and each of the 
SF-36 subscales. First, the CCI was tested as an associate of psychological well-being and health 
status over time; secondly, we assessed which individual comorbidities mainly accounted for the 
association between CCI and psychological well-being and health status.
 A priori, we adjusted for gender, educational level, indication for ICD therapy, the presence 
of cardiac resynchronization therapy (CRT), ICD shocks, atrial fibrillation, smoking, the use of 
amiodarone, beta-blockers, and diuretics, the presence of psychological treatment, and Type D 
personality in multivariable analyses. All independent variables were defined as fixed variables (i.e. 
not varying over time). Analyses were performed using PASW Statistics 19 statistical software (PASW 
IBM Corp., Armonk, NY, USA). For all tests, a p-value of <.05 was considered statistically significant. 
The described effects in the results section are the relationship of CCI at any time point with the 




Of the 448 patients, 18 had missing data on one or more psychological measures. Twenty-nine 
patients had additional missing data on one or more clinical baseline characteristics. No systematic 
differences were found between patients included (n=401) and patients excluded (n=47) from 
analyses (all p>.05). The population was predominantly male (78%), with a mean age of 58±12 
years. Baseline characteristics of the study population are presented in Table 1. The prevalence of 
comorbid conditions included in the CCI is displayed in Figure 1.










Figure 1. Prevalence (%) of the different comorbid conditions in the total study population
* Excluding metastatic tumors
Abbreviations: CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; MI, myocardial 
infarction; PAD, peripheral arterial disease
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 The most common non-cardiac comorbid conditions were renal failure, diabetes mellitus, 
and cerebrovascular disease. The number of comorbid conditions in patients varied from 0 to 6, 
with 25% of the patients having ≥3 comorbid conditions. Nineteen percent of the patients had ≥2 
non-cardiac comorbidities. CCI scores ranged from 0 to 10, with the mean CCI score being 3.5±2.4. 
In the 12 months period post implantation, 15% of patients received a shock, of which 4% was 
inappropriate.




Mean age (±SD) 58.4 (12.2)
Men 314 (78.3)
Single/no partner 26 (6.5)
Low education † 231 (57.6)
Clinical risk factors
Primary prevention indication 265 (66.1)
CRT 112 (27.9)
Shocks during follow-up ‡ 58 (14.5)
LVEF ≤35% § 300 (74.8)
Mean QRS (ms) (±SD) 130.3 (36.2)
CAD 231 (57.6)
Previous PCI 105 (26.2)
Previous CABG 83 (20.7)









Psychological treatment || 77 (19.2)
* Results are presented as N (%), unless otherwise indicated. † Education less than or equal to 13 years; ‡ both 
appropriate (N=44; 11.0%) and inappropriate (N=16; 4.0%) shocks; § 53/401 (13.2%) missing; || both psychotropic 
medication and treatment by a psychologist
Abbreviations: ACE, angiotensin-converting enzyme; CABG, coronary artery bypass graft surgery; CAD, coronary 
artery disease; CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection fraction; MI, myocardial 
infarction; N, number; PCI, percutaneous coronary intervention; QRS, QRS duration; SD, standard deviation.
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CCI as a determinant of psychological well-being and health status
Figure 2 depicts mean scores for anxiety, depression and health status during the 12-month follow-
up period. First, intraclass correlations were computed as a measure of correlation between the 
different measurement occasions (i.e. baseline, 3, 6 and 12 months follow-up). The consecutive 
measurements of anxiety and depression both showed an intraclass correlation of 0.30. With regard 
to health status, intraclass correlations varied from 0.37 to 0.73 for role limitations - emotional and 
general health, respectively, indicating a moderate to high correlation between the measurement 
moments, supporting the use of this specific repeated measures technique. 
 In Table 2, the results of the mixed modeling analyses are expressed as estimates, 95% confidence 
intervals (CIs), t- and p-values. A higher CCI prior to implantation was associated with more 
symptoms of depression over the follow-up period (p=.003). No association was found between 
CCI and anxiety. In multivariable analyses, the CCI remained a significant predictor of depressive 
symptoms at any time point (p=.003) (Table 2). 
Table 2. Charlson Comorbidity Index (CCI) as a determinant of anxiety, depression and health status (adjusted 
analysis)*
Estimate 95% CI t p
Anxiety -0.06 [-0.19 – 0.08] -0.84 .40
Depression 0.21 [0.07 – 0.35] 2.95 .003
SF-36 subscales
Physical functioning -2.57 [-3.57 – -1.58] -5.08 <.001
Role limitations - physical -1.67 [-3.10 – -0.23] -2.29 .023
Bodily pain -1.31 [-2.19 – -0.43] -2.92 .004
Social functioning -0.36 [-1.20 – 0.49] -0.83 .41
Mental health -0.19 [-0.80 – 0.43] -0.60 .55
Role limitations - emotional -1.05 [-2.32 – 0.22] -1.62 .11
Vitality -0.64 [-1.41 – 0.13] -1.64 .10
General health -0.97 [-1.82 – -0.12] -2.25 0.025
* Adjusted for gender, educational level, indication for ICD therapy, CRT, the occurrence of shocks (both 
appropriate and inappropriate) during 12 months post implantation, atrial fibrillation, smoking, the use of 
amiodarone, beta-blockers, and diuretics, the presence of psychological treatment, and Type D personality
 With respect to the health status, in univariable analyses, a higher CCI prior to implantation 
was associated with poorer physical health status over the follow-up period, in terms of physical 
functioning (p<.001), role limitations - physical (p<.001), more bodily pain (p=.002), poorer role 
limitations - emotional (p=.026), vitality (p=.010) and general health (p<.001). In multivariable 
analyses, the association between CCI and health status remained significant for physical functioning 
(p<.001), role limitations - physical (p=.023), bodily pain (p=.004) and general health (p=.025) (Table 
2). 
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The individual components of the CCI as determinants of psychological well-being and 
health status
Subsequently, we investigated whether specific comorbidities included in the CCI accounted for 
the significant effects on psychological well-being and health status as displayed in Table 2. Chronic 
heart failure, COPD, cerebrovascular disease and renal failure were the most important predictors 
of depression and impaired health status (for all subscales, shown in Table 3). No individual effect 
of the different comorbidities was found on symptoms of anxiety. In multivariable analyses, 
when all comorbidities were entered in the model simultaneously, chronic heart failure, COPD, 
cerebrovascular disease and renal failure remained the most important predictors. Additionally, 
although age alone did not strongly predict psychological well-being and health status, it was an 
important determinant when all comorbidities were combined into one model.
DISCUSSION
To our knowledge, this is the first study in ICD patients to examine the influence of comorbidity 
burden on psychological well-being and health status. We found that patient’s comorbidity 
burden was an important predictor of psychological well-being and health status over the 12 
months post implantation. Having a higher comorbidity burden was associated with more 
symptoms of depression, but not anxiety, and with poorer physical functioning, more physical 
role limitations, more bodily pain and a poorer general health. Importantly, this association was 
present independent of the patient’s pre implantation personality profile, which has also shown 
to be an important predictor of anxiety, depression and health status in patients with an ICD.20 Our 
results correspond in part to findings of previous studies in the general older population6,7 and 
in patients with acute MI,8 where a higher comorbidity burden was found to be associated with 
more depressive symptoms and functional impairment. In patients with CRT, who also comprise 
an important group in our sample, the relationship between comorbidities and psychological well-
being has not been investigated yet. However, as the course of health status in patients with CRT is 
comparable to the course of health status found in our study,21,22 we expect that patients with CRT 
show a similar association between comorbidity burden and psychological well-being as patients 
with a defibrillator only.
 We found no association between comorbidity score and anxiety. Around 25% of ICD patients 
report increased levels of anxiety.20,23 However, the type of impairments in patients with multiple 
comorbidities might more easily induce symptoms of depression, by interfering with the patient’s 
physical activity level, sleeping pattern, and social relationships, which in turn may lead to feelings 
of hopelessness and guilt.6,8 This pattern corresponds more with depressive rather than anxious 
symptomatology.  
 No association was found between CCI score and mental health status. One would probably 
expect that in case of a positive association between CCI score and depressive symptoms, an 
association between CCI score and mental health status would also be present. However, the 
mental health status subscales of the SF-36, as used in the current study, may be too generally 
        
Comorbidity burden, emotional distress and health status   |   47
formulated and do not measure specific psychological problems, including symptoms of anxiety 
and depression. In addition, the mental health subscale has shown to lack sensitivity to measure 
changes in mental health.24
 Chronic heart failure, COPD, cerebrovascular disease, and renal failure were the most important 
associates of depressive symptoms and poorer health status. These comorbidities have both a worse 
short-term and long-term prognosis when compared to the other comorbidities. In addition, these 
patients may experience more restrictions both in physical and mental functioning. Their adverse 
impact on psychological well-being and health status is illustrated in our study. Cancer did not seem 
to have an influence on health status and symptoms of anxiety and depression in our patient group. 
However, as patients were asked to report on life time presence of cancer, a time span between 
the actual presence of cancer and the assessment of psychological problems could account for the 
absence of the relationship. 
The finding that comorbid conditions are associated with poorer well-being and impaired health 
status is important for clinical practice. The variability in clinical presentation makes it difficult for 
physicians to detect psychological distress.9 Physicians might attribute patients’ psychological 
symptoms to their comorbidities rather than to psychological difficulties. However, it remains an 
important issue to focus on in daily practice, as both health status and depression have shown to be 
independent predictors of health care utilization in heart failure patients.25,26 In addition, previous 
studies have shown that patients with comorbidities respond less well to psychological therapy 
than patients without such comorbidities.27,28 
 The limitations of this study should be acknowledged. First, it would have been interesting 
to investigate whether changes in CCI scores over time were predictive of psychological status 
during follow-up. However, information on comorbidities was only available at baseline. In 
addition, information on psychological well-being was based on self-report measures instead of 
clinical diagnoses according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision (DSM-IV-TR). However, minor depressive symptoms have also been associated 
with functional decline and mortality in cardiac patients.29,30 Finally, the relatively short follow-up 
period does not allow drawing conclusions on the long-term relationship between CCI scores and 
psychological status.
 This study also has important strengths. Research on the relationship between comorbid 
conditions and psychological functioning has mainly been focusing on symptoms of depression, 
while the influence on symptoms of anxiety and general daily functioning has been largely ignored. 
Furthermore, we used a powerful statistical technique to analyze the data, reducing non-response 
bias and increasing statistical power. 
 In conclusion, we found that patients with a higher comorbidity score reported more symptoms 
of depression and poorer health status on several domains. As the variability in clinical presentation 
of patients with comorbid conditions may hinder physicians from detecting psychological distress 
and referring the patient to adequate, tailor-made psychological care, in case of comorbidities, 
clinicians should be vigilant of the possibility that patients’ psychological well-being and health 
status is at higher risk of being affected.
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ABSTRACT
Background: Beta-blockers are frequently prescribed to implantable cardioverter-defibrillator (ICD) 
patients. Beta-blocker therapy has been proposed to induce emotional distress such as depression 
and anxiety, but a paucity of studies has examined the relationship between beta-blockers and 
distress. We investigated the association between beta-blocker therapy, including type and dosage, 
and symptoms of anxiety and depression in a consecutive cohort of patients receiving an ICD.
Methods: Between 2003 and 2010, 448 consecutively implanted ICD patients were enrolled in the 
prospective Mood and personality as precipitants of arrhythmia in patients with an Implantable 
cardioverter Defibrillator: A prospective Study (MIDAS), of which 429 completed the Hospital Anxiety 
and Depression Scale (HADS) and the ICD Patient Concerns questionnaire (ICDC) at baseline. 
Results: Eighty percent of all patients received beta-blocker therapy. In univariate analysis, beta-
blocker therapy was not significantly associated with symptoms of anxiety, depression and ICD 
concerns (β=-0.030, β=0.007 and β=-0.045, respectively; all p>0.36). Type of beta-blocker showed a 
trend towards significance for mean levels of ICD concerns (p=.09). No association was found between 
dosage and emotional distress (all p>.21). After adjustment for relevant clinical and demographic 
variables, the association of beta-blocker therapy and symptoms of anxiety, depression and ICD 
concerns remained non-significant (β=0.009, β=0.037 and β=0.019, respectively; all p>.47).
Conclusions: In patients receiving an ICD, beta-blocker therapy is not associated with symptoms of 
anxiety, depression and ICD concerns. Further research is warranted that examines the link between 
beta-blocker therapy and emotional distress in this vulnerable patient group.
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INTRODUCTION
The implantable cardioverter-defibrillator (ICD) has evolved to treatment of first choice in the 
prevention of arrhythmic death, both as primary and secondary prevention.1,2 The majority of ICD 
patients report acceptable levels of quality of life (QoL),3,4 with  patients reporting increases in QoL 
some months after the implantation.5 However, a subgroup of patients experiences adaptation 
problems, which include the manifestation of depression, anxiety, concerns about the ICD giving a 
shock, and posttraumatic stress.3,6,7 
 In addition to the ICD implant, ICD patients are often prescribed beta-blockers, lipid-lowering 
drugs, calcium antagonists and angiotensin-converting enzyme (ACE)-inhibitors to treat their 
underlying heart disease, with beta-blockers being among the most frequently prescribed drugs.8 
Beta-blockers are of major importance in the treatment post myocardial infarction (MI), reducing the 
odds of death after long-term use with up to 23%.9 Beta-blockers also enhance survival in patients 
with chronic heart failure,10,11 patients with idiopathic dilated cardiomyopathy12 and patients with 
different types of arrhythmias.13 Nevertheless, despite these well-established benefits, there is an 
ongoing debate concerning possible side-effects of beta-blocker therapy on the central nervous 
system,14 which include the manifestation of depression.15-18 However, many of these studies are 
dated, are based on small sample sizes or used prescribed antidepressants as a marker of depression 
rather than assessing depression.15,17 In addition, the evidence is not consistent, with some studies 
finding no association between the use of beta-blockers and symptoms of depression,14,19-22 mixed 
results depending on beta-blocker type23 or even a reduction of depressive symptoms in beta-
blocker users.24,25 In contrast, less research has been conducted on the association between the use 
of beta-blockers and symptoms of anxiety, although there are some indications of beta-blockers 
having a protective effect in relation to symptoms of anxiety.26-28 Moreover, most of these studies 
were conducted in patients with MI, heart failure or hypertension. Although a subset of patients 
with heart failure is treated with ICD therapy, none of these studies have focused specifically on 
patients with an ICD. Therefore, we investigated the association between beta-blocker therapy and 
symptoms of anxiety and depression, and examined whether beta-blocker type and dosage are 
correlated with psychological functioning in patients receiving an ICD.
METHODS
Patients and study design
Between August 2003 and February 2010, a consecutive series of 448 patients implanted with an 
ICD at the Erasmus Medical Center, Rotterdam, the Netherlands, were enrolled in the prospective 
Mood and personality as precipitants of arrhythmia in patients with an Implantable cardioverter 
Defibrillator: A prospective Study (MIDAS). Exclusion criteria included a life-expectancy of <1 year, 
being on the waiting list for heart transplantation, having a history of psychiatric illness other than 
affective/anxiety disorders, or insufficient knowledge of the Dutch language. The Medical Ethics 
Committee of the Erasmus Medical Center approved the study. An ICD nurse approached patients 
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while being admitted to hospital, provided information regarding the study and asked them to 
complete a set of standardized and validated psychological questionnaires at baseline (i.e. 1 day 
prior ICD implantation). All patients provided written informed consent before enrollment in the 
study.
Measures
Demographic and clinical variables
All demographic and clinical variables were collected at baseline. Demographic variables included 
gender, age, marital status and education. Clinical variables were obtained from patients’ medical 
records, and included indication for ICD therapy (primary or secondary prevention), treatment 
with cardiac resynchronization therapy (CRT), left ventricular ejection fraction (LVEF) ≤35%, QRS 
duration, the presence of coronary artery disease (CAD), previous MI, prior percutaneous coronary 
intervention (PCI) and coronary artery bypass grafting (CABG), symptomatic heart failure (defined 
as New York Heart Association (NYHA) class III+IV), atrial fibrillation, diabetes, smoking, and cardiac 
(i.e beta-blockers, amiodarone, diuretics, ACE-inhibitors, statins, and digoxin) and psychotropic 
medication. For patients on beta-blocker therapy, information on type and dosage was also 
obtained from patients’ medical records. In order to be able to compare the dosages of different 
types of beta-blockers, we used the maximum recommended therapeutic dosages, as prescribed by 
the Pharmacotherapeutic Reference Book, a yearly published issue by the Dutch National College of 
Health Insurances.29
Anxiety and depression
Symptoms of anxiety and depression were measured with the Hospital Anxiety and Depression 
Scale (HADS), a 14-item self-report questionnaire, which performs well in screening for separate 
symptoms of anxiety and depression in patients in non-psychiatric hospital settings.30 The scale 
consists of 7 items measuring symptoms of anxiety (HADS-A) and 7 items assessing symptoms of 
depression (HADS-D), all scored on a 4-point Likert scale. Scores range from 0 to 3, with a score 
range of 0-21 for both subscales, with a high score indicating more symptoms.31 A cut-off score of 
8 or above, representing an optimal balance between sensitivity and specificity, is used to detect 
patients with clinically relevant levels of anxiety and depression.30 The HADS is a valid and reliable 
scale, with mean Cronbach’s alphas of 0.83 and 0.82 for the HADS-A and HADS-D, respectively, and a 
sensitivity score of 0.80 for both subscales.30 Test-retest reliability over 3 weeks is high with a Pearson 
coefficient of 0.89 and 0.86 for the HADS-A and HADS-D respectively.32
ICD concerns
Patient concerns related to ICD treatment were assessed with the Dutch version of the 8-item Patient 
ICD Concerns questionnaire (e.g. “I am worried about my ICD firing” and “I am worried about symptoms/
pain associated with my ICD firing”) (ICDC).33 Items are rated on a 5-point Likert scale from 0 (not at 
all) to 4 (very much so), with a score range from 0 to 32, and with a higher score indicating more 
ICD related concerns. The ICDC is a disease-specific measure that assesses a different construct than 
general measures of anxiety and depression. The measure has also been shown to predict mortality 
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in ICD patients.34 Both the original and the Dutch translation of the ICDC have good psychometric 
properties, with a Cronbach’s alpha of 0.94 and 0.91, respectively.33,35 For the current study, scores on 
the ICDC were divided into equal tertiles and dichotomized into a high score of ≥7 and a low score 
of ≤6. 
Statistical analyses
Baseline demographic and clinical variables for patients on beta-blocker versus no beta-blocker 
therapy were compared with the χ2 test (Fisher’s Exact test when appropriate) for nominal variables 
and with Student’s t-test for continuous variables, respectively. The association between beta-
blocker therapy and symptoms of depression and anxiety and ICD concerns was assessed in main 
analysis using univariable and multivariable linear regression. In multivariable analyses using 
an enter approach, we adjusted for variables that have been associated with emotional distress 
in the arrhythmia literature, which include atrial fibrillation and symptomatic heart failure,36,37 
indication for ICD therapy,38 diabetes mellitus,39 and the use of amiodarone and psychotropic 
medication,37 and variables that were expected to be related to emotional distress, including CAD 
and age. The rationale for a priori selection of variables is recommended by others.40 We checked 
for multicollinearity between the independent variables using Spearman’s ρ, with a threshold of 
>0.70 indicating multicollinearity. Results of the linear regression analyses are presented as β’s with 
accompanying p-values. In a secondary analysis, the association between beta-blocker type and 
dosage and emotional distress, and possible interaction effects were examined with univariable 
analysis of variance (ANOVA), with a post hoc Bonferroni test when the ANOVA showed a significant 
main effect to investigate between group differences. For all tests, a p-value <.05 (two-sided) was 
considered significant. All statistical analyses were performed using SPSS 17.0 statistical software 
(SPSS Inc., Chicago, IL, USA).
RESULTS
Participants versus non participants
A total of 448 patients were enrolled in the MIDAS study. Of these, 19 refused to participate. All 
remaining 429 patients (response rate = 96%) filled in sufficient items to obtain summary scores 
on the psychological measures and thus were eligible for analysis. Patients who refused to 
participate were more likely to have ischemic heart disease, atrial fibrillation and diabetes (all 
p<0.05). No systematic differences in medication use between responders and non responders were 
demonstrated (all p>.05).
Baseline characteristics
Baseline characteristics for the total patient sample and stratified by beta-blocker use are listed in 
Table 1. Of all patients, 342 (80%) were on beta-blocker therapy compared to 87 (20%) without beta-
blocker therapy. The mean age was 58±12 years, 79% of the patients were male. Mean scores of 
anxiety, depression and ICD concerns were 5.53 (±4.00), 4.99 (±3.97) and 9.97 (±7.71) respectively. 
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N 429 (100) 342 (79.7) 87 (20.3)
Demographics
Mean age (±SD) 58.43 (12.1) 58.84 (11.5) 56.83 (14.5) .17
Men 337 (78.6) 268 (78.4) 69 (79.3) .85
Single/no partner † 28 (6.6) 20 (5.9) 8 (9.2) .27
Lower education ‡ 245 (58.2) 194 (57.7) 51 (60.0) .71
Clinical risk factors
Primary  prevention    
   indication
282 (65.7) 231 (67.5) 51 (58.6) .12
CRT 122 (28.4) 103 (30.1) 19 (21.8) .13
LVEF ≤35% § 318 (85.7) 263 (86.8) 55 (80.9) .21
Mean QRS (±SD) || 129.89 (36.4) 130.65 (36.2) 126.92 (37.1) .39
CAD 247 (57.6) 204 (59.6) 43 (49.4) .09
Previous MI 210 (49.0) 177 (51.8) 33 (37.9) .02
Previous PCI 111 (25.9) 91 (26.6) 20 (23.0) .49
Previous CABG 87 (20.3) 71 (20.8) 16 (18.4) .62
Symptomatic heart 
failure ¶
137 (31.9) 113 (33.0) 24 (27.6) .33
Atrial fibrillation 95 (22.1) 69 (20.2) 26 (29.9) .05
Diabetes 62 (14.5) 54 (15.8) 8 (9.2) .12
Smoking # 46 (10.8) 37 (10.9) 9 (10.3) .89
Medication use
Amiodarone 80 (18.6) 51 (14.9) 29 (33.3) <.001
Diuretics 244 (56.9) 201 (58.8) 43 (49.4) .12
ACE-inhibitors 307 (71.6) 264 (77.2) 43 (49.4) <.001
Statins 253 (59.0) 225 (65.8) 28 (32.2) <.001
Digoxin 65 (15.2) 52 (15.2) 13 (14.9) .95
Psychotropic medication ** 70 (16.5) 55 (16.2) 15 (17.4) .79
Antidepressants †† 14 (3.3) 2 (2.3) 12 (3.5) .57
Benzodiazepines 29 (6.8) 8 (9.2) 21 (6.1) .31
Hypnotics 5 (1.2) 0 (0.0) 5 (1.5) .26
>1 type 4 (0.9) 1 (1.1) 3 (0.9) .81
* Results are presented as N (%), unless otherwise indicated. † 3/429 (0.7%) missing; ‡ Education less than or 
equal to 13 years, 8/429 (1.9%) missing; § 58/429 (13.5%) missing; || 1/429 (0.2%) missing; ¶ defined as NYHA 
class III and IV; # 2/429 missing (0.5%); ** 4/429 missing in general (0.9%), in 18/70 (25.7%) type of psychotropic 
medication was missing; †† SSRI (N=11), TCA (N=1), lithium (N=1), serotonergic/noradrenergic antidepressant 
(N=1). Abbreviations: ACE, angiotensin-converting enzyme; CABG, coronary artery bypass grafting; CAD, coronary 
artery disease; CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection fraction; MI, myocardial 
infarction; N, number; PCI, percutaneous coronary intervention; QRS, QRS duration; SD, standard deviation
Beta-blocker users were more likely to have had a previous MI (p=.02), and were more often treated 
with ACE-inhibitors (p<.001) and statins (p<.001). In contrast, beta-blocker users were less likely 
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to be treated with amiodarone compared with patients not on beta-blocker therapy (p<.001). No 
differences on symptoms of depression, anxiety and ICD concerns between beta-blocker users and 
non beta-blocker users were found (all p>.36). 
Unadjusted analyses
Baseline scores on the HADS-A, HADS-D and ICDC of beta-blocker users were compared with those 
of non beta-blocker users. In univariable analysis, there was no significant association between 
beta-blocker therapy and symptoms of anxiety (β=-0.030, p=.54), depression (β=0.007, p=.89) and 
ICD concerns (β=-0.045, p=.36). In order to investigate the relationship between beta-blocker type 
and dosage and possible interaction effects with emotional distress, we performed univariable 
ANOVA analyses. The association between beta-blocker type and emotional distress is presented in 






















Figure 1. Association between beta-blocker type and emotional distress (unadjusted analysis)
Table 2. Descriptives beta-blockers *
Type † Bisoprolol Metoprolol Carvedilol Sotalol Nebivolol p-value
N 107 117 86 18 6 -
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* Daily dosages and percentages of the maximum therapeutic dosages are presented as mean ± SD. † Atenolol, 
labetalol and pindolol omitted from analysis because N=1; in total, information on dosage missing in 8/342 
patients (2.3%). ‡ maximum recommended therapeutic dosages as prescribed by the Pharmacotherapeutic 
Reference Book, a yearly published issue by the Dutch National College of Health Insurances 30
Overall, type of beta-blocker was significantly associated with higher scores on the ICDC only 
(F=2.681, p=.03). After performing a post-hoc Bonferroni test, sotalol and bisoprolol were the 
only types of beta-blockers showing a trend towards significant differences in mean levels of ICD 
concerns. However, the difference fell short of significance (p=.09). No association between beta-
blocker dosage and emotional distress was found (all p>.21), nor an interaction effect between type 
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of beta-blocker and percentage of the maximum recommended therapeutic dosage in relation 
to distress (all p>.06). As there was no association between beta-blocker type and dosage and 
emotional distress, respectively, these variables were not included in multivariable analysis. 
Table 3. Multivariable associations between beta-blocker therapy and emotional distress *
Anxiety Depression ICD concerns
β p β p β p
Step 1
+ CAD -0.001 .98 0.028 .59 0.030 .57
+ Atrial fibrillation -0.091 .09 0.069 .20 -0.064 .23
+ Amiodarone 0.043 .42 0.013 .82 0.056 .29
Step 2
+ ICD indication 0.038 .49 0.056 .32 -0.018 .76
+ NYHA 0.023 .66 0.117 .03 -0.087 .11
+ DM 0.068 .18 0.022 .67 0.032 .54
+ Psychotropic medication 0.285 <.001 0.281 <.001 0.219 <.001
+ Age -0.146 .01 -0.036 .53 -0.138 .02
Step 3
+ LVEF≤35% -0.108 .047 -0.059 .28 -0.021 .71
Step 4
+ Beta-blocker 0.009 .86 0.037 .47 0.019 .72
* Abbreviations: CAD, coronary artery disease; DM, diabetes mellitus; ICD, implantable cardioverter defibrillator; 
LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association class
Adjusted analyses
Prior to adjusted analysis, we checked for multicollinearity between the independent variables 
using Spearman’s ρ. There were no problems with multicollinearity as all Spearman’s ρ’s were <.36. 
Adjusting for the a priori selected covariates, we composed a four-step model. In step 1, variables 
significantly associated with beta-blocker therapy and variables showing a trend towards an 
association with beta-blocker therapy were included (CAD, atrial fibrillation and amiodarone). In step 
2, ICD indication, NYHA functional class, diabetes mellitus, psychotropic medication and age were 
added. Because we had no information on LVEF for 13.5% of patients, LVEF was added in step 3. In 
order to assess the unique association between beta-blocker therapy and emotional distress, beta-
blocker use was added in the final model (step 4, Table 3). The association between beta-blocker 
therapy and symptoms of anxiety, depression and ICD concerns remained non significant (β=0.009, 
β=0.037 and β=0.019, respectively; all p>.47) when controlling for the appropriate covariates. 
DISCUSSION
In the present study, we examined the association between beta-blocker therapy and emotional 
distress in a consecutive cohort of patients receiving an ICD. Our results neither support a 
relationship between beta-blocker use and symptoms of anxiety, depression and ICD- concerns, 
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respectively, nor a type- or dose-dependent relationship. The relationship between beta-blocker 
use and symptoms of depression has been previously studied, specifically in post MI patients.14,21,22 
However, little is known about the relationship between beta-blocker therapy and anxiety in the 
general cardiovascular literature. In addition, to our knowledge this study is one of the first to 
investigate this relationship in patients implanted with an ICD. 
 In order to induce neuropsychological side-effects, beta-blockers have to be able to cross the 
blood-brain barrier and thus be lipophylic.14 Therefore, hydrophilic beta-blockers cannot induce an 
anxiolytic effect due to their inability to bind on β-receptors in the brain, while lipophylic beta-
blockers would. In our sample however, we found no significant differences between the various 
types of beta-blockers. Moreover, the question remains whether beta-blockers are able to cross the 
blood-brain barrier in the beginning, which also depends on the size of their molecules.
 Overall, we found no indication that beta-blocking agents may be linked to anxiety, although this 
could be due to differences in pharmacokinetic characteristics of the various types of beta-blockers. 
Swartz (1998) found rapid improvements in levels of anxiety and obsessive-compulsive disorder 
symptoms after administration of the lipophylic beta-blocker betaxolol,28 which is a long-acting 
beta-blocker. In general, beta-blockers prescribed to our patients are short-acting agents,29 which 
could explain the absence of an anxiolytic effect. Although results from studies in both animals and 
humans indicate that the β
1
-adrenoceptor in the basolateral amygdalae plays an important role 
in anxiety-like behavior,27,41 suggesting that inhibition of this receptor by selective beta-blocking 
agents could produce anxiolytic effects, the relatively short half-life time of the beta-blockers 
prescribed to our patients might reduce this effect. In addition, beta-blocker dosages may also 
play a role. One might hypothesize that autonomic arousal involved in the somatic experience of 
anxiety is only suppressed by beta-blockers at higher dosages. As the subjective, cognitive/affective 
experience of anxiety always follows the somatic arousal in response to fear,42 suppression of the 
subjective experience of anxiety - which patients report in the questionnaires - by beta-blockers 
may not occur at low dosages. In our sample, patients were prescribed relatively low percentages 
of the maximum therapeutic recommended dosage (ranging from 19-48% depending on beta-
blocker type), which could explain the absence of an anxiolytic effect. 
 Twenty percent of the patients in the present study did not receive beta-blocker therapy. There 
were no indications that absence of beta-blocker therapy was due to problems with tolerating the 
beta-blockers. The prescription rates in the present patient cohort were comparable with those in 
other cohorts of ICD patients.43,44 
 The absence of an association between beta-blocker therapy and symptoms of depression 
is concurrent with the results of multiple recent studies.14,19-22 In contrast to early findings in this 
field, when the hypothesis of the depression-inducing effect of beta-blockers was developed, 
more recent results find no support for this hypothesis. Rabiner et al. (2000) reported that there 
are certain beta-blockers, including pindolol and penbutolol, that bind to serotonin receptors in 
the brain, thereby increasing the amount of free serotonin, which could explain the absence of a 
negative effect of beta-blockers on mood.45 In addition, arguments have been made that physical 
symptoms, including fatigue, are sometimes being misinterpreted as depression.46 This could lead 
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to an overestimation of the prevalence of depressive symptoms. Besides, instead of examining the 
presence of depressive symptoms, a number of studies have investigated the relationship between 
beta-blocker therapy and the use of antidepressants, with antidepressant use serving as a proxy 
measure for depression.15,17 Although symptoms of depression and the use of antidepressants are 
likely to be correlated, as was the case in our study, recent research suggests that ICD patients with 
clinical significant levels of depressive symptoms are undertreated.47 It is unclear as to whether these 
studies15,17 have used standardized and psychometrically sound instruments to measure depressive 
symptoms, or whether they did not assess these symptoms at all. In a recent comprehensive review 
on studies mainly investigating patients with hypertension, MI or heart failure, Verbeek et al. (2011) 
conclude that the risk of a beta-blocker induced depression is small and that only in vulnerable 
subpopulations, including patients with a positive personal or family history of depression, one 
should stay vigilant with prescribing certain types of beta-blockers, in particular propranolol.48
 The results of this study should be interpreted with some caution. First, there was a relatively 
large difference between the number of patients who were prescribed beta-blocker therapy and the 
number of patients not using beta-blockers. However, this reflects clinical practice. Second, although 
a difficulty in most of these types of studies, we had no information on compliance rates, so that an 
underestimation of the real taken medication cannot be ruled out. Third, we used a cross-sectional 
study design given that we did not have information about changes in beta-blocker use - including 
type and dose - over time. Hence, we are not able to draw conclusions about cause and effect, and 
long-term effects of beta-blockers on emotional functioning remain unclear. Fourth, we relied on 
self-report measures to assess anxiety and depression rather than a clinical diagnostic interview. 
However, the instruments we used have good psychometric properties, enabling standardized, well-
validated and reliable assessment, and have been frequently used in ICD patients.30-33,35 Moreover, 
we used a disease-specific measure of anxiety, which is generally more sensitive to tap symptoms 
pertinent to patients.49
 In conclusion, we found no association between beta-blocker use and symptoms of anxiety, 
depression and ICD concerns, and thus no evidence that beta-blockers might have an anxiolytic 
effect, nor induce depressive symptoms in ICD patients. Given the major reduction of morbidity and 
mortality associated with beta-blocker therapy, beta-blocker therapy should not be withheld from 
patients. Since anxiety and depression are common problems in ICD patients, which have been 
associated with decreased quality of life,4 and risk of tachyarrhythmias and mortality,34,50 we should 
strive for treatment of both the physical and psychological problems of these patients. Research 
is warranted that further elucidates the link between anxiety and depression and beta-blocker 
therapy in this specific patient group.
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ABSTRACT
Background: Statin therapy is an important secondary prevention measure in cardiovascular 
disease. However, side effects associated with statin use may potentially affect patients’ quality 
of life. Little is known about the influence of statin therapy on the well-being and health status 
of cardiac patients in general, and patients with an implantable cardioverter-defibrillator (ICD) in 
particular. We investigated the association between statin therapy and symptoms of anxiety and 
depression, and patients’ health status during the 12 months after implantation, reckoning with 
statin type and dosage. 
Methods: Consecutively implanted ICD patients (N=409; 78% men) completed the Hospital Anxiety 
and Depression Scale (HADS) and the Short Form Health Survey 36 (SF-36) at baseline, 3, 6, and 
12 months after implantation. Data were analyzed using general linear mixed modeling repeated 
measures multivariable analysis of variance. 
Results: Of the 409 patients, 60% were prescribed statins. Statin use was independently associated 
with poorer role limitations - physical (p=.001), social functioning (p=.007) and role limitations - 
emotional (p=.007) during the 12 months after implantation, independent of statin type, dosage 
and other potential confounders. The associations between statin therapy and depression (p=.06) 
and statin therapy and physical functioning (p=.05) were borderline significant, and no association 
was found with anxiety (p>.05). 
Conclusions: In conclusion, statin therapy was associated with impaired health status on 3 of the 
8 SF-36 health status subdomains. This is the first study in ICD patients to examine the association 
between statin therapy and patient well-being. Future research is warranted to replicate these 
findings. 
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INTRODUCTION
The effect of statin therapy on psychological functioning in patients with cardiovascular disease 
is inconclusive. Some studies have found a link between statin therapy and increased depressive 
symptoms1 and impaired psychomotor and attentional functioning.2 However, statins have also 
been linked to improved psychological functioning, with a decrease in depressive symptoms,3-6 
major depressive disorder (MDD),7 and symptoms of anxiety and hostility.3 Other studies have found 
no association between statin therapy and psychological functioning.8,9 No studies to date have 
examined the association between statin therapy and psychological functioning in ICD patients, nor 
the potential influence of statin type on these outcomes. Lipophilic and hydrophilic statins might 
exert differential effects on psychological functioning, because lipophilic statins are capable of 
crossing the blood-brain barrier, while hydrophilic statins are not.10 Therefore, the aims of this study 
were to investigate (1) the association between statin use and psychological functioning, defined as 
symptoms of anxiety and depression, and patients’ health status, and (2) the impact of specific types 
and dosages of statins on psychological functioning.
METHODS
Patients and study design
Consecutive patients (N=448) implanted with a first-time ICD in the Erasmus Medical Center, 
Rotterdam, the Netherlands, between August 2003 and February 2010, were enrolled in the 
Mood and personality as precipitants of arrhythmia in patients with an Implantable cardioverter 
Defibrillator: A prospective Study (MIDAS). Exclusion criteria were a life-expectancy of <1 year, being 
on the waiting list for heart transplantation, a history of psychiatric illness other than affective/
anxiety disorders, or insufficient knowledge of the Dutch language. The Medical Ethics Committee 
of the Erasmus Medical Center approved the study protocol, and the study was conducted 
according to the Helsinki Declaration. An ICD nurse provided written and oral information on the 
study before ICD implantation to all patients, and all patients provided written informed consent. 
The aim of the present study was part of the broader objective to create a more complete picture of 
the interrelation between ICD patients’ psychological functioning and clinical risk profile.
Measures
Demographic and clinical variables
Patients’ medical records and purpose-designed questions in the questionnaires were used to 
obtain baseline demographic and clinical information. The demographic variables included age, 
gender, marital status and educational level. The clinical variables included indication for ICD 
therapy (primary versus secondary), treatment with cardiac resynchronization therapy (CRT), 
left ventricular ejection fraction (LVEF) ≤35%, QRS duration, mean heart rate, the presence of 
coronary artery disease (CAD), symptomatic heart failure (defined as New York Heart Association 
(NYHA) functional class III+IV), atrial fibrillation, peripheral artery disease (PAD), prior percutaneous 
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coronary intervention (PCI) or coronary artery bypass grafting (CABG), smoking, and use of cardiac 
(i.e. beta-blockers, amiodarone, diuretics, ACE-inhibitors, and digoxin) and psychotropic medication. 
Information with respect to statin use, including the type and dosage, was also collected at baseline. 
Because statin use was stable during the 12 months of follow-up in almost all patients, we used the 
baseline information on statin use for analyses during all follow-up occasions.
Type and dosage of statins
In our cohort, 5 types of statins were prescribed: rosuvastatin, atorvastatin, simvastatin, pravastatin 
and fluvastatin. Because of differences in pharmacological efficacy and potency, we assigned relative 
weights to the different types and calculated a relative dose for each patient. According to the 
literature, the following relative potencies were allocated: fluvastatin, 1; pravastatin, 2; simvastatin, 
4; atorvastatin, 8; and rosuvastatin, 16.11,12 Thus, rosuvastatin is 16 times more potent than fluvastatin 
in the same dosage. Subsequently, the original statin dosage was multiplied by the relative potency 
to obtain a relative dosage for each patient, enabling comparisons among the different statin types. 
Furthermore, a distinction was made between lipophilic (atorvastatin, simvastatin and fluvastatin) 
and hydrophilic (rosuvastatin and pravastatin) statins according to their capacity to penetrate the 
blood-brain barrier to compare the effects of the statin types on patients’ psychological functioning.
Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS), a 14-item self-report questionnaire with 7 items 
measuring anxiety (HADS-A) and 7 items measuring depression (HADS-D),13 was administered 
at baseline, and at 3, 6 and 12 months after implantation. All items are rated on a 4-point Likert 
scale, with scores ranging from 0 to 3 (total score range of 0-21), and higher scores reflecting more 
symptoms.13 The psychometric properties of the HADS are good.14 
Health status
Patients’ health status at baseline, and at 3, 6 and 12 months after implantation was assessed with the 
validated Dutch language version of the Short Form Health Survey 36 (SF-36).15 The questionnaire 
consists of 36 items that contribute to 8 subscales: physical functioning, role limitations - physical, 
bodily pain, social functioning, mental health, role limitations - emotional, vitality and general 
health. Each subscale has a score range from 0 to 100, with higher scores indicating better health 
status.16 The psychometric characteristics of the SF-36 are adequate.15
Statistical analyses
The baseline demographic and clinical variables for patients with versus without statin therapy were 
compared with the χ2 test for nominal variables and the Student’s t-test for continuous variables, 
respectively. To assess the longitudinal association between statin therapy and psychological 
functioning, generalized linear mixed modeling was used. The major advantage of this technique 
is that missing data on 1 measurement occasion do not lead to exclusion of that patient from the 
analyses. Thus, the available data were used optimally. The described effects in the Results section 
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are the relation of statin use at any measurement point with the level of psychological functioning 
over time, including all measurement occasions. We adjusted for variables that have been associated 
with impaired psychological functioning in the published arrhythmia literature, including atrial 
fibrillation,17 symptomatic heart failure,18 CAD,19 diabetes mellitus,20 appropriate and inappropriate 
shocks during follow-up,21 the use of amiodarone18,22 and psychotropic medication,23 and smoking.24 
In addition, we adjusted for variables that were expected to be related to psychological functioning 
or functioning of the cardiovascular system, including age, sex, educational level, PAD, and the 
use of beta-blockers. Statin use, including type and dosage, was set as a fixed variable (i.e. not 
varying over time) after ascertaining the stability of statin use in our data set during the 12-month 
follow-up period. All covariates were also set as fixed variables. The results of the generalized linear 
mixed modeling analyses are presented as estimates with accompanying t- and p-values, and 95% 
confidence intervals (CI). In a secondary analysis, the association between statin type (lipophilic 
versus hydrophilic statins) and psychological functioning was longitudinally assessed with 
generalized linear mixed modeling, adjusting for the same covariates. For all tests, a p-value <.05 
(two sided) was considered significant. Analyses were performed using PASW Statistics 19 statistical 
software (PASW IBM Corp., Armonk, NY, USA).
RESULTS
Patient baseline characteristics
The original patient sample consisted of 448 patients, of whom 39 had missing information on ≥1 
covariates and were therefore automatically excluded from the analyses. Also, 14 patients died 
during the follow-up period. However, owing to the use of this specific statistical technique, all 
obtained measurement occasions until moment of death could be included, leaving 409 patients 
for analyses. We compared the baseline characteristics of the patients included in and excluded 
from the analyses. No significant differences in the demographic and clinical baseline characteristics 
were found between the 2 groups (all p>.05). The general response rate was 96% at baseline and 
81% at 12 months after implantation.
 The baseline demographic and clinical characteristics of the total patient sample and stratified 
by statin therapy are listed in Table 1. Of all patients, 246 (60%) were using statins. The mean age of 
the total study sample was 59±12 years and 78% of the patients were men. The median equivalent 
dosage was 160 mg/day (interquartile range 80-320). During the follow-up period, 59 (14%) patients 
experienced a shock (both appropriate and inappropriate). No difference in the prevalence of 
shocks was found between statin users and non statin users (p=.06). In Figure 1, mean scores of 
anxiety, depression and the 8 health status domains, stratified by statin use, are shown. 
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Table 1. Baseline characteristics for the total study population and stratified by statin use 
Statin therapy
Total (N = 409) Yes (N = 246) No (N = 163) p
Variable
Mean age (±SD) (years) 58.5 (12.2) 61.6 (9.0) 53.8 (14.6) <.001
Men 320 (78%) 213 (87%) 107 (66%) <.001
Single/no partner 26 (6%) 13 (5%) 13 (8%) .28
Lower education * 234 (58%) 143 (59%) 91 (57%) .68
Primary prevention indication 141 (35%) 86 (35%) 55 (34%) .80
CRT 113 (28%) 80 (33%) 33 (20%) .007
LVEF ≤35% † 305 (86%) 197 (88%) 108 (84%) .32
Mean QRS (±SD) 130.2 (36.4) 132.9 (34.7) 126.0 (38.6) .06
CAD 236 (58%) 205 (83%) 31 (19%) <.001
PAD 29 (7%) 25 (10%) 4 (3%) .003
Previous PCI 107 (26%) 95 (39%) 12 (7%) <.001
Previous CABG 85 (21%) 77 (31%) 8 (5%) <.001
Symptomatic heart failure † 133 (33%) 81 (33%) 52 (32%) .83
Atrial fibrillation 91 (22%) 50 (20%) 41 (25%) .25
Diabetes 59 (14%) 48 (20%) 11 (7%) <.001
Smoking † 44 (11%) 23 (9%) 21 (13%) .26
Mean heart rate 68.2 (13.4) 68.7 (14.1) 67.5 (12.2) .40
Amiodarone use 76 (19%) 43 (18%) 33 (20%) .48
Beta-blocker use 325 (80%) 219 (89%) 106 (65%) <.001
Diuretics use 232 (57%) 151 (61%) 81 (50%) .019
ACE-inhibitors use 293 (72%) 195 (79%) 98 (60%) <.001
Digoxin use 63 (15%) 34 (14%) 29 (18%) .28
Psychotropic medication use 67 (16%) 38 (15%) 29 (18%) .53
* Education ≤13 years; † defined as NYHA functional class III+IV. Abbreviations: CABG, coronary artery bypass 
grafting; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection 
fraction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention
The association between statin use and emotional distress
We separately assessed the relation between statin use and the individual psychological measures. 
Overall, anxiety, depression and health status significantly improved between baseline and 3 months 
after implantation (all p<.001) and remained stable between 3 and 12 months after implantation. 
In the unadjusted analyses, statin use was significantly associated with increased depressive 
symptoms (p=.024), and with impaired health status on the domains physical functioning (p=.001), 
role limitations - physical (p<.001), social functioning (p=.005), role limitations - emotional (p=.001) 
and general health (p=.039). No association was found between statin use and symptoms of anxiety, 
and the health status domains bodily pain, mental health, and vitality.
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Table 2. Longitudinal association between statin therapy and anxiety, depression and health status (adjusted 
analysis)*
Estimate t p 95% CI
Psychological distress
Anxiety -0.81 -1.60 .11 -1.80 – 0.18
Depression -0.97 -1.87 .06 -1.99 – 0.05
SF-36 subdomains
Physical functioning 6.42 1.93 .05 -0.11 – 12.94
Role limitations – physical 18.02 3.33 .001 7.40 – 28.64
Bodily pain 4.31 1.34 .18 -2.03 – 10.65
Social functioning 8.11 2.68 .008 2.16 – 14.07
Mental health 2.36 0.96 .34 -2.46 – 7.19
Role limitations – emotional 14.26 2.87 .004 4.49 – 24.03
Vitality 4.81 1.74 .08 -0.64 – 10.25
General health 4.06 1.34 .18 -1.89 – 10.01
Abbreviations: CI, confidence interval; SF-36, Short Form Health Survey 36. * Statin users were the reference 
group. Adjusted for gender, age, educational level, indication for ICD therapy, occurrence of shocks (both 
appropriate and inappropriate) during 12 months after implantation, coronary artery disease, symptomatic 
heart failure, atrial fibrillation, diabetes mellitus, peripheral arterial disease, smoking, the use of amiodarone, 
beta-blockers, and psychotropic medication
Results of the adjusted analyses are listed in Table 2. After adjusting for demographic and clinical 
covariates, the association between statin use and depressive symptoms (p=.06) and between 
statin use and impaired physical functioning (p=.05) was reduced to borderline significance, and 
the association between statin use and general health was no longer statistically significant. Statin 
use remained significantly related to role limitations - physical (p=.001), impaired social functioning 
(p=.007) and role limitations - emotional (p=.006). Just as in the unadjusted analyses, statin use was 
still not related to anxiety, bodily pain, mental health, or vitality.
 A significant time by group interaction effect was seen between the measurements at baseline 
and 3 months after implantation, with non statin users experiencing a greater reduction in 
depressive symptoms (from baseline to 3 months follow-up, an extra improvement on the scale 
of 0.86 points reflected by the estimate (e)=0.86; p=.009), and a larger improvement in physical 
functioning (e=6.34; p=.019), role limitations - physical (e=16.54; p=.001), social functioning 
(e=10.82; p=.001), mental health, (e=3.98; p=.039), role limitations - emotional (e=16.28; p.002), and 
vitality (e=4.75; p=.030) than statin users during this 3-month period. In addition, non statin users 
improved significantly more on role limitations - physical from 3 to 6 months after implantation 
(e=11.55; p=.007), and in physical functioning (e=4.72; p=.010) and general health (e=3.18; p=.048) 
from 6 to 12 months after implantation. The most important other associates of poor psychological 
functioning were the use of psychotropic medication, symptomatic heart failure, the occurrence of 
shocks during follow-up, and lower education (results not shown).
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 With respect to the second aim of our study, we compared psychological functioning of 
patients using different types of statins, reckoning with the relative dosage of each statin type. The 
number of patients using the different statin types is displayed in Figure 2. We found no significant 
relation between statin type and psychological functioning after adjusting for the relative statin 
dosage. Dichotomizing statin type into lipophilic versus hydrophilic also did not result in significant 
differences in psychological functioning.  








1 = Pravastatin (H)
2 = Rosuvastatin (H)
3 = Simvastatin (L)
4 = Atorvastatin (L)















Figure 2. Statin prescription pattern stratified by type *
* H = Hydrophilic; L = Lipophilic
DISCUSSION
This is the first study to investigate the association between statin use and symptoms of anxiety 
and depression, and health status in patients with an ICD. We found that patients using statins had 
an impaired health status with respect to the role limitations - physical, social functioning, and role 
limitations - emotional domains of the SF-36, independent of the type and dosage of statin and 
other potential demographic and clinical confounders. Patients receiving statin therapy differed 
systematically on some baseline characteristics from non statin users and had more advanced 
disease. Thus, this subset of patients constitutes a group that warrants particular attention, given 
their increased risk of poor health status. 
 Attention to the impact of drug therapy on psychological functioning is important, because 
patients’ functioning and quality of life can be impaired due to side effects. In ICD patients, this is 
particularly important, because these patients often use anti-arrhythmic agents, such as amiodarone, 
together with statin therapy. These drugs can interact with each other, increasing the risk of severe 
or hampering side effects,22,25 Examination of the patient’s tolerance for specific types and dosages 
and closer monitoring during follow-up might reduce the possible burden that patients experience.
Several studies have investigated the relation between statin use and psychological functioning, 
with mixed results. Depression in particular has been the target of investigation, with a number of 
studies reporting improved depressive mood in patients using statins,3-5,7 other studies reporting 
worse psychological functioning,1,2 and still other studies not finding any significant associations.8,9 
Comparing these studies is difficult owing to differences in methodological design, study samples (i.e. 
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general population versus patients with established heart disease), statin types, and psychological 
measures. In addition, several studies included a relatively low number of patients using statins6 or 
reported a low prevalence of depression.4,7 Future research should include larger sample sizes, and 
compare the influence of types matched by means of a daily equivalent dosage, as we were not 
able to demonstrate a significant relationship between statin type and psychological functioning, 
probably due to the small number of patients using pravastatin, rosuvastatin and fluvastatin. In 
addition, future research should focus on a broader spectrum of psychological measures, because 
depression has been the main focus of investigation so far.
 We found no association between statin use and anxiety. However, the type of impairments in 
patients with side effects might more easily induce depressive rather than anxious symptoms, by 
interfering with the patient’s physical activity level and social relations, possibly inducing feelings 
of hopelessness and guilt. This pattern corresponds more with depressive rather than anxious 
symptomatology, and is also reflected by the trend that we found for the relation between statin 
use and depressive symptoms.
 The results of this study should be interpreted in the light of the following limitations. First, 
we had no information on compliance with prescribed statin therapy, although compliance with 
statins has proven to be better than compliance with other cardiac medications.26 Second, because 
information on serum cholesterol levels was lacking in a considerable number of patients, we did 
not include serum cholesterol as a covariate in adjusted analyses. However, previous results have 
shown that baseline cholesterol levels had no influence on the relation between statin use and 
psychological functioning.3 Third, we did not have a clear picture of the differences in psychological 
functioning between statin users and non statin users before to ICD implantation. However, we have 
presumed a relatively stable difference in psychological functioning between statin and non statin 
users both before and after implantation, with a short-term decrease in psychological functioning 
around implantation for both statin and non statin users.
 Strengths of the present study included the prospective, repeated measures design, the high 
response rate, and the use of generalized linear mixed modeling which is the latest statistical 
approach for analyzing prospective data with repeated measures. In addition, we had detailed 
information on the patients’ baseline demographic and clinical characteristics.
 Additional research is warranted to replicate these findings, because, to our knowledge, this is 
the first study in ICD patients to examine the association between statin therapy and psychological 
functioning. In the clinical management and care of ICD patients, it is important to be aware of the 
potential influence of statin therapy on health status, and to discuss this with patients, because 
decreased psychological functioning is negatively associated with medication adherence.
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ABSTRACT
Background: We investigated the relationship between Type D personality, depression and anxiety, 
and heart rate variability (HRV) in 64 patients with an implantable cardioverter-defibrillator (ICD). 
Methods: HRV was obtained via 24-hour Holter monitoring, and 24-hour, 30 minutes daytime rest 
and 30 minutes nighttime sleep HRV were analyzed. 
Results: In adjusted analyses, significant associations (standard deviation of normal-to-normal (NN) 
intervals (SDNN): p=.043 and standard deviation of NN intervals over 5-minute periods (SDANN): 
p=.010) and a trend (HRV triangular index: p=.09) were found for Type D personality, and trends 
were found for depression (lower root mean square of successive differences in NN intervals 
(RMSSD): p=.10 and lower proportion of NN intervals deviating >50 ms from the preceding interval 
(pNN50): p=.09). During daytime rest, similar results were found for anxiety and depression. During 
nighttime sleep, only noteworthy adjusted associations were found for depression (lower RMSSD: 
p=.06; lower pNN50=.043). A Benjamini-Hochberg correction for multiple testing lead to reduction 
of the number of significant relationships, but there was still support for lower autonomic control 
patients with Type D personality and depression. 
Conclusions: A shift towards sympathetic dominance and reduced vagal activity was observed in 
ICD patients with emotional distress. This may trigger the development of ventricular tachycardia, 
resulting in a poorer prognosis. Future research with larger sample sizes is warranted.
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INTRODUCTION
Patients with an implantable cardioverter-defibrillator (ICD) constitute a high-risk group in terms 
of emotional distress, with prevalence rates of 20-35% for symptoms of anxiety and depression1,2 
and 20-30% for the distressed personality type (Type D),3 reflecting  the combined tendency to 
experience a wide range of negative emotions, while inhibiting the expression of these emotions in 
social contexts.4 Anxiety appears to be particularly important in ICD patients, due to the potential of 
the device to provide uncontrollable and often unpredictable shocks.1
 Emotional distress including depression and anxiety, as well as more stable personality traits such 
as Type D, have been associated with cardiac events and poor prognosis in both persons without7 
and patients with cardiac diseases.3,5,6 In both patients with coronary artery disease (CAD) and 
patients with an ICD, emotional distress is known to increase the risk of ventricular arrhythmias8,9 
and mortality,10,11 independent of traditional biomedical risk factors. In heart failure patients and 
patients who were treated with percutaneous coronary intervention (PCI) though, null findings have 
been reported for the association of Type D personality and depression with mortality as well.12-14
 We know little about the mechanisms that may explain the association between emotional 
distress and worse prognosis in ICD patients. One potential mechanism involves the autonomic 
nervous system, which may be deregulated in patients with an ICD.15 Heart rate variability (HRV) is a 
widely used noninvasive measure reflecting the autonomic regulation of the heart,16 and is measured 
by beat-to-beat changes in heart rate.17 Reduced HRV (i.e. increased sympathetic and/or decreased 
parasympathetic activity) is a well-known predictor of cardiac mortality, including sudden cardiac 
death due to ventricular fibrillation, in post myocardial infarction patients.18,19 Hence, HRV might be 
an important explaining mechanism of the relationship between emotional distress and prognosis. 
In the general cardiac population, there is evidence to suggest that HRV is decreased in patients 
with clinical levels of depression20 and anxiety21 as compared to patients without emotional distress. 
However, to date, only one study has investigated the relationship between emotional distress and 
HRV in ICD patients,22 and evidence on the association between Type D personality and HRV is only 
present in non-medical samples, reporting absence of a relationship23 and, in contrast, a reduced 
HRV in European-Americans with Type D personality.24
 As this merits further examination, the purpose of our study was to investigate the relationship 
between psychological risk factors that have been demonstrated to be associated with increased risk 
of ventricular tachyarrhythmias and mortality25 and HRV, with a specific focus on Type D personality, 
depression and ICD related anxiety.
METHODS
Patients and study design
A subset of 79 patients from the prospective Mood and personality as precipitants of arrhythmia in 
patients with an Implantable cardioverter Defibrillator: A prospective Study (MIDAS) comprised the 
current sample. Information on the MIDAS study, its design and patient inclusion has been described 
previously.26 This subset of patients received a Holter monitor 10 days after implantation during a 
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scheduled wound healing control visit to measure 24-hour HRV. HRV measurement was planned 10 
days post implantation so that patients would not be burdened directly after implantation. After 
excluding incomplete cases with respect to information on HRV and psychological risk factors, 64 
patients were available for statistical analyses when examining the relationship between Type D 
personality and HRV, and 63 patients when examining the association between depression and 
HRV, and ICD concerns and HRV. A flow chart of the patient selection is displayed in Figure 1. The 
Medical Ethics Committee of the Erasmus Medical Center, the Netherlands approved the study 
protocol and the study was conducted according to the Helsinki Declaration. An ICD nurse provided 
oral and written information regarding the study while patients were admitted to the hospital. At 
10 days post implantation, instructions about the Holter monitor (i.e. that being hooked up to the 
Holter monitor would not interfere with the therapy given by the ICD and vice versa) were provided. 
Patients were asked to complete a set of standardized and validated questionnaires at 10 days post 
implantation. Before participation in the study, all patients provided written informed consent.
Measures
Demographic and clinical variables
Information on demographic and clinical characteristics was obtained from patients’ medical records 
at baseline (i.e. the time of implantation) and purpose-designed questions in the questionnaires 
at 10 days post implantation. Demographic variables included age, gender, marital status and 
educational level. Clinical variables included indication for ICD therapy (primary versus secondary 
prevention), treatment with cardiac resynchronization therapy (CRT), left ventricular ejection 
fraction (LVEF) ≤35%, QRS duration, the presence of CAD, symptomatic heart failure (defined as New 
York Heart Association (NYHA) functional class III+IV), atrial fibrillation, prior PCI or coronary artery 
bypass grafting (CABG), smoking, and use of cardiac (i.e. beta-blockers, statins, amiodarone, diuretics, 
angiotensin-converting enzyme (ACE)-inhibitors, and digoxin) and psychotropic medication. 
Heart rate variability
Heart rate variability (HRV) was measured via 24-hour Holter monitoring from a 7-lead configuration. 
A sampling rate of 1440 Hz was used to digitize electrocardiogram (ECG) data. Computer software 
(Holter LX® Analysis Pro Software, NorthEast Monitoring, Maynard, MA, USA) was used to scan 
for rhythm disturbances (of both ventricular and atrial origin) and to detect and label each QRS 
complex. All ECG recordings were processed by a qualified Holter analyst, who was not otherwise 
involved in the study. Holter recordings with >100/h premature ventricular contractions (PVCs) were 
excluded from analyses (N=12). Rhythm disturbances were discarded automatically by the computer 
program. On average, 75 of the 82 recordings (91%) contained normal sinus rhythm, which was then 
used to calculate the HRV measures. Only non-paced means of HRV measures were used in order to 
create a clear picture of pure autonomic functioning independent of pacemaker action.
 The following time domain measures were used as a measure of HRV: the standard deviation of 
all normal-to-normal (NN) intervals (SDNN) and the HRV triangular index, both reflecting overall 
variability in heart rate (HR), the standard deviation of the average NN interval calculated over 
        
Emotional distress and heart rate variability   |   83
5-minute periods (SDANN), as an estimate of long-term components of HRV, and the proportion of 
NN intervals deviating >50 ms from the preceding interval (pNN50), a measure of parasympathetic 
activity of the heart. Finally, the root mean square of successive differences in NN intervals (RMSSD) 
was calculated, which reflects parasympathetic efferent activity to the heart.27 
Information on activity levels during the monitoring period
In order to capture HRV during resting activity and sleep, patients completed an activity diary. In 
this diary, patients registered two 30-minute periods of resting activity, such as reading or watching 
television. In addition, the time of going to bed and waking up were recorded. The diary enabled 
comparison between HRV of the overall 24-hour period and HRV during resting and night-time 
sleep. Potential noise, including noise from physical activity, was minimized during the resting and 
nighttime sleep HRV measurement occasions. During nighttime sleep, a 30-minute period was 
selected between 2.00 am and 3.00 am to calculate HRV variables. On average, this period was 3 
hours after going to bed, hereby avoiding interfering mechanisms associated with falling asleep and 
waking up. Data consisted of 6 5-minute intervals for each separate resting activity and 6 5-minute 
intervals during sleep that were combined into one mean value for SDNN, RMSSD and pNN50, both 
for resting activity and nighttime sleep.
Type D personality
Type D was measured at baseline with the 14 item Type D Scale (DS14), with items rated on a 5-point 
Likert scale from 0 to 4. The DS14 is composed of a 7-item negative affectivity (NA) and a 7-item 
social inhibition (SI) subscale, both with a total score range from 0 to 28. Patients with a score of 
³10 on both subscales were defined as having a Type D personality, which has been defined as 
the best cut-off using item response therapy.4,28 With Cronbach’s alphas of 0.88 and 0.86 for NA 
and SI, respectively, the DS14 has shown to be a valid and internally consistent measure which is 
stable over time.4 Type D is not confounded by indicators of disease severity, such as left ventricular 
ejection fraction.29
Depression
The Hospital Anxiety and Depression Scale (HADS) was used to measure depressive symptoms.30 The 
HADS is a 14-item self-report questionnaire consisting of 7 items measuring symptoms of anxiety 
(HADS-A) (not used in the current study) and 7 items measuring symptoms of depression (HADS-D). 
A 4-point Likert scale is used to rate the items, with scores ranging from 0 to 3 (total score range 
of 0-21) and higher scores reflecting more symptoms. The psychometric properties of the HADS 
are good, with mean Cronbach’s alphas of 0.83 and 0.82 for the HADS-A and HADS-D subscales, 
respectively.31,32 The HADS is a valid instrument for measuring separate symptoms of anxiety and 
depression in a non psychiatric hospital setting.31,32  
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ICD concerns
Patients’ concerns related to their ICD were measured with the 8-item ICD Patient Concerns 
questionnaire (ICDC),33 a disease-specific anxiety questionnaire originally developed in the United 
Kingdom,34 abbreviated and validated for the Dutch setting.33 Items are rated on a 5-point Likert 
scale from 0 (not at all) to 4 (very much so). All items are summed to a total score with a maximum of 
32, with a higher score reflecting more ICD concerns.33 The internal consistency of the ICDC is good, 
with a Cronbach’s alpha of 0.91.33 
Statistical analyses
HRV distributions were examined for outliers. Values >3 standard deviations (SD) from the mean 
and exceeding the plausible range proposed by the HRV Task Force,17 were not included in analyses. 
With respect to the 10 24-hour HRV measures, 4 patients had one or more outlying values (N
values
=9). 
Regarding the HRV measures during resting activity, 7 patients had one or more outlying values 
(N
values
=25) and for the HRV measures during sleep, 4 patients had one or more outlying values 
(N
values
=22). HRV distributions were examined for normality via skewness and Shapiro-Wilk tests. As 
none of the HRV variables were normally distributed, natural log (ln) transformation was performed. 
 Baseline demographic and clinical variables for patients with complete versus incomplete data 
were compared with the χ2 test (Fisher’s Exact test when appropriate) for nominal variables and 
Student’s t-test for continuous variables, respectively. Baseline demographic and clinical variables 
for patients with emotional distress (i.e. Type D personality and the presence of clinically significant 
levels of depression and ICD concerns as determined by frequently used cut-off scores of ≥8 for 
depression32 and ≥13 for ICD concerns3 were also compared with the χ2 test (Fisher’s Exact test when 
appropriate) for nominal variables and Student’s t-test for continuous variables, respectively. The 
relationship between the psychological measures and HRV was assessed with linear regression 
analyses using the natural log transformed HRV measures. Results of these analyses are presented 
as standardized β-coefficients with accompanying p-values, and effect sizes (f2) as indicators of the 
strength of the associations. Analyses for Type D personality were repeated using the continuous 
subscales NA and SI and their interaction, and results were compared with the dichotomous 
measure of Type D personality. 
 In multivariable analyses, we adjusted for age, rhythm control by CRT-D, the use of beta-blockers, 
and the use of psychotropic medication, as these covariates are known to influence HRV.35-38 As beta-
blockers mainly act on ventricular receptors controlled by the sympathetic nervous system, beta-
blocker use was omitted as a covariate in the analyses of the parasympathetic and non-autonomic 
nervous system HRV measures, to preserve statistical power. For all tests, a p-value of <.05 (two-
sided) was considered significant.
 We decided to report a correction for multiple testing in addition to the regular results. It is 
important to acknowledge that we are dealing with multiple, dependent comparisons in the current 
study, as the outcome variables are all part of the same biological regulatory system. A simple 
Bonferroni correction would therefore not suffice and would lead to an increase of false negatives. 
Instead, we followed the Benjamini-Hochberg procedure, which controls for the false discovery 
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rate.39 Following this procedure, the individual p-values were put in order from smallest to largest. 
The smallest p-value was ranked as i=1, the next p-value as i=2, etc. Each individual p-value was 
then compared to (i/m)*Q, with m=the total number of tests and Q=the chosen false discovery 
rate, which was set at Q=.05 according to common guidelines. If p<(i/m)*Q, the result is regarded 
significant, controlled for the false discovery rate.39 All statistical analyses were performed using 
PASW Statistics 19 statistical software (PASW IBM Corp., Armonk, NY, USA).  
 
Patients with HRV data 10 days 
post implantation [N=79]  
PVCs >100/h or data 
PVCs >100/h missing [N=12] 
Patients with accurate 
HRV data [N=67]  
Data Type D missing [N=3] 
Data depression missing [N=4] 
Data ICD concerns missing [N=4] 
Analyses Type D [N=64]
Analyses depression [N=63] 
Analyses ICD concerns [N=63]  
Figure 1. Flow chart of patient inclusion in the analyses
Abbreviations: h, hour; HR, heart rate; HRV, heart rate variability; ICD, implantable cardioverter-defibrillator; N, 
number; PVCs, premature ventricular contractions
RESULTS
Patient baseline characteristics
Patients included in and patients excluded from analyses were compared on baseline characteristics. 
Excluded patients were less likely to have a LVEF ≤35% (p=.048) and use psychotropic medication 
(p=.035). No other systematic differences were found between these 2 groups.
 Baseline demographic and clinical characteristics of the total patient sample are displayed in 
Table 1. The mean age was 58±13 years, and 83% of the patients (N=53) were male. In total, 23% 
(N=15) were classified as having a Type D personality. Mean depression score was 3.3±3.2, mean 
ICD concerns score was 8.0±7.4. Mean values for the original, non-transformed HRV measures are 
displayed in Table 2. 
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Mean age (±SD) (years) 52.78 (13.4)
Men 53 (82.8%)
Single/no partner † 4 (6.3%)
Lower education †‡ 35 (55.6%)
Clinical factors
Primary prevention indication 13 (81.2%)
CRT 113 (20.3%)
LVEF ≤35% § 54 (91.5%)
Mean QRS (±SD) 130.39 (35.3)
CAD 35 (54.7%)
Previous PCI 17 (26.6%)
Previous CABG 8 (12.5%)
Symptomatic heart failure # 17 (26.6%)
Atrial fibrillation 7 (10.9%)
Diabetes 9 (14.1%)
Smoking † 6 (9.5%)







Psychotropic medication † 15 (23.8%)
* Data are presented as N (%), unless otherwise indicated. Abbreviations: ACE, angiotensin-converting enzyme; 
CABG, coronary artery bypass grafting; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; 
LVEF, left ventricular ejection fraction; N, number; PCI, percutaneous coronary intervention; QRS, QRS duration; 
SD, standard deviation. † 1 (1.6%) missing; ‡ education less than or equal to 13 years; § 5 (7.8%) missing; # 
defined as NYHA functional class III+IV.
 When comparing demographic and clinical baseline characteristics of patients with versus 
without emotional distress (i.e. Type D personality, and clinically significant symptoms of depression 
and ICD concerns), we found that patients with emotional distress significantly more often used 
psychotropic medication (Type D personality: p=.017; depression: p=.002; ICD concerns: p=.037). 
In addition, we found that patients with depression more often suffered from symptomatic heart 
failure (p=.048) and had a higher heart rate (p=.030). No other systematic differences were found 
between patients with versus without emotional distress. 
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Table 2. Mean values (SD) of heart rate variability components over 24 hours, resting activity and sleep (N=64) *
Time domain measures Frequency domain measures
24 hours
SDNN (ms) 103.86 (35.73) Total power (ms2) †‡ 0.13 (0.12)
SDANN (ms) 82.44 (30.59) VLF (ms2) ‡ 0.09 (0.09)
pNN50 (%)† 6.65 (7.66) LF(ms2) ‡§ 0.04 (0.03)
RMSSD † 29.78 (14.48) Hf (ms2) ‡ 0.02 (0.03)
HRV triangular index 26.35 (9.77) LF/HF ratio # 4.31 (3.12)
Resting activity
SDNN (ms) || 40.72 (19.21)
pNN50 (%) 25.79 (14.19)
RMSSD || 5.67 (7.74)
Sleep
SDNN (ms) ‡ 45.00 (23.90)
pNN50 (%) ** 25.69 (13.29)
RMSSD ‡ 6.33 (8.04)
* For descriptive purposes, the original, non transformed values for each HRV measure are mentioned. 
† 2 outliers (3.1%); ‡ 7 missing (10.9%); § 3 outliers (4.7%); # 6 missing (9.4%); || 14 missing (21.9%); ** 15 missing 
(23.4%). Abbreviations: HF, high frequency; HRV, heart rate variability; LF, low frequency; N, number; NN; normal-
to-normal intervals; pNN50, proportion of the total number of successive NN intervals greater than 50 ms; 
RMSDD, square root of the mean squared difference of successive NN intervals; SDANN, standard deviation of 
the average NN interval; SDNN, standard deviation of the NN interval; VLF, very low frequency
Association between emotional distress and HRV over 24 hours
 Type D personality - In unadjusted analyses, Type D personality was associated with lower overall 
autonomic control, as reflected by lower levels of SDNN (p=.014), SDANN (p=.004) and HRV triangular 
index (p=.016) (Table 3). When adjusting for the selected covariates, the association between Type D 
personality and SDNN (p=.043) and SDANN (p=.010) remained significant, and the relation with HRV 
triangular index (p=.09) was reduced to trend level. No significant relationships were found between 
Type D personality and the other HRV measures, although a trend was observed for patients with 
a Type D personality to show a reduced parasympathetic control as measured by a lower pNN50 
(p=.08). 
 Results from the analyses including the continuous subscales were comparable to those using 
the dichotomous Type D classification for the NA x SI interaction term (unadjusted analyses: SDNN: 
β=0.63, p=.10; SDANN: β=0.61, p=.11; HRV triangular index: β=0.66; p=.08, all other HRV measures: 
p>.15). No significant associations were found between the individual subscales of the DS14 and 
HRV. Effect sizes regarding the association between Type D personality and HRV measures were 
small to medium, range f2 [0.01-0.13] in adjusted analyses.
 Depression - In unadjusted analyses, depression was only associated with lower pNN50 (p=.050), 
that is, decreased parasympathetic cardiac control. This association was reduced to trend level in 
adjusted analyses (p=.09). Depression was also related to lower RMSSD values on a trend level in 
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both unadjusted (p=.09) and adjusted (p=.10) analyses. Effect sizes with respect to these associations 
were small, range f2 [0.00-0.06] in adjusted analyses.
 ICD concerns - Analogous to Type D personality, a higher level of ICD concerns was related to 
lower overall autonomic cardiac control, reflected by a lower SDNN (p=.033), SDANN (p=.030) and 
HRV triangular index (p=.027). However, these associations became borderline (SDANN: p=.10) or 
non-significant in adjusted analyses. ICD concerns were not associated with other HRV measures 
in this sample. Small effect sizes, range f2 [0.00-0.05] in adjusted analyses, were found for the 
relationship between ICD concerns and HRV.
   
Association between emotional distress and HRV during resting activity and sleep
In Table 4, results of the unadjusted and adjusted analyses on the relationship between emotional 
distress and HRV during resting activity and sleep are displayed. 
 Type D personality - Type D personality was associated with a lower overall autonomic control 
during the 30-minute resting activity as reflected by significant lower SDNN in unadjusted (p=.026) 
analysis. In addition, parasympathetic cardiac control was decreased, reflected by a lower pNN50 
(p=.023). When adjusting for relevant covariates, we found a trend for the relationship between Type 
D personality and overall autonomic control (p=.08) with a small to medium effect size, while the 
association between Type D personality and lower parasympathetic control remained significant 
(p=.028), again with a small to medium effect size, range f2 [0.01-0.12] in adjusted analyses. No 
significant relationships were found between Type D personality and HRV during sleep. 
 Depression - In unadjusted analysis of the resting activity data, a significant association was 
found between depressive symptoms and lower parasympathetic control (pNN50: p=.033). This 
relationship remained significant in adjusted analysis (p=.006) with a medium to large effect size 
(f2=0.22 in adjusted analyses). The relationship between depression and lower RMSSD (p=.08) 
became borderline significant in adjusted analysis. The use of psychotropic medication largely 
accounted for this effect. During sleep, pNN50 was significantly decreased in patients with more 
depressive symptoms (p=.043), which was supported by a small to medium effect size. Furthermore, 
we found a trend for a lower RMSSD in patients with depressive symptoms (p=.06) in adjusted 
analysis, both indicative of decreased parasympathetic control. Again, the use of psychotropic 
medication largely accounted for this effect.
 ICD-concerns - No significant associations were found between ICD concerns and HRV, neither in 
unadjusted or adjusted analyses, nor during resting activity nor during sleep. Effect sizes regarding 
these associations were rather small, range f2 [0.00-0.04] in adjusted analyses.
The Benjamini-Hochberg correction
After applying the Benjamini Hochberg correction (see the formula in Tables 3 and 4), the association 
between Type D personality and SDNN remained significant regarding 24-hour HRV in unadjusted 
analysis.  In addition, trends were found for the relation between Type D personality and 24-hour 
SDNN and HRV triangular index, also in unadjusted analysis. 
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With respect to HRV measured during resting activity, the relation between Type D personality 
and SDNN remained significant after correction for the false positive rate in unadjusted analysis, as 
well as the association between depression and pNN50 in adjusted analysis. During sleep, the only 
significant association and association on a trend level between depression and RMSSD and pNN50 
respectively, became non-significant after the Benjamini-Hochberg correction (see Table 4).
DISCUSSION
The current study examined the association between emotional distress (i.e. Type D personality, 
depression and patient ICD concerns) and time and frequency measures of HRV in a subsample 
of a consecutive cohort of patients with an ICD. Results demonstrated that Type D personality was 
independently associated with lower overall autonomic control over the 24-hour period and lower 
parasympathetic cardiac control during rest. We found trends for depression being associated with 
decreased parasympathetic functioning during rest and over the 24-hour period, and a trend for 
ICD related concerns to be associated with decreased overall autonomic control over 24 hours. After 
applying the Benjamini-Hochberg correction, adjusting for the false discovery rate, we only found 
a strong indication for Type D personality being related to a lower 24-hour SDANN in unadjusted 
analysis, to lower SDNN during resting activity in unadjusted analysis and for depression to be 
associated with lower pNN50 in adjusted analysis.
 When comparing the results of the 24-hour measurement and the measurements during resting 
activity and sleep, largely similar findings were revealed with respect to Type D personality. An 
even more pronounced decline of parasympathetic control in Type D patients was detected when 
patients performed a resting activity when compared to the 24-hour measurement. The relationship 
between depression and decreased parasympathetic control was also more clearly manifested 
during the resting activity and sleep measurements, indicating an inability of the parasympathetic 
nervous system to recover during rest in patients with a Type D personality and/or depressive 
symptomatology. In contrast, the relationship between ICD concerns and HRV was only visible 
during the 24-hour measurement, and only with respect to overall HRV measures.
 When comparing the different types of distress, ICD concerns may be identified as a specific 
type of anxiety, while Type D personality and depression are mood related types of distress. In more 
detail, several items of the ICD Patient Concerns questionnaire specifically examine ICD patients’ 
anxiety related to engaging in active behavior. Anxiety is associated with symptoms of arousal and 
therefore with sympathetic control, explaining why we only found significant decreases in HRV for 
the 24-hour, sympathetic driven HRV-measures. Although we do not have data of pure sympathetic 
HRV measures to support this hypothesis, this may imply that the arousal response in patients 
with increased levels of ICD concerns may be stronger than in patients with lower levels of ICD 
concerns. The mental association between becoming active and fear for the ICD firing may result in 
physiological arousal and sympathetic activation in patients with increased levels of ICD concerns 
which is only visible during 24-hour measurement with periods of active behavior.
 Overall autonomic and parasympathetic control were the HRV indices most likely to be 
associated with emotional distress in our patients. This corresponds to results of Francis et al. (2009), 
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who found a reduced parasympathetic control as measured by a lower RMSSD and pNN50 in ICD 
patients with elevated depressive symptoms,22 and to findings in patients who were treated with 
PCI, also pointing towards lower parasympathetic control in patients with depressive and anxious 
symptomatology.40 Only a few studies have examined the relation between HRV and Type D 
personality, looking at healthy adults and only taking frequency measures of HRV into account. 
These studies demonstrated that during rest there were no differences in HF and LF HRV, which was 
confirmed in the current study.7,24
 The question remains how the relationship between emotional distress and disturbed autonomic 
functioning may be facilitated. According to the psychophysiological reactivity model of Lovallo 
and Gerin (2003), responses to psychological stress that contribute to cardiovascular reactivity take 
place on three levels. The cortical and limbic systems facilitate cognitive-emotional responses (level 
I), the hypothalamus and brainstem support autonomic and endocrine outputs in response to stress 
(level II), and on the peripheral level altered tissue function may influence stress reactivity (level 
III).41 Level I reactivity has also been described as temperament, with personal habitual response 
style being linked to physiological response disposition.41 People with higher levels of negative 
affectivity for example have shown to de-activate their limbic system, including the amygdala and 
hippocampus, while facing threatening stimuli, whereas people with high levels of social inhibition 
tend to over-activate brain areas related to decision making and action goals.42 These higher level 
cognitive-emotional processes control autonomic response patterns (level II), including activity 
of the hypothalamus-pituitary-adrenocortical axis and the secretion of neurotransmitters such as 
serotonin. Recent studies have shown an improvement in HRV in cardiac patients using selective 
serotonin reuptake inhibitors (SSRIs).43 With serotonin acting as an inhibitor of the sympathetic 
branch of the autonomic nervous system, autonomic dysregulation may be centrally modulated by 
serotonergic pathways in the brain, which are affected in patients with emotional distress. The role 
of psychotropic medication in relation to HRV should be investigated further, as available results 
are inconclusive.43,44 Level II reactions are interrelated with peripheral tissue reactions (level III) that 
could impact on the development of cardiovascular disease. An example of this is oxidative stress, 
which is increased in chronic heart failure patients with a Type D personality.45 
 Moreover, behavioral mechanisms could also play a role. In a broader context, patients with 
emotional distress are known to be at higher risk for unhealthy lifestyle patterns, including reduced 
physical activity and smoking. Reduced levels of physical activity are related to impaired autonomic 
balance in terms of increased sympathetic and decreased parasympathetic tone.46 Smoking results 
in similarly disturbed autonomic functioning.47 Further studies on these explanatory behavioral 
pathways are warranted.
 Associations between Type D personality and HRV measures tended to be stronger than 
associations of respectively depression and ICD concerns with HRV, as we found only significant 
adjusted results for Type D personality. This may be due to the fact that Type D personality is a 
more stable patient characteristic than symptoms of depression and anxiety and thus shows a more 
consequent and long term association with the autonomic nervous system. Additionally, previous 
research has shown that negative affectivity, one of the components of Type D personality, may 
be a combining element, linking individual negative emotions such as depression and anxiety, 
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to impaired autonomic control.48,49 Our findings correspond to those of Rottenberg (2007), who 
finds small to medium effect sizes with respect to the relationship between depression and 
cardiac vagal control in a meta-analysis.50 Future research should focus on specific subtypes of 
emotional distress, for example depression, in relation to autonomic functioning. In addition, other 
biomarkers of emotional distress could be included in future research, as the picture of the complex 
interrelationship between emotional distress and autonomic functioning will be more complete 
when mapping HRV to other central and autonomic nervous system dysfunctions.50,51 
 The results of this study should be interpreted with appropriate caution. First, the sample size 
was relatively small. With a larger sample size, we would have had more statistical power and might 
have been able to demonstrate more associations. Regarding the interpretation of our results, it 
is important to acknowledge that one should both pay attention to the initial results, and to the 
results corrected according to the Benjamini-Hochberg procedure. Because of the multiple testing, 
adequate application of a correction is desirable. However, as a result of the correction, the least 
significant results automatically turn non-significant, while these are not necessarily the false 
positive findings. Thus, careful interpretation of both results and replication of our findings with 
larger sample sizes are warranted. Second, the cross-sectional study design does not allow for 
drawing conclusions on causality. Third, we did not have information on emotional distress based on 
a structured clinical interview and were, in case of depression and anxiety, not able to differentiate 
between subclinical symptoms and clinical disorders. The relationship between emotional distress 
and HRV is expected to be stronger in patients with clinical diagnoses of emotional distress.21 
Finally, there are a number of other variables that could be influential in the relationship between 
emotional distress and HRV. Exerting a vagal effect on the heart, digoxin is one of these variables. 
However, due to the fact that only a small percentage of the patients were using digoxin (9.4% of 
the patients with Type D personality and 9.5% of the patients with depression and anxiety), we did 
not include the use of digoxin as a covariate in adjusted analyses. The potential influence of digoxin 
should nevertheless be examined in future studies.
 The strengths of this study include the use of ambulatory 24-hour measurement in a real-life 
setting for evaluating HRV, taking into account activity levels, as data was available for patients 
during resting activity and sleep. Furthermore, both time and frequency domain measures were 
included, as there is as yet no consensus about the best available index of HRV for clinical use.52 
Third, although depression and anxiety have been investigated in relation to HRV in cardiac patients, 
Type D personality has not. 
 In conclusion, we found that patients with a Type D personality suffered from a lower overall 
autonomic control over 24 hours and lower parasympathetic control during rest. There was also an 
indication for a disturbed parasympathetic nervous system in patients with depression, especially 
during rest. The shift towards sympathetic dominance and reduced vagal activity, observed in ICD 
patients with emotional distress, may trigger the development ventricular tachycardia.53 Reduced 
autonomic nervous control may thus increase the risk of ventricular arrhythmias in ICD patients, 
resulting in a poorer prognosis.54 Future research with larger sample sizes, including fMRI studies 
investigating the role of specific brain areas in autonomic regulation, are warranted to replicate and 
expand on these findings.
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ABSTRACT
Background: A paucity of studies has investigated the role of autonomic cardiac regulation as 
well as cardiac conduction in relation to prognosis in implantable cardioverter-defibrillator (ICD) 
patients. Therefore, we examined the association of heart rate and QRS duration with long-term 
mortality risk in first-time ICD patients, adjusting also for measures of emotional distress. 
Methods: Resting heart rate and QRS duration were assessed prior to ICD implantation in 448 
patients. Primary study endpoint was all-cause mortality (up to 6.0 years follow-up, median follow-
up 5.6 years (IQR: 1.9). The impact of heart rate and QRS duration on time to all-cause mortality was 
separately assessed with Cox proportional hazard regression analysis, adjusting for clinical factors 
and symptoms of depression and anxiety. 
Results: Mean (SD) heart rate was 68.0±13.3 bpm and mean QRS duration 130.9±36.9 ms. Heart 
rate of ≥80 bpm was associated with increased risk of mortality (HR=1.86; 95% CI=1.15-3.00; 
p=.011) in unadjusted analysis. In adjusted analyses, this relationship remained significant both 
with depression (HR=1.86, 95% CI=1.12-3.09; p=.017) and anxiety (HR=1.82, 95% CI=1.10-3.03; 
p=.021) and clinical measures as covariates. QRS duration of ≥120 ms was associated with impaired 
prognosis in unadjusted analysis (HR=2.00, 95% CI=1.27-3.14; p=.003), but was reduced to non-
significance in adjusted analysis when medical comorbidities were included (HR=1.15, 95% CI=0.70-
1.89; p=.60). 
Conclusions: This study shows that increased heart rate is associated with impaired prognosis. Since 
heart rate is a relatively easy measurable parameter of autonomic functioning, heart rate should be 
included as a measure for risk stratification in daily clinical practice. 
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INTRODUCTION
In patients at high risk for sudden cardiac death due to ventricular arrhythmias, the implantable 
cardioverter-defibrillator (ICD) is treatment of first choice, with mortality risk reductions of 37% for 
all-cause mortality to 57% compared to antiarrhythmic drug treatment.1-3 Despite the unequivocal 
benefits of ICD therapy, risk stratification in these patients still remains a major challenge in clinical 
cardiology practice.4
 In order to optimize care for ICD patients and reduce health care costs, it is crucial to identify 
factors associated with risk for morbidity and mortality. Deregulation of the autonomic nervous 
system, evident in the presence of an increased heart rate, has been shown to impact survival in the 
general population5,6 as well as in cardiac patients.7,8 Autonomic deregulation is particularly relevant 
in ICD patients, since the autonomic nervous system plays an important role in the generation 
of ventricular arrhythmias by impacting on the electrical and contractile functions of the heart.9 
Only one study has examined the role of heart rate as prognostic factor in ICD patients. This study 
showed a strong association of heart rate with survival and hospitalization for decompensated 
heart failure.10 However, this study did not adjust for the patient’s mood status, which has shown to 
be an independent predictor of ventricular tachyarrhythmias and mortality.4
 Few studies examined the relation between QRS duration and mortality risk in ICD patients, 
with longer QRS duration - indicating a conduction delay in the heart’s ventricles - being associated 
with mortality risk.11-13 However, relatively small samples12,13 and different definitions of prolonged 
QRS duration have been used.11,12 Given the relative paucity of studies examining the association 
between cardiovascular physiological functioning and prognosis in ICD patients, we investigated 
the association between heart rate and QRS duration and long-term mortality risk in patients with 
an ICD, while also adjusting for patients’ mood state (i.e. symptoms of anxiety and depression) in 
addition to traditional clinical risk factors.
METHODS
Patients and study design
Between August 2003 and February 2010, consecutive patients (N=448) were enrolled in the 
Mood and personality as precipitants of arrhythmia in patients with an Implantable cardioverter 
Defibrillator: A prospective Study (MIDAS) in the Erasmus Medical Center, Rotterdam, in collaboration 
with Tilburg University, the Netherlands. Exclusion criteria were a life-expectancy <1 year, being on 
the waiting list for heart transplantation, a history of psychiatric illness other than affective/anxiety 
disorders, and insufficient knowledge of the Dutch language. 
 The Medical Ethics Committee of the Erasmus Medical Center approved the study protocol. Prior 
to ICD implantation, written and oral information on the study was given to patients by an ICD 
nurse, after which written informed consent was obtained.
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Measures
Demographic and clinical variables
Purpose-designed questions were used to collect data on demographic characteristics (i.e. age, 
gender, marital status and education), while the Central Bureau of Statistics Netherlands provided 
information on patients’ socio-economic status (SES). Baseline clinical characteristics were captured 
from patients’ medical records, including indication for ICD therapy (primary versus secondary 
prevention), treatment with cardiac resynchronization therapy (CRT), left ventricular ejection 
fraction (LVEF) ≤35%, QRS duration, the presence of coronary artery disease (CAD), symptomatic 
heart failure (defined as New York Heart Association (NYHA) functional class III+IV), atrial fibrillation, 
prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), smoking, 
use of cardiac (i.e. beta-blockers, statins, amiodarone, diuretics, ACE-inhibitors, and digoxin) and 
psychotropic medication, and systolic (SBP) and diastolic blood pressure (DBP). Hypertension was 
defined as a SBP of ≥140 mmHg, and a DBP of ≥90 mmHg. Furthermore, the abbreviated Charlson 
Comorbidity Index (CCI) was constructed using information on the presence of renal failure, previous 
myocardial infarction (MI), chronic heart failure, diabetes mellitus, peripheral arterial disease, 
cerebrovascular disease, chronic obstructive pulmonary disease and cancer.14 The sum score of this 
index was subsequently adjusted for age, with addition of 1 extra point for each decade >50 years 
of age. 
Electrocardiographic measures
Information on heart rate and QRS duration was collected several days before ICD implantation 
via an electrocardiogram (ECG) in a standardized, clinical setting and as part of the regular medical 
check-up prior to ICD implantation. Registration of the ECG took place while patients were lying 
down on a bed and information was collected for 10 consecutive seconds. The ECG was interpreted 
using auto-interpretation, which was always checked and confirmed by an experienced cardiologist. 
A cut-off heart rate of ≥80 bpm, based on two large studies on heart rate as prognostic factor in 
CAD,15,16 was used to compare patients with increased versus normal heart rate. For QRS duration, 
a cut-off of QRS ≥120 ms, based  on a risk stratification model for first-time ICD implantation,17 was 
used to compare patients with prolonged versus normal QRS duration.
Depression and anxiety
Symptoms of depression and anxiety were measured at baseline (1 day prior to implantation) using 
the Hospital Anxiety and Depression Scale (HADS), a 14-item self-report questionnaire consisting 
of 7 items measuring anxiety (HADS-A) and 7 items measuring depression (HADS-D).18 All items are 
rated on a 4-point Likert scale, with scores ranging from 0 to 3 and higher scores reflecting more 
symptoms.18 Psychometric qualities of the HADS are good.19 In the current study, a cut-off score of 
≥8 was used to detect patients with clinically significant levels of anxiety and depression.20
Endpoint
All-cause mortality was used as endpoint in this study. The Dutch municipal register was consulted 
for information on survival status up to 6 years post implantation.
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Statistical analyses
Baseline demographic and clinical variables for patients with complete versus incomplete data were 
compared with the Chi-square test (Fisher’s Exact test when appropriate) for nominal variables, and 
Student’s t-test for continuous variables.
 Assumptions of the proportional hazards were checked by using log-minus-log plots for nominal 
variables and partial residual plots for continuous variables. The association between heart rate and 
time to all-cause mortality, and QRS duration and time to all-cause mortality was separately assessed. 
Covariates - indication for ICD implantation,21 age-adjusted CCI,22 hypertension,23 appropriate and 
inappropriate shocks during follow-up,24,25 and use of beta-blockers26 and amiodarone27 - were a 
priori selected based on the literature and included using the Enter method. Patient anxiety and 
depression were included in a final step, as these psychological factors have been associated 
with poor prognosis28,29 and previous research has demonstrated a relation between depression 
and heart rate variability.30 In order to avoid multicollinearity, separate analyses were performed 
with patient anxiety and depression as covariates and mortality as endpoint, resulting in four Cox 
proportional hazard regression models: (1) heart rate and depression; (2) heart rate and anxiety; 
(3) QRS duration and depression; and (4) QRS duration and anxiety. Results of the Cox regression 
analyses were reported using hazard ratios (HR) with corresponding 95% confidence intervals (CI). A 
p-value of <.05 (two-sided) was used to indicate statistical significance. Cumulative survival curves 
for mortality risk predicted by heart rate ≥80 bpm and QRS duration ≥120 ms with accompanying 
log-rank tests were constructed using the Kaplan-Meier method. Results were repeated with 
continuous values for heart rate and QRS duration. Patients who underwent heart transplantation 
were excluded from analyses, while patients who were transferred to another hospital or lost to 
follow-up were censored alive at time of file closure. Data were analyzed with PASW Statistics 19 
(PASW IBM Corp., Armonk, NY, USA). 
RESULTS
Patient baseline characteristics
In total, 448 patients were included in the study. Twenty-six patients had missing values on the 
hypertension (N=2), age-adjusted CCI (N=6) and emotional distress measures (N=18). Patients with 
incomplete data were more likely to have a secondary prevention indication (p<.001), to suffer 
from CAD (p=.012), atrial fibrillation (p=.028), to have a shorter QRS duration (p=.002) and to have 
a low SES (p=.019). In addition, 23 patients underwent heart transplantation at some point during 
follow-up. These patients were excluded from the analyses, since their prognosis was expected to 
be significantly worse than for patients not undergoing heart transplantation, which was confirmed 
by higher rates of symptomatic heart failure (p<.001) and atrial fibrillation (p=.001), and more 
frequent use of digoxin (p<.001), diuretics (p=.002) and psychotropic medication (p=.014). Patients 
with missing data on covariates were also excluded from the analyses, leaving 399 patients. Table 1 
displays baseline demographic and clinical characteristics of the complete sample. The mean age 
was 59±12 years, and 317 (79%) of the patients were male. 
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Table 1. Baseline characteristics for the total study sample * 
Patients (N=399)
Demographics
Mean age (±SD) 58.8 (12.2)
Men 317 (79.4)
Lower SES † 185 (46.6) ‡
Clinical factors
Primary  prevention indication 258 (64.7)
CRT 117 (29.3)
LVEF ≤35% ‡ 292 (85.1)
CAD 234 (58.6)
Previous PCI 103 (25.8)
Previous CABG 84 (21.1)
Symptomatic heart failure †§ 118 (29.7) ‡
Atrial fibrillation 82 (20.6)
Diabetes 56 (14.0)
Smoking † 45 (11.3) ||
Cardiovascular physiological measures
Mean heart rate (bpm, ±SD) 68.0 (13.3)
Mean systolic blood pressure (mmHg, ±SD) 121.4 (18.2)
Mean diastolic blood pressure (mmHg, ±SD) 73.6 (11.6)








Psychotropic medication # 61 (15.4) ††
Psychological measures
Mean score depression (±SD) 5.0 (4.0)
Mean score anxiety (±SD) 5.6 (4.1)
* Data presented as N (%), unless otherwise indicated. † N=2 (0.5%) missing; ‡ N=56 (14.0%) missing; § defined as 
New York Heart Association (NYHA) functional class III+IV, # N=4 (1.0%) missing. Abbreviations: ACE, angiotensin-
converting enzyme;  bpm, beats per minute; CABG, coronary artery bypass grafting; CAD, coronary artery disease; 
CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection fraction; N, number; PCI, percutaneous 
coronary intervention; QRS, QRS duration; SD, standard deviation; SES, socio-economic status
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All-cause mortality
During a mean follow-up period of 4.8±1.5 years (range 0.1-6.0 years, inter quartile range 1.9), 83 
patients (20.8%) died. In adjusted analyses, 25 patients (6.3%) were censored as alive due to hospital 
transfer (and absence of clinical follow-up), just as 22 (5.5%) patients who were lost to follow-up for 
other reasons. 
Heart rate and QRS duration as predictors of mortality
All variables, except the use of beta-blockers and the occurrence of shocks during follow-up met 
the proportional hazards assumptions. In order to enable their inclusion in the analyses, these two 
variables were transformed into time-dependent variables.














Heart rate below 80 bpm
Heart rate from 80 bpm
p=.010
Number of patients at risk
Baseline 1 year 2 years 3 years 4 years 5 years 6 years
Heart rate <80 bpm 323 314 302 293 277 269 263
Heart rate ≥80 bpm 76 71 63 57 55 55 53
Total # of patients 399 385 365 350 332 324 316
Figure 1. Cumulative survival curve stratified by heart rate ≥ 80 bpm
 
 Heart rate – Cumulative hazard functions were significantly different for patients with a heart 
rate of ≥80 bpm versus <80 bpm (log-rank χ2=6.60; p=.010) (Figure 1). A heart rate of ≥80 bpm 
was associated with a cumulative increased risk for all-cause mortality (HR=1.86; 95% CI=1.15-
3.00; p=.011) in unadjusted Cox regression analysis. After adjusting for the a priori selected clinical 
covariates (indication for ICD implantation, the age-adjusted CCI, hypertension, occurrence of 
appropriate and inappropriate shocks during follow-up, and use of beta-blockers and amiodarone), 
the relationship between heart rate of ≥80 bpm and risk for all-cause mortality remained significant 
(HR=1.85, 95% CI=1.11-3.06, p=.017), also when additionally adjusting for depressive symptoms 
(HR=1.86; 95% CI=1.12-3.09; p=.017), and when adjusting for symptoms of anxiety instead of 
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depression (HR=1.82; 95% CI=1.10-3.03; p=.021) (Table 2). Repeating the results with continuous 
values for heart rate yielded similar findings in both unadjusted (HR=1.02; 95% CI=1.01-1.03; 
p=.025) and adjusted analyses (depression as covariate: HR=1.02; 95% CI=1.01-1.04; p=.027; anxiety 
as covariate: HR=1.02; 95% CI=1.01-1.04; p=.025).
 QRS duration – Cumulative hazard functions were significantly different for patients with a 
QRS duration of ≥120 ms versus <120 ms (log-rank χ2=9.44; p=.002) (Figure 2). In unadjusted Cox 
regression analysis, a QRS duration ≥120 ms was associated with a cumulative increased risk for 
all-cause mortality (HR=2.00; 95% CI=1.27-3.14; p=.003) (Figure 2). However, when adjusting for 
the a priori selected clinical covariates, the relation between QRS duration ≥120 ms and risk for 
all-cause mortality was non-significant and remained so after additional adjustment for depressive 
symptoms (HR=1.15; 85% CI=0.70-1.89; p=.60) and symptoms of anxiety (HR=1.14; 95% CI=0.70-
1.88, p=.60) (Table 3). Inclusion of the CCI in adjusted analysis accounted for the non-significant 
effect of QRS duration ≥120 ms on mortality. Again, repeating the results with continuous values of 
QRS duration led to comparable results, with a significant association between QRS duration and 
risk for all-cause mortality in unadjusted analysis (HR=1.01; 95% CI=1.01-1.02; p=.003), and a non-
significant relationship in adjusted analysis (depression as covariate: HR=1.00; 95% CI=1.00-1.01; 
p=.70; anxiety as covariate: HR=1.00; 95% CI=1.00-1.01; p=.79).














QRS below 120 ms
QRS from 120 ms
p=.002
Number of patients at risk
Baseline 1 year 2 years 3 years 4 years 5 years 6 years
QRS duration <120 ms 200 197 191 183 175 174 171
QRS duration ≥120 ms 199 188 174 167 157 150 145
Total # of patients 399 385 365 350 332 324 316
Figure 2. Cumulative survival curve stratified by QRS duration ≥ 120 ms
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Table 2. Heart rate and mortality (Cox proportionate hazard regression analysis) *
Heart Rate
Block 1 HR 95% CI p
Heart rate 1.86 1.15-3.00 .011
Block 2 HR 95% CI p
Heart rate 1.85 1.11-3.06 .017
Secondary prevention indication 1.18 0.74-1.90 .48
CCI 1.32 1.20-1.44 <.001
Hypertension 0.76 0.24-2.43 .65
Shocks during follow-up † 1.25 1.08-1.44 .004
Use of beta-blocker 1.21 0.96-1.52 .10
Use of amiodarone 2.04 1.23-3.36 .005
Block 3 – with depressive symptoms HR 95% CI p
Heart rate 1.86 1.12-3.09 .017
Secondary prevention indication 1.23 0.77-1.98 .39
CCI 1.30 1.19-1.43 <.001
Hypertension 0.83 0.26-2.66 .75
Shocks during follow-up † 1.24 1.07-1.43 .005
Use of beta-blocker 1.23 0.98-1.54 .08
Use of amiodarone 1.86 1.11-3.11 .018
Depression 1.95 1.25-3.04 .003
Block 3 – with anxiety symptoms HR 95% CI p
Heart rate 1.82 1.10-3.03 .021
Secondary prevention indication 1.21 0.76-1.94 .43
CCI 1.32 1.21-1.45 <.001
Hypertension 0.77 0.24-2.47 .66
Shocks during follow-up † 1.24 1.07-1.44 .004
Use of beta-blocker 1.21 0.96-1.51 .11
Use of amiodarone 2.02 1.22-3.34 .006
Anxiety 1.32 0.83-2.11 .24
* Analyses were separately performed with patient depression and anxiety as covariates, respectively. 
† Appropriate and inappropriate shocks. Abbreviations: CCI, Charlson Comorbidity Index; CI, confidence interval; 
HR, hazard ratio; ICD, implantable cardioverter-defibrillator
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Table 3. QRS duration and mortality (Cox proportionate hazard regression analysis) *
QRS Duration
Block 1 HR 95% CI p
QRS duration 2.00 1.27-3.14 .003
Block 2 HR 95% CI p
QRS duration 1.09 0.67-1.79 .72
Secondary prevention indication 1.15 0.72-1.84 .56
CCI 1.33 1.21-1.47 <.001
Hypertension 0.73 0.23-2.33 .59
Shocks during follow-up † 1.23 1.06-1.43 .007
Use of beta-blocker 1.17 0.94-1.46 .17
Use of amiodarone 1.84 1.13-3.00 .014
Block 3 – with depressive symptoms HR 95% CI p
QRS duration 1.15 0.70-1.89 .60
Secondary prevention indication 1.21 0.75-1.95 .43
CCI 1.31 1.19-1.45 <.001
Hypertension 0.79 0.25-2.54 .69
Shocks during follow-up † 1.22 1.05-1.41 .011
Use of beta-blocker 1.18 0.95-1.47 .15
Use of amiodarone 1.65 1.00-2.72 .051
Depression 1.96 1.26-3.07 .003
Block 3 – with anxiety symptoms HR 95% CI p
QRS duration 1.14 0.70-1.88 .60
Secondary prevention indication 1.19 0.74-1.90 .48
CCI 1.34 1.21-1.47 <.001
Hypertension 0.74 0.23-2.38 .62
Shocks during follow-up † 1.23 1.06-1.43 .007
Use of beta-blocker 1.17 0.93-1.45 .18
Use of amiodarone 1.82 1.12-2.96 .017
Anxiety 1.39 0.86-2.22 .18
* Analyses were separately performed with patient depression and anxiety as covariates, respectively. 
† Appropriate and inappropriate shocks. Abbreviations: CCI, Charlson Comorbidity Index; CI, confidence interval; 
HR, hazard ratio; ICD, implantable cardioverter-defibrillator
DISCUSSION
In the current study, we investigated the relationship between two electrocardiographic measures 
influenced by cardiovascular physiological functioning – heart rate and QRS duration – and risk 
of all-cause mortality up to 6 years of follow-up in patients with an ICD. Increased heart rate, both 
when assessed continuously and using a cut-off of ≥80 bpm, was associated with a higher mortality 
risk. QRS duration, however, was only associated with increased mortality risk when comorbidity 
burden, measured with the age-adjusted CCI, was not taken into account. 
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 Our results match the results of the only previous study among ICD patients on this topic, in 
which a strong relationship between increased mean heart rate and mortality and heart failure 
hospitalization was found,10 and the results in other cardiac populations.7,8,31 In patients with heart 
failure, who comprise a large subgroup within the ICD population, the association between heart 
rate and prognosis seems less straightforward than in other cardiac patients. Indeed, tachycardia 
acts as a compensatory response to impaired cardiac output up to a certain point, after which it also 
becomes a marker of excessive autonomic activation.8 Optimal cut-off levels thus may differ across 
different subtypes of heart disease, which should be further investigated with respect to optimizing 
risk stratification. Since heart failure is common among ICD patients, we chose a relatively high 
cut-off of HR ≥80 bpm to evaluate the impact of heart rate on mortality and also used continuous 
measures of heart rate. 
 Prior studies have shown a significant relationship between prolonged QRS duration and 
prognosis in ICD patients.11-13 In our sample, QRS duration did not uniquely contribute to patients’ 
mortality risk, although there was a shared prognostic value of QRS duration and the presence of 
comorbidities in relation to mortality.
 Several mechanisms may explain the relationship between heart rate and prognosis.32 Higher 
heart rate increases vascular oxidative stress, and is associated with decreased restoration of 
endothelial function, a key event in the development of atherosclerosis, through increasing levels 
of circulating inflammatory markers. Furthermore, increasing heart rate promotes arterial stiffness 
and hampers angiogenesis, a natural defense mechanism to compensate for arterial occlusion. 
Moreover, arterial plaques tend to be less stable at increased heart rate. Increased heart rate also 
affects the myocardium, as coronary blood flow mainly occurs during diastole, which is firmly 
decreased with increasing heart rate.32 
 The current study is the first to include emotional distress as potential confounder in 
the relationship between heart rate and mortality. This is important, as emotional distress is 
independently related to risk of ventricular arrhythmias and mortality in ICD patients.4 Although 
depression was associated with poorer prognosis, it did not substantially affect the relationship 
between heart rate and prognosis. Future research is warranted that focuses on the simultaneous 
presence of multiple clinical and psychological risk factors for mortality in this patient population, 
as they may interact to exacerbate patient risk.
 Treatment should thus focus on reduction of resting heart rate. However, the vast majority 
of patients in the current sample have been prescribed one or more heart rate reducing agents. 
Interestingly, the use of beta-blockers and amiodarone was associated with an increased risk of 
mortality. Patients who are prescribed heart rate lowering agents likely constitute a high-risk group 
with poorer prognosis, despite the use of these agents. Insufficient medication adherence or incorrect 
use may also play a role, with approximately 30% of heart failure patients not complying with the 
prescribed treatment.33 Less traditional methods of reducing heart rate, such as biofeedback, have 
shown encouraging results in terms of heart rate control in healthy persons, although sustained 
effects are unknown and research among cardiac patients is yet lacking.34,35 Future research should 
reveal whether this behavioral approach is effective in reducing heart rate in ICD patients.
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 This study has some limitations. Due to incomplete data on cause of death, we were only able to 
focus on all-cause mortality as primary endpoint. Second, due to limited availability of other related 
autonomic measures, such as heart rate variability and baroreflex sensitivity measures, creation of 
a more comprehensive autonomic prediction model remains a future ambition. Moreover, we have 
not been able to assess changes in autonomic functioning during follow-up and its relation with 
prognosis due to availability of only pre implantation data. The relatively large follow-up range is 
also a limitation of the current study.
 Strengths of the current study include the relatively long mean follow-up period, and the use 
of both dichotomous and continuous measures of heart rate and QRS duration, pointing towards 
the same conclusion. Furthermore, we adjusted for several aspects of physical and psychological 
functioning in statistical analyses, which might serve as potential  confounders.
 In conclusion, we found that heart rate was associated with an increased risk of all-cause 
mortality up to 6 years follow-up in a consecutive cohort of ICD patients with a first-time  implant. 
The relationship between QRS duration and risk of all-cause mortality was explained by the presence 
of comorbid conditions. Although heart rate seems a relatively crude measure of autonomic 
functioning, it also appears to be an easy to assess, inexpensive marker of poor prognosis, which is 
broadly available as one of the standard measurable parameters in clinical practice. For this reason, 
application of heart rate as a measure for risk stratification should be encouraged in clinical practice.
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ABSTRACT
Background: Partners’ emotional distress is often ignored in clinical practice. We (1) focused on 
the relationship between anxiety and depression within implantable cardioverter-defibrillator (ICD) 
patients and partners; and the relationship between anxiety and depression between patients and 
partners, and (2) examined whether partner distress trajectory was associated with patient health 
status trajectory. 
Methods: Consecutively implanted patients and their partners (N=433) recruited by an ICD nurse 
filled out the Hospital Anxiety and Depression Scale (HADS) on 5 occasions up to 12 months follow-
up. Patients’ health status was measured simultaneously with the Short Form Health Survey-36 (SF-
36). Latent growth curve models were constructed. 
Results: Individual differences in baseline distress and change in distress correlated between 
patients and partners. Patients’ baseline and change in health status scores were largely explained by 
patients’ own baseline and change in anxiety scores. Importantly, partner distress predicted better 
patient health status at baseline (partner anxiety: lower baseline patient social functioning (b=-0.07, 
p=.042); partner depression: more baseline patient bodily pain (b=-0.07, p=.024) and during follow-
up (higher partner distress during follow-up: worse patient health status recovery during follow-up 
on all subscales except role limitations - emotional (b’s ranging from -.11 to -.18). 
Conclusions: Patient-partner distress patterns were highly similar, and although patients’ own 
emotional distress largely predicted their health status at baseline and change therein during follow-
up, on top of that, development of partner distress during follow-up was also predictive of how well 
patients’ health status level recovered after implantation. Partners should not be neglected in the 
adaptation process post implantation. 
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INTRODUCTION
The implantable cardioverter-defibrillator (ICD) is the first line treatment for patients at risk of sudden 
cardiac death due to ventricular tachyarrhythmias, both as primary and secondary prevention.1-3 
Although the majority of patients reach acceptable levels of psychological functioning after 
implantation, a subgroup (25%) remains at high risk of developing emotional distress, directly after 
implantation or at a later stage.4-8 Distress levels may in part be attributable to the uncontrollable 
and unpredictable course of ICD therapy and the associated uncertainty,6,7 but also to the underlying 
heart disease (e.g. symptomatic heart failure)9 and patients’ pre implantation personality.10 
 The way patients cope with stress has traditionally been examined using individual-oriented 
stress models.11 However, the presence of a partner may influence patients’ appraisal of situational 
demands, and partners may also augment the available coping resources.12 Dyadic coping models 
such as Bodenmann’s systemic-transactional model of stress and coping13 extend the individual-
oriented stress model to a model in which the partner is involved in stress appraisal and coping. In 
this model, the process of stress-coping is perceived as a dyadic exchange of action (i.e. the stress 
signals of one partner) and reaction (i.e. dyadic coping of the other partner), as well as common 
dyadic coping efforts. In patients with acute or chronic illness, dyadic coping may be particularly 
important, as it has shown to positively influence not only psychological well-being14 but also 
physical health.15 
 Instead of focusing on the ICD patient as an isolated individual, coping with an ICD should thus 
be understood as a dyadic concern, in which patients and partners affect each other’s emotional 
well-being. Partners may play an essential role in adaptation to the ICD, and emotional distress in 
partners may lead to undesirable behaviour, such as overprotectiveness and discouragement of 
an active lifestyle of the patient.16,17 On the other hand, in the context of the systemic-transactional 
model of dyadic coping, the patient’s way of coping with the ICD may also impact on the partner’s 
emotional well-being.13 Furthermore, ICD implantation may affect shared aspects of the relationship, 
including emotional, social and sexual functioning.18,19
 Specific to ICD patients, shock therapy occurs on an irregular and unpredictable basis. Patients 
and their partners are thus at increased risk of a state of permanently increased vigilance, with 
uncertainty and uncontrollability being important underlying themes in daily life. Dyadic coping 
theory has shown that perceived controllability in both patients and partners determines the 
appraisal of the stressor, the interaction between patient and partner, and the subsequent coping 
response.13 Because of the uncontrollable nature of the permanently present threat, i.e. ventricular 
arrhythmia followed by shock delivery, the interrelationship of ICD patients’ and their partners’ well-
being is a relevant topic for further examination.
 Emotional distress levels of partners of ICD patients are at least as high if not higher than those 
of patients.20-22 In addition, partners may experience difficulties with a change in role patterns from 
being a partner on equal terms to being a caregiver.23 Emotional distress in partners has shown to 
be associated with poorer prognosis in cardiac patients.24 A complete picture of the emotional well-
being of partners of ICD patients and the association of emotional well-being between patients 
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and partners within the couple over time is thus important, and could provide us with targets 
for interventions aiming to improve both patients’ and partners’ quality of life and possibly even 
patients’ prognosis.
 In a recent study, patients’ distress was found to be correlated with partners’ distress (i.e. symptoms 
of anxiety and depression), with the type of distress corresponding within dyads (i.e. patients’ 
anxiety was associated with partners’ anxiety, and patients’ depression with partners’ depression).25 
However, in that study, using a multilevel approach, correlations of patient and partner distress were 
averaged over time, while the influence of change in distress across several points in time of both 
patients and partners and the influence of this on patients’ health status remains unknown. 
 Therefore, the aim of the current study was (1) to longitudinally examine the relationship 
between anxiety and depression within patients and partners; and the relationship between anxiety 
and depression between patients and partners. Since health status has been associated with poorer 
prognosis,26 we were also interested in (2) finding out whether partner distress (baseline distress 
and change in distress) was associated with patient health status at baseline and change in patient 
health status during follow-up.
 
METHODS
Patients and study design
Between August 2003 and February 2010, 448 consecutive patients implanted with a first-time ICD 
in the Erasmus Medical Center, Rotterdam, the Netherlands, with their partners, were enrolled in the 
Mood and personality as precipitants of arrhythmia in patients with an Implantable cardioverter 
Defibrillator: A prospective Study (MIDAS). Exclusion criteria consisted of a life-expectancy of <1 
year, being on the waiting list for heart transplantation, a history of psychiatric illness other than 
affective/anxiety disorders, and insufficient knowledge of the Dutch language. Having a partner 
was an explicit inclusion criteria for the study, although during the initial phase of the project some 
patients without a partner have been included (N=11). These patients were not included in the 
statistical analyses.
 The study was conducted according to the Helsinki Declaration and approved by the Medical 
Ethics Committee of the Erasmus Medical Center. Prior to ICD implantation, an ICD nurse provided 
written and oral information on the study. After obtaining written informed consent from both 
patients and partners, the couples were asked to separately complete a similar set of standardized 
and validated questionnaires at baseline (i.e. one day prior to implantation), and at 10 days, 3, 6 and 
12 months post implantation, resulting in a dyadic longitudinal design with 5 measurement points.
Measures
Demographic and clinical variables
Purpose-designed questions were used to obtain information on demographic characteristics (i.e. 
age, gender, marital status and educational level) of both patients and partners. Information on 
socio-economic status (SES) was obtained from Statistics Netherlands. 
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 Information on clinical patient characteristics, including indication for ICD therapy (primary 
versus secondary prevention), treatment with cardiac resynchronization therapy (CRT), left 
ventricular ejection fraction (LVEF) ≤35%, QRS duration, the presence of coronary artery disease 
(CAD), symptomatic heart failure (defined as New York Heart Association (NYHA) functional class 
III+IV), atrial fibrillation, prior PCI or coronary artery bypass grafting (CABG), smoking, and use 
of cardiac (i.e. beta-blockers, statins, amiodarone, diuretics, ACE-inhibitors, and digoxin) and 
psychotropic medication, were captured from patients’ medical records at the time of implantation. 
The prevalence of shock therapy, both appropriate and inappropriate, was captured during follow-
up via device interrogation. In addition, information on comorbid medical disorders in patients 
was collected at the time of implantation. From this information, an age-adjusted version of the 
Charlson Comorbidity Index (CCI) was constructed.27
Anxiety and depression
Symptoms of anxiety and depression were assessed in patients and partners with the Hospital 
Anxiety and Depression Scale (HADS) at baseline, 10 days, 3, 6 and 12 months post implantation. 
This 14-item self-report questionnaire consists of 7 items measuring symptoms of anxiety (HADS-A) 
and 7 items measuring symptoms of depression (HADS-D). Items are scored on a 4-point Likert 
scale, with scores ranging from 0 to 3 (total score range of 0-21) and higher scores reflecting more 
symptoms.28 Cronbach’s alphas of 0.84 and 0.83 for the anxiety and depression subscales were 
found for the current study. The three-week test-retest reliability (0.89 and 0.86 for the HADS-A 
and HADS-D subscales) of the HADS is high.29 The HADS has been developed to measure separate 
symptoms of anxiety and depression in a non-psychiatric hospital setting.30 In the current study, 
continuous sum scores for anxiety and depression were used as markers of emotional distress.
Health status
The validated Dutch language version of the Short Form Health Survey 36 (SF-36) was used to 
measure patients’ health status at baseline, 10 days, 3, 6 and 12 months post implantation.31 The 
questionnaire consists of 36 items that contribute to eight subscales: physical functioning, role 
limitations - physical, bodily pain, social functioning, mental health, role limitations - emotional, 
vitality and general health. Scores range from 0 to 100 for each subscale, with higher scores 
indicating better health status.32 Scale reliabilities as indicated by Cronbach’s alphas range from 0.66 
to 0.92.31 Continuous sum scores for the eight subdomains of health status were calculated, and 
scores of the SF-36 were transformed by dividing the sum score of all scales by 10 for analytical 
purposes.
Statistical analyses
Latent growth curve analysis – To take full advantage of the longitudinal study design we used 
latent growth models.33 These models can be seen as a direct extension of multilevel and structural 
equation models and allow for inter-individual variation in baseline (intercept) and change over 
time (slope), which makes them ideally suitable for modelling outcome trajectories across time. The 
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growth curves will be parameterized, such that the random intercept represents inter-individual 
differences at baseline and the random slope represents inter-individual variation in change 
during the 12 months post implantation. To allow for non-linear trajectories, the loadings on the 
random slope for in-between time points are unrestricted, allowing them to be interpreted as the 
proportional change relative to the total change from starting point to end point. In these models, 
variances can be explained at two levels: (1) the structural level, which reflects inter-individual 
differences in baseline values and change in distress and health status by means of a random 
intercept and random slope factor across time, and (2) the measurement level, which reflects further 
intra-individual variation by means of residual time-specific factors. The structural random factors 
(i.e. baseline and change) are allowed to correlate between patient and partner to further account 
for the dyadic structure; the same holds for the residuals for each measurement occasion. The 
random slope is regressed on the random intercept to control change for the variation in baseline.
All models were specified starting from the covariance matrix and estimated through the Lavaan 
library in the statistical software package R (http://www.r-project.org/). Full information maximum 
likelihood was used to make use of all available information for each individual under the missing at 
random assumption and in line with the intention-to-treat principle. Model fit was evaluated based 
upon commonly recommended goodness-of-fit indices,34 including the χ2 of exact model fit, the 
root mean square error of approximation (RMSEA) and the comparative fit index (CFI).
 To assess the first aim of the study, a total of four parallel growth curves were constructed: a 
trajectory (1) assessing the relation between anxiety and depression within patients; (2) assessing 
the relation between anxiety and depression within partners; (3) the relation of anxiety between 
patients and partners; and (4) the relation of depression between patients and partners. Within 
patients/partners, the trajectories of anxiety and depression were highly similar in shape and the 
individual variation in intercept and slope was very strongly correlated (ranging from .79 to .94). 
Therefore, for the second aim of the study, eight latent growth curve models were constructed 
mapping out patient health status trajectories (one model for each scale) in relation to partner 
anxiety and partner depression separately. In this way, problems due to multicollinearity between 
the predictors anxiety and depression was avoided. 
 Hierarchical latent growth curve models were build, with stepwise inclusion of a priori selected 
covariates, based on the literature: (1) demographic and clinical covariates, including partner 
gender,15 patient indication for ICD implantation,21 symptomatic heart failure,35 the occurrence 
of shock(s) during follow-up,36 age-adjusted version of the CCI,37 and a combined level of socio-
economic status (SES) for patients and partners,38 (2) baseline and change factors of patient levels 
of anxiety and depression in the separate anxiety and depression models, and (3) baseline and 
change factors of partner levels of anxiety and depression in the separate anxiety and depression 
models. Furthermore, in order to extract change distress levels from initial distress levels, for each 
growth curve, change in distress was adjusted for baseline influences of distress by including the 
random intercepts of the growth curves as predictors for the random slopes. Results for the latent 
growth curve models are presented as unstandardized regression coefficients (b). For continuous 
predictors, a b of -0.22 for partners’ baseline anxiety for example means that for each extra point of 
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partners’ anxiety at baseline, patients’ health status decreases with 2.2 points (a decrease of 0.22*10 
as a result of score transformation). For dichotomous predictors, contrast coding was used, meaning 
for example that for the presence of symptomatic heart failure a 1 was coded and for the absence of 
symptomatic heart failure a -1 was coded. A b of -0.64 for baseline health status in this case means 
that patients with symptomatic heart failure score 6.4 point lower on health status than average, 
while patients without symptomatic heart failure score 6.4 points higher on health status than 
average.
RESULTS
Patient and partner baseline characteristics
Overall, 448 patients were included in the study, of which 11 (2.5%) had no partner. In addition, 
4 patients (1%) had missing data on a covariate, leaving 433 dyads of patient and partner in total 
for analysis. Included patients were compared with patients excluded from analyses. The latter 
were significantly more likely to have undergone CABG (46.7% versus 19.2%, p=.017) and to use 
psychotropic medication (38.5% versus 15.7%, p=.045). No other systematic differences between 
included and excluded patients were found, nor differences in baseline characteristics among 
included and excluded partners. 
 Table 1 displays baseline demographic characteristics of both patients and partners, as well as 
baseline clinical patient characteristics. The mean age of patients was 59±12 years, and 341 (79%) of 
the patients were male. Partners’ mean age was 56±12 years and 94 (22%) of the partners were male. 
Fifty-seven patients (13.2%) received one or more shocks during the first year post implantation. 
Distress trajectories for patients and partners
A model containing a total of four parallel growth curves were fitted on the HADS data: one 
trajectory for anxiety for patients and partners, respectively, and one for depression for patients and 
partners, respectively. The latent growth model provided an excellent fit to the data (χ2
(df=230)=
427, 
p<.001, CFI=.975, RMSEA=.044), and was able to explain on average 75% and 80% of the variance 
in anxiety and 76% and 81% of the variance in depression at each time point for patients and 
partners, respectively. Results are presented in Table 2, in line with an example of the accompanying 
growth curve presentation in Figure 1. As indicated in the model, change in distress depended on 
the baseline distress level of the individual. To give an impression of the expected change, simple 
slopes were computed for an individual scoring average on baseline distress and all other predictors 
(anxiety patient: b=-0.64, Z=-2.53, p=.012; anxiety partner: b=-1.34, Z=-4.59, p<.001; depression 
patient: b=-0.20, Z=-0.81, p=.42; depression partner: b=-0.70, Z=-2.61, p=.009). These simple slopes 
showed that on average, distress decreased during follow-up. However, there is still a large amount 
of variation around these average change patterns, as indicated by the large variances of the random 
slopes (see Table 2). The shape of the trajectories was comparable for anxiety and depression, but 
slightly different between patients and partners. For both patients and partners, about 47-51% of the 
change to final level of distress already occurred after 10 days post implantation. However, whereas 
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for patients at 3 months post implantation almost all decline in distress had taken place with the 
trajectory stabilizing, for partners the trajectory was more gradually decreasing and flattened out 





) which are shown in Figure 1 and Table 2.






Mean age (±SD) 58.54 (12.08) 56.20 (11.97)
Men 341 (78.8) 94 (21.7)
Lower SES † 203 (46.9) 203 (46.9)
Clinical factors
Primary  prevention indication 284 (65.6)
CRT 121 (27.9)
LVEF ≤35% ‡ 320 (73.9)
Mean QRS (±SD) 129.47 (36.32)
CAD 251 (58.0)
Previous PCI 114 (26.3)
Previous CABG 83 (19.2)
Symptomatic heart failure § 137 (31.6)
Atrial fibrillation 101 (23.3)
Diabetes 62 (14.3) #
Mean score age-adjusted CCI 3.51 (2.37)
Smoking 43 (9.9) || 104 (24.0) **








Psychotropic medication 65 (15.0) †† 65 (15.0) **
* Data are presented as N (%), unless otherwise indicated. † Based on ZIP-code and calculated per household 
by the Netherlands Institute for Social Research; ‡ N=62 (%) missing; § defined as NYHA functional class III+IV; # 
N=2 (%) missing; || N=17 (%) missing; ** N=21 (%) missing; †† N=19 (%) missing. Abbreviations: ACE, angiotensin-
converting enzyme; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCI, Charlson 
Comorbidity Index; CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection fraction; N, number; 
PCI, percutaneous coronary intervention; QRS, QRS duration; SD, standard deviation; SES, socio-economic status.
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Table 2. Dyadic bivariate latent growth curve model for anxiety and depression for patients and partners †
Patient Partner
Anxiety Depression Anxiety Depression
Baseline Intercept  (1) 5.689 *** 4.915 *** 6.835 *** 4.986 ***
Prevention indication (2) -.034 -.244 .299 .395
Symptomatic heart failure (3) .171 .204 .229 .596 **
Gender partner (4) .381 .270 -.601 * -.272
SES (5) .185 -.014 -.148 -.247
Shock(s) (6) .123 .012 .003 -.106
CCI (7) -.045 .175 * -.084 -.154
Variance 11.484 11.624 14.613 12.852
R2 .018 .033 * .026 .037 *
F(6,427) 1.314 2.402 1.891 2.723
p .249 .027 * .081 .013 *
Change Intercept (1) .492 .557 .280 .417
Baseline patient -.205 *** -.153 ** -.010 .060
Baseline partner .004 -.001 -228 *** -.283 ***
Prevention indication (2) .307 * .370 * .318 .115
Symptomatic heart failure (3) .143 -.032 .327 .037
Gender partner (4) -.195 -296 .072 .030
SES (5) -.030 -.019 .053 .005
Shock(s) (6) .893 *** .747 *** .376 .438 *
CCI (7) -.053 -.005 -.091 .067
Variance 3.240 2.758 4.412 3.899
R2 .240 .232 .183 .224
F(8,427) 22.472 *** 21.49 *** 15.884 *** 20.521 ***
p .012 * .42 <.001 *** .009 **
Trajectory § L
1
0 0 0 0
L
2
.470 .470 .510 .498
L
3
1.027 .991 .782 .637
L
4
.987 .954 .878 .952
L
5
1 1 1 1
Residual Variance 3.737 3.566 3.437 2.649
Overall R2 .748 .763 .798 .813
† Results are presented as b’s as in regular regression analysis. (1) Predictor 1 in predictor box Figure 1; (2) predictor 
2 in predictor box Figure 1, etc. Contrast coding was used for the dichotomous independent variables, with 
prevention indication: -1=primary indication, +1=secondary indication; symptomatic heart failure: -1=no, 
+1=yes; shock(s) during follow-up: -1=no, +1=yes; gender partner: -1=female, +1=male. Correlations between 
intercepts and slopes of the trajectories are displayed in the results section of the manuscript. * p<.05; ** p<.010; 
*** p<.001; # Indication of percentage change in distress score for each measurement occasion. Abbreviations: 
CCI, Charlson Comorbidity Index; L, loadings on random slope factor for each measurement occasion; SES, socio-
economic status.
        
















































































































Figure 1. Dyadic bivariate latent growth curve model for patients’ and partners’ anxiety
* All predictors are included in the statistical model, but in order to preserve readability only regression 
coefficients of baseline patient and partner anxiety on change of patient and partner anxiety are shown. For 
regression coefficients of remaining predictors, see ‘Baseline’ and ‘Change’ sections of Table 2. The numbers 
following the predictors in Table 2 correspond to the predictor numbers in the predictor box of Figure 1. For the 
same reasons, residual correlations between patients and partners for each measurement occasion are omitted 
in the graphical representation of the model. Abbreviations: b(i): unstandardized regression coefficient in the 
regression equation for the random intercept (i.e. baseline); b(s): unstandardized regression coefficient in the 
regression equation for the random slope (i.e. change); L
x
: loading on random slope factor; R(i,s): correlation 
random intercept and slope; V(e): residual variance; V(i): variance random intercept; V(s): variance random slope.
 For all four trajectories, a significant negative effect of baseline on change was observed (b=-
0.15 to -0.28). This means that people who reported relatively high distress levels at baseline, on 
average experienced a relatively larger reduction in distress over time. The residual correlation (i.e. 
after accounting for baseline distress and the covariates) in slope between patients and partners 
was .26 (Z=2.27, p=.023) for anxiety and .44 (Z=3.80, p<.001) for depression, which indicates that 
patients who experienced a relatively strong decrease in distress tended to have partners with also 
a relatively strong decrease in distress. With respect to the intercept (i.e. baseline distress) a similar 
pattern was observed: the patient-partner residual correlation in intercept was .35 (Z=5.29, p<.001) 
for anxiety and .32 (Z=5.18, p<.001) for depression. Thus, individual differences in baseline distress 
and change in distress correlated between patients and partners, with distress trajectories being 
relatively similar between patients and partners. 
 The included covariates - patient indication for ICD implantation, symptomatic heart failure, 
shock(s) during follow-up, partner gender, the age-adjusted version of the CCI and SES - were 
only able to explain a limited amount of the inter-individual variation in baseline distress (see R2 
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for baseline in Table 2). However, some noteworthy effects were found. With respect to the inter-
individual variation in baseline distress, partners of patients with symptomatic heart failure reported 
more baseline depressive symptoms than partners of patients without heart failure (b=0.60, Z=2.67, 
p=.008). Moreover, female partners tended to report significantly more anxiety at baseline than male 
partners (b=-0.60, Z=-2.42, p=.015), and patients with a higher CCI score tended to experience more 
depressive symptoms (b=.18, Z=2.09, p=.036). With respect to distress change, the key determinant 
was the occurrence of shock(s) during follow-up (see also R2 for change in Table 2). Patients who 
did not receive a shock during follow-up showed a significantly larger decrease in anxiety (b=0.89, 
Z=4.41, p<.001) and depression (b=0.75, Z=3.65, p<.001) as compared to patients who did receive a 
shock during follow-up. Shocks were also associated with less reduction in depressive symptoms in 
partners (b=0.44, Z=-2.17, p=.030). Since these results do not provide insight into the direction (i.e. 
positive or negative) of the growth curves for the shocked versus non-shocked patients and with 
shock being an important predictor of distress in the current study, simple slopes were computed, 
again for an average individual with and without shock (anxiety: without shock: b=-1.54, Z=-6.99, 
p<.001; with shock: b=0.25, Z=0.61, p=.54 and depression: without shock: b=-0.95, Z=-4.43, p<.001; 
with shock: b=-0.38, Z=-1.37, p=.17). This shows that whereas absence of shocks during follow-up 
was associated with a reduction in distress over time, this reduction during follow-up did not occur 
in patients who experienced a shock. Finally, patients with a primary prevention indication showed 
a significantly larger decrease in anxiety (b=.31, Z=2.08, p=.038) and depression (b=0.37, Z=2.52, 
p=.012) than patients with a secondary prevention indication.
Linking dyadic anxiety trajectories to patients’ health status
To examine whether partners’ distress would have an additional influence on patients’ health status, 
we built hierarchical models with cumulative addition of three blocks: (1) the six a priori selected 
covariates; (2) baseline and change factors of patient levels of emotional distress in the separate 
anxiety and depression models; and (3) baseline and change factors of partner levels of anxiety and 
depression in the separate anxiety and depression models. In Tables 3 and 4, the results of these 
latent growth models are presented. Overall, the models provided excellent fit to the data for all 
health status subscales (see top part Tables 3 and 4) and explained between 46-79% of the variance 
in patients’ health status scores. Due to strong correlation between the mental health subscale and 
the anxiety scale of the HADS, it was not possible to incorporate the mental health subscale in the 
anxiety model. In the depression model, the subscales mental health, role limitations - emotional 
and vitality could not be included due to strong correlation between patient depression, partner 
depression and the concerning subscales.
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 Emotional distress and patients’ baseline health status. The demographic and clinical covariates 
(step 1) explained between 3.2-14.4% of the variance. The presence of symptomatic heart failure 
and having a secondary prevention indication were the strongest predictors of lower health status 
at baseline (Table 3). Patients’ own baseline anxiety scores explained an additional 6.7-49.1% of the 
variance, depending on the particular subscale (step 2). Patients’ own anxiety scores were related to 
patients’ health status score on all subscales (all p<.001). In the third step, partners’ baseline anxiety 
scores were added, explaining 0.1-2.4% of the variance beyond the covariates and patients’ own 
anxiety scores. Each point of increase in partners’ baseline anxiety score was significantly associated 
with a 0.7 lower health status score on the social functioning subscale (b=-.07, Z=-2.03, p=.042). For 
the other subscales, partners’ baseline anxiety did not significantly predict patients’ baseline health 
status scores on top of the other included predictors. Similar results were found for the association 
between patients’ and partners’ depressive symptoms and patients’ baseline health status. For 
details, see Table 4.
 Emotional distress and patients’ change in health status over time. The demographic and clinical 
covariates altogether explained 3.2-14.3% of the variance in the change of patient health status 
over time. ICD indication, gender of the partner and the CCI were the most important associates 
of patients’ health status during follow-up, with patients with a secondary prevention indication, 
a male partner and lower CCI scores generally improving more on health status during follow-up 
(Table 3). In the second step patients’ own baseline anxiety and change in anxiety were added, 
with an additional 15.7-45.1% of the variance being explained. Patients’ own change in anxiety 
was the most important predictor of patients’ change in health status (p<.001 for all subscales 
except physical functioning (p>.05)), followed by patients’ baseline anxiety score. Partners’ anxiety 
explained 1.2-13.6% of additional variance in the model. Each point of increase in partners’ baseline 
anxiety was associated with a 4.2 point decrease in patient physical functioning during follow-up 
(b=-.42, Z=-5.38, p<.001). Moreover, increase in partner anxiety during follow-up was associated 
with impaired patient health status on all subscales except role limitations - physical (Table 3: b’s 
ranging from -.11 to -.18). Change in partner anxiety was a predictor of changes in patients’ health 
status on top of patients’ and partners’ baseline levels of anxiety, and on top of changes in patients’ 
own health status.
 Similar results were found for the association between patients’ and partners’ depressive 
symptoms and change in patients’ health status. These results are shown in Table 4. Importantly, 
increase in partner depression during follow-up was associated with worse recovery in patients’ 
health status with respect to physical functioning (b=-.25, Z=-3.25, p=.001), bodily pain (b=-.15, 
Z=-2.07, p=.039), social functioning (b=-.18, Z=-2.75, p=.006) and general health (b=-.19, Z=-2.87, 
p=.004), on top of baseline depression in patients and partners.
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Table 4. Patient health status trajectory linked to covariates and dyadic depression trajectories
Goodness of Fit PF RL-P BP SF MH RL-E VT GH
χ2(df=172) 464 410 428 483 - - - 456
RMSEA .063 .057 .059 .065 - - - .062
CFI .941 .943 .935 .929 - - .945
Baseline Intercept health status 6.663 ** 5.409 ** 7.738 ** 8.804 ** - - - 6.846 ***
Predictors Prevention indication -.068 ** -.129 -.293 * -.466 ** - - - .241 **
Symptomatic heart failure -.562 * -.511 * -.110 -.371 * - - - -.306 **
Gender partner -.354 -.230 -.251 * -.061 - - - -.019
SES -.145 -.101 -.247 ** -.266 * - - - -.138 *
Shock(s) .193 .109 .112 -.058 - - - .108
CCI -.139 * -.033 -.007 .093 - - - -.099 **
Depression baseline patient -.266 ** -.416 ** -.223 *** -.351 ** - - - -.295 ***
Depression baseline partner -.017 -.082 -.067 * -.060 - - - -.031
Variance 3.551 4.473 1.884 3.187 - - - 2.049
covariates R2 .144 .063 .072 .069 - - - .126
+patient R2 .294 .367 .327 .389 - - - .411
+partner R2 .292 .374 .339 .390 - - - .412
Change Slope health status 2.456 *** 2.584 ** 3.093 ** 6.242 *** - - - .381
Predictors Baseline health status -.263 *** -.164 -.231 * -.622 *** - - - -.064
Prevention indication .122 -.128 .249 * .284 ** - - - -.001
Symptomatic heart failure -.170 -.393 .018 -.101 - - - -.102
Gender partner .048 .131 .299 * .095 - - - .043
SES .036 -.107 .143 * -.007 - - - .028
Shock(s) .084 -.214 -.013 -.014 - - - -.179
CCI -.087 * -.036 -.027 .000 - - - .115 **
Depression baseline patient -.150 *** -.214 * -.152 ** -.265 *** - - - -.109 **
Depression change patient -.886 *** -1.140 *** -.553 *** -.772 *** - - - -.595 ***
Depression baseline partner -.011 -.019 .053 -.025 - - - -.002
Depression change partner -.249 ** -.220 -.147 * -.181 ** - - - -.187 **
Variance 0.164 1.976 .194 .134 - - - .436
baseline R2 .107 .015 .092 .394 - - - .016
+covariates R2 .162 .093 .235 .426 - - - .094
+patient R2 .858 .639 .784 .928 - - - .656
+partner R2 .940 .664 .868 .963 - - - .732
Trajectory L
1
0 0 0 0 - - - 0
L
2
.457 .098 -.058 .357 - - - .242
L
3
.892 .791 .837 .850 - - - .771
L
4
.956 .934 .863 .925 - - - .839
L
5
1 1 1 1 - - - 1
Residual Variance 1.612 7.444 3.396 2.473 - - - 1.045
Overall R2 .764 .551 .456 .608 - - - .792
† For analytical purposes, scores were transformed by dividing the sumscore for each scale by 10. The subscales mental 
health, role limitations-emotional and vitality were excluded due to very high correlations between depression scores 
and these particular subscales. Results are presented as unstandardized b’s as in regular regression analysis. Contrast 
coding was used for the dichotomous independent variables, with prevention indication: -1=primary indication, 
+1=secondary indication; symptomatic heart failure: -1=no, +1=yes; shock(s) during follow-up: -1=no, +1=yes; gender 
partner: -1=female, +1=male. * p ≤ .050; ** p ≤ .010; *** p ≤ .001. Abbreviations: BP, bodily pain; CCI, Charlson Comorbidity 
Index; CFI, comparative fit index; GH, general health; L, loadings on random slope factor for each measurement occasion; 
PF, physical functioning; r, correlation between random factors; RL-E, role limitations – emotional; RL-P, role limitations – 
physical; RMSEA, root mean square error of approximation; SES, socio-economic status; SF, social functioning; VT, vitality
        















































































Figure 2. Dyadic anxiety linked to patients’ health status (physical functioning as example)
* All predictors are included in the statistical model, but in order to preserve readability only regression coefficients 
of baseline patient and partner anxiety on change of patient and partner anxiety are shown. For regression 
coefficients of remaining predictors, see ‘Baseline’ and ‘Change’ sections in the physical functioning column of 
Table 3. All factors within the left dashed rectangle are correlated, but for reasons of intelligibility, we have only 
shown the associations between the anxiety factors and omitted the associations between the predictor box 
and the anxiety factors. The numbers following the predictors in Table 3 correspond to the predictor numbers 
in the predictor box of Figure 2. For the same reasons, residual correlations between patients and partners 
for each measurement occasion are omitted in the graphical representation of the model. Abbreviations: b(i): 
unstandardized regression coefficient in the regression equation for the random intercept (i.e. baseline); b(s): 
unstandardized regression coefficient in the regression equation for the random slope (i.e. change); V(e): residual 
variance; V(i): variance random intercept; V(s): variance random slope.
DISCUSSION
The findings of the current study showed that individual differences in baseline distress and change 
in distress correlated between patients and partners, with distress trajectories over time being 
relatively similar for patients and partners. Moreover, we found that patients’ baseline health status 
scores and change in health status scores during follow-up were strongly related to patients’ own 
baseline distress scores. On top of that, partners’ baseline anxiety was associated with lower social 
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functioning of patients, while partners’ baseline depression was associated with an increase in 
patients’ bodily pain. With regard to change in patient health status, higher partner baseline anxiety 
predicted decreases in patient physical functioning during follow-up. Additionally, increases in 
partner anxiety during follow-up were related to decreased patient health status for the domains 
physical functioning, bodily pain, social functioning, emotional role limitations, vitality and general 
health during follow-up, and increases in partner depression during follow-up with worse recovery 
of physical functioning, bodily pain, social functioning and general health. Importantly, although 
the amounts of explained variance of partner distress were not particularly high, worsening of 
partner distress during follow-up remained a predictor of changes in patients’ health status on top 
of patients’ and partners’ baseline levels of distress, with results being largely similar for anxiety and 
depression.
 The included demographic and clinical covariates predicted only a small amount of variance in 
all models. Nevertheless, with respect to partners’ baseline distress levels, we found that partners 
of patients with symptomatic heart failure were more distressed than partners of patients without 
symptomatic heart failure. This adds to the findings of previous studies showing that patients’ clinical 
characteristics, including comorbid medical conditions, contribute to partners’ risk of emotional 
distress.21,23 Female partners were also more distressed than male partners. This finding is in line 
with previous results among chronically ill patients and their partners.15 Increased distress in female 
partners could be attributed to several mechanisms, including greater psychosocial burden due to 
the condition of the spouse,39 a perception of failing in the caregiver role,39 increased attentiveness 
to emotions and use of less effective coping styles.41 
 In our study, patients with a primary prevention indication showed a more favorable course 
of psychological well-being, as anxiety and depressive symptoms more sharply decreased among 
these patients compared to patients with a secondary prevention indication. Previous research 
has found similar results.23 Importantly, the current study found a hampering effect of shocks on 
the recovery of anxiety and depression of patients, and depression of partners during follow-up. 
The impact of shocks on emotional distress may partly depend on the interval between shock and 
assessment of emotional distress,42 and as yet evidence on the impact of shocks on health status is 
mixed.42-45
 Patients’ and partners’ emotional distress patterns were comparable in course, and partners’ 
changes in emotional distress were associated with patients’ health status recovery during the first 
12 months post implantation, indicating that patients and partners go through a similar process of 
adaptation and emotion regulation after ICD implantation. Being part of a couple is highly effective 
when it comes to emotion regulation. Social baseline theory46 explains that close proximity is 
the baseline assumption of the human brain, and that social proximity and interaction decrease 
physical and mental costs of environmental demands via two mechanisms: risk distribution and 
load sharing. While the former may mainly be of interest from an evolutionary perspective, the latter 
may be particularly interesting in this context, because load sharing makes the patient perceive 
the environment as less threatening and less difficult to cope with. This produces large savings in 
terms of neural and peripheral physiological reactions, which can be beneficial for the ability to 
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cope mentally with the challenging situation, but also for cardiac functioning. For example, the 
absence of social proximity could lead to impaired control of emotions as a result of reduced 
mesolimbic functioning and to the release of stress hormones in the peripheral system.46 Thus, 
optimal psychological functioning of the partner increases the likelihood that the patient will be 
able to adapt to the new situation of living with an ICD both mentally and physically. 
 This study has some limitations. First, we were not able to include a measure of dyadic coping 
styles in the current study. Coping can influence the emotional distress pattern of patients and 
partners, and previous research has shown that patients with emotional distress are more likely 
to use ineffective coping strategies, such as avoidance and withdrawal,47 which tend to be similar 
in both partners within the dyad.48 Non-adaptive coping is thus a risk factor that runs within the 
dyad when emotional distress is present. A related concept that was not measured in the current 
study is relationship quality. Although there is evidence for a link between relationship quality and 
patient and partner outcomes, there is also evidence that being part of a relationship on its own is 
predictive of affect and health.49 Furthermore, this study was conducted mainly amongst Caucasian 
patients living in a western society. Dyadic interaction and expression of emotions may be culture-
dependent, making these results not necessarily generalizable to patients of other origins. 
 An important strength of this study is the sound statistical methodology, benefiting fully of 
the longitudinal design of the study. Furthermore, the focus on the interrelationship between 
both patients’ and partners’ distress on the one hand and on patients’ health status on the other 
hand is new in arrhythmia research. In addition, the large sample size, particularly regarding the 
participating partners, and the high participation rate, are advantages of the study. 
 In conclusion, we found that distress patterns of patients and partners were highly similar, and 
that although patients’ own emotional distress played an important role in predicting their health 
status at both baseline and change therein during follow-up, on top of that, the development of 
partner distress during follow-up was also predictive of how well patients’ health status was able to 
recover after implantation. The influence of the distress recovery of partners was visible on a wide 
range of patient health status subscales during follow-up. Since partner distress is a risk factor for 
poor coping, and partners play a key role in the recovery of patients, interventions should not only 
be focused on psychological functioning of the patient but also that of  the partner.
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ABSTRACT
Background: Emotional distress levels in partners of implantable cardioverter-defibrillator (ICD) 
patients are even higher than in ICD patients. We investigated the influence of partner distress on 
long-term mortality risk in patients with an ICD. 
Methods: Distress was measured in 418 first-time ICD patients and their partners with the Hospital 
Anxiety and Depression Scale (HADS) at baseline. Study endpoint was all-cause mortality (up to 6 
years follow-up). Cox proportional hazard regression analyses were used to separately assess the 
impact of partners’ depression and anxiety on time to mortality. 
Results: In total, 78 patients (18.7%) died during follow-up (mean follow-up 4.9±1.5 years, range 
0.1-6.0 years). Depression and anxiety, defined as a score of ≥8 on the HADS-D and HADS-A, were 
present in 24.4% and 27.3% of the patients, and 22.2% and 43.1% of the partners, respectively. 
Partner depression was associated with patients’ mortality risk in unadjusted analysis (HR=1.64; 
95% CI=1.01-2.65; p=.044). After inclusion of patients’ own emotional distress in the analyses, this 
relationship became non-significant (HR=1.43, 95% CI=0.86-2.38, p=.17). There was no association 
between partner anxiety and patients’ prognosis (HR=1.13, 95% CI=0.71-1.78, p=.61) in adjusted 
analysis. 
Conclusion: Partner depression was associated with risk of patient mortality, but when adjusting 
for patient levels of distress this fell short of statistical significance. Partners’ psychological well-
being seems to affect patients’ psychological well-being more than patients’ physical prognosis. 
Future research should focus on the impact of persistent, long-term emotional distress in partners, 
and on comorbid distress within the patient-partner dyad in relation to patient prognosis.
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INTRODUCTION
The implantable cardioverter-defibrillator (ICD) is the treatment of first choice for patients at risk for 
sudden cardiac death (SCD) due to life-threatening ventricular tachyarrhythmias, both as primary 
and secondary prevention.1-3 Emotional distress, including symptoms of anxiety, depression and 
posttraumatic stress, is prevalent in about 25% of patients with an ICD and influences their quality of 
life4-7 but also prognosis.8,9 In addition to the patient’s psychological profile, the partner’s emotional 
functioning also plays an important role in their adaptation process.10 Previous research has shown 
that emotional distress is at least as prevalent in partners of ICD patients as it is in patients.11,12 
Moreover, partner emotional distress is correlated with patient emotional status in terms of 
depressive and anxious symptoms.11
 However, little is known about the association between partner emotional distress and patient 
clinical outcomes, both in the cardiac and non-cardiac population. Research on the relationship 
between marital quality and mortality risk in patients with heart failure has shown that reduced 
marital quality was predictive of a higher risk for mortality up to 8 years follow-up.13 Behavioral 
factors, including the ability to discuss the disease with each other and observed positivity of the 
partner, were particularly important determinants of survival. However, this long-term predictive 
effect was only significant for women with heart failure.13,14 Although some research has focused on 
marital status and marital quality in relation to patient prognosis, the association between partner 
distress and patient prognosis remains unknown in the cardiac population, and the ICD population 
in specific. Partner distress may play a role in patient prognosis beyond the well-established effect 
of patients’ own emotional distress on their prognosis.15,16 Therefore, the aim of the current study 
was to investigate the influence of partner emotional distress, defined as the presence of significant 
symptoms of depression and anxiety, on risk of long-term mortality (up to 6 years follow-up) in 
patients with an ICD. 
METHODS
Patients and study design
The Mood and personality as precipitants of arrhythmia in patients with an Implantable cardioverter 
Defibrillator: A prospective Study (MIDAS) was set up in the Erasmus Medical Center, Rotterdam, in 
collaboration with Tilburg University, the Netherlands, to examine the psychological functioning of 
patients with a first-time ICD implantation and their partners. Between August 2003 and February 
2010, 448 consecutive patients and their partners were enrolled in the study. Patients with a life-
expectancy of <1 year, on the waiting list for heart transplantation, a history of psychiatric illness 
other than affective/anxiety disorders, or insufficient knowledge of the Dutch language were 
excluded from participation. 
 The study was conducted according to the Helsinki Declaration, and the study protocol was 
approved by the Medical Ethics Committee of the Erasmus Medical Center. An ICD nurse provided 
written and oral information on the study to patients and their partners prior to ICD implantation, 
after which written informed consent was obtained from both patients and partners. The couples 
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were asked to complete a similar set of standardized and validated questionnaires at baseline (i.e. 
one day prior to implantation).
Measures
Demographic and clinical variables
Demographic characteristics (i.e. age, gender, marital status and educational level) of both patients 
and partners were collected via purpose-designed questions in the questionnaires. Information 
on patients’ and partners’ socio-economic status (SES) was obtained from the Central Bureau of 
Statistics Netherlands. Information on clinical patient characteristics including indication for ICD 
therapy (primary versus secondary prevention), treatment with cardiac resynchronization therapy 
(CRT), left ventricular ejection fraction (LVEF) ≤35%, QRS duration, the presence of coronary artery 
disease (CAD), symptomatic heart failure (defined as New York Heart Association (NYHA) functional 
class III+IV), atrial fibrillation, prior percutaneous coronary intervention (PCI) or coronary artery 
bypass grafting (CABG), smoking, and use of cardiac (i.e. beta-blockers, statins, amiodarone, 
diuretics, ACE-inhibitors, and digoxin) and psychotropic medication, were collected from patients’ 
medical records at the time of implantation. Furthermore, the Charlson Comorbidity Index (CCI) 
was constructed using data indicating the presence of renal failure, previous MI, chronic heart 
failure, diabetes mellitus, peripheral arterial disease, cerebrovascular disease, chronic obstructive 
pulmonary disease and cancer. In order to obtain a comorbidity index that is in accordance with the 
original CCI, a weight of 2 was assigned to renal failure and any malignancy, and a weight of 1 to 
the other comorbid conditions. The sum score of this index was subsequently adjusted for age, with 
addition of 1 extra point for each decade above age 50.
Anxiety and depression
The Hospital Anxiety and Depression Scale (HADS) was used to measure symptoms of anxiety and 
depression in patients and partners at baseline. This is a 14-item self-report questionnaire consisting 
of 7 items measuring symptoms of anxiety (HADS-A) and 7 items measuring symptoms of depression 
(HADS-D).17 Items are rated following a 4-point Likert scale ranging from 0 to 3 (total score range 
0-21), with higher scores reflecting more symptoms.17 A cut-off score of ≥8 reflects optimal balance 
between sensitivity and specificity18 and was used in the current study to define patients with 
clinically significant levels of anxiety and depression. The HADS has good psychometric properties, 
with mean Cronbach’s alphas of 0.83 and 0.82 and a three-week test-retest reliability of 0.89 and 
0.86 for the HADS-A and HADS-D subscales, respectively.19 The HADS is a valid instrument designed 
to measure separate symptoms of anxiety and depression in a non-psychiatric hospital setting.18
Endpoint
All-cause mortality was used as endpoint in this study. Information on survival status up to 6.0 years 
post implantation was obtained via the Dutch municipal register and patients’ medical records. The 
administrative date for end-of-study was set at June 1st 2013, as this was the time of updating the 
mortality data from the Dutch municipal register.
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Statistical analyses
Baseline demographic and clinical variables for patients with complete versus incomplete data were 
compared with the χ2 test (Fisher’s Exact test when appropriate) for nominal variables, and Student’s 
t-test for continuous variables. 
 The assumption of proportional hazards was checked by inspection of the log-minus-log plots 
for nominal variables and partial residual plots for continuous variables. In case of violation of the 
assumption, that variable was transformed into a time-dependent variable, enabling inclusion 
in the analyses without violating the proportional hazards assumption. Cox proportional hazard 
regression analyses were used to separately assess the impact of dichotomous partner depression 
and anxiety on time to all-cause patient mortality. In multivariable analyses using the Enter method, 
indication for ICD implantation, the age-adjusted CCI as an index for comorbidity burden, the use of 
amiodarone, and the presence of appropriate and inappropriate shocks were included as covariates. 
In addition, patient depression was included as covariate in the analysis examining the relation of 
partner depression to patient mortality, and anxiety was included in the analysis of the association 
between partner anxiety and patient mortality in order to avoid the problem of multicollinearity. 
Covariates were a priori selected based on the literature. Results of the Cox regression analyses 
are reported using hazard ratios (HR) with their corresponding 95% confidence intervals (CI). 
Additionally, p-values are reported with a value <.05 (two-sided) indicating statistical significance. 
Cumulative survival curves for mortality risk predicted by the presence of anxiety and depression 
in partners were constructed using the Kaplan-Meier method. The log-rank test was used to 
compare the proportion of cumulative survival stratified by group. Patients who underwent heart 
transplantation during the study (N=21) were censored as alive at the time of heart transplantation 
in both unadjusted and adjusted analyses due to removal of their ICD system. Furthermore, patients 
who were transferred to another hospital and therefore lost to follow-up (N=4) were censored as 
alive because clinical variables could not be obtained from the moment of losing contact. Results 
were repeated with continuous scores of partner depression and anxiety. PASW Statistics 19 
statistical software was used to analyze the data (PASW IBM Corp., Armonk, NY, USA). 
RESULTS
Patient and partner baseline characteristics
Overall, 448 patients were included in the study, of whom 11 (2.5%) had no partner. In addition, 18 
patients (4.0%) and 30 partners (6.8%) did not complete the questionnaires. In total, 418 (93.3%) 
dyads of patient and partner were included in the adjusted analyses. Patients with complete data 
were compared with patients who did not participate in the analyses due to incomplete data. 
Patients who were not included in analyses were more likely to have a low SES (defined as a SES 
ranking of 1 or 2 on a scale of 1-10; p=.030), to suffer from CAD (p<.001), symptomatic heart failure 
(p=.027) and diabetes (p=.017), and to use psychotropic medication (p=.012).
 Baseline demographic and clinical characteristics of patients and demographic characteristics 
of partners are shown in Table 1. The mean age of patients was 58±12 years, and 321 (79%) of the 
patients were male. Partners’ mean age was 56±12 years and 90 (22%) of the partners were male. 
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Mean age (±SD) 58.3 (12.1) 56.0 (12.0)
Men 328 (78.5) 92 (22.0)
Lower SES † 192 (45.9) ‡ 192 (45.9) ‡
Clinical factors
Primary  prevention indication 275 (65.8)
CRT 120 (28.7)
LVEF ≤35% § 309 (73.9)
Mean QRS (±SD) 129.4 (36.4)
CAD 236 (56.5)
Previous PCI 107 (25.6)
Previous CABG 80 (19.1)
Symptomatic heart failure # 136 (32.5) ‡
Atrial fibrillation 94 (22.5)
Diabetes 58 (13.9)
Smoking 43 (10.3) || 106 (25.4) **








Psychotropic medication 64 (15.3) †† 67 (16.0) **
* Data are presented as N (%), unless otherwise indicated. † Based on ZIP-code and calculated per household by 
the Netherlands Institute for Social Research, ‡ N=2 (0.5%) missing; § N=59 (14.1%) missing; # defined as NYHA 
functional class III+IV, N=2 (0.5%) missing; || N=4 (1.0%) missing; ** N=3 (0.7%) missing; †† N=6 (1.4%) missing. 
Abbreviations: ACE, angiotensin-converting enzyme; CABG, coronary artery bypass grafting; CAD, coronary 
artery disease; CRT, cardiac resynchronization therapy; LVEF, left ventricular ejection fraction; N, number; PCI, 
percutaneous coronary intervention; QRS, QRS duration; SD, standard deviation; SES, socio-economic status
All-cause mortality
In total, 78 patients (18.7%) died during follow-up (mean follow-up period 4.9 ±1.5 years, range 0.1-
6.0 years). Patients who underwent heart transplantation before ending of the study (N=21, 5.0%) 
were censored, as their ICD was explanted. In adjusted analyses, 28 additional patients (6.7%) were 
censored due to hospital transfer (and absence of clinical follow-up), just as 22 (5.3%) patients who 
were lost to follow-up. 
Emotional distress within the dyad
In Table 2, mean continuous scores of depression and anxiety for patients and partners are reported, 
as well as the Pearson correlation between patients’ depression and anxiety, and partners’ depression 
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and anxiety. Using the cut-off score of ≥8 on the HADS-D to identify patients and partners with 
clinically significant levels of emotional distress, in 61.7% of the cases, neither the patient nor 
the partner showed depressive symptoms, while in 8.4% of the cases both patients and partners 
reported significant depressive symptoms. For 13.7% we found that the patient was not depressed 
while the partner was depressed, and for 16.1% we found that the patient was depressed while the 
partner was not depressed.
 With respect to anxiety, in 44.6% of the dyads neither the patient nor the partner was anxious, 
while in 14.9% of the dyads both the patient and the partner were anxious. In 28.0% of the cases, 
only the partner was anxious, while in 12.5% of the dyads only the patient experienced anxiety 
symptoms.
Table 2. Mean levels of and correlations between emotional distress of patients and partners *
Depression patient Anxiety  patient Depression partner Anxiety  partner
HADS-score 4.93 ± 3.95 5.48 ± 3.97 4.90 ± 3.86 7.16 ± 4.40
Correlation Depression patient Anxiety  patient Depression partner Anxiety  partner
Depression patient 1
Anxiety patient 0.661** 1
Depression partner 0.237** 0.261** 1
Anxiety partner 0.198** 0.292** 0.714** 1
* Results are presented as mean score on the HADS-D and HADS-A ± standard deviation.
**Pearson correlation coefficient r is significant on a p<.001 level (two-tailed). 
Relationship between partner distress and patient risk of all-cause mortality
Proportional hazards assumptions were checked and met for all variables, except for the occurrence 
of shocks during follow-up, which was therefore transformed into a time-dependent variable. 
Results of the Cox regression analyses are presented in Table 3.
 Depression – Cumulative hazard functions were significantly different for patients with versus 
without a depressed partner (log-rank χ2=4.13; p=.042) (Figure 1). In unadjusted Cox regression 
analysis, partner depression was associated with a cumulative increased risk for all-cause mortality 
(HR=1.64; 95% CI=1.01-2.65; p=.044). When adjusting for the a priori selected clinical covariates, 
the relationship between partner depression and risk of mortality was reduced to trend level 
(HR=1.63; 95% CI=1.00-2.67; p=.053), and when adding patients’ own depression to the model, the 
relationship between partner depression and patient mortality became non-significant (HR=1.43; 
95% CI=0.86-2.38; p=.17), with patient depression being a significant predictor of patient mortality 
(HR=1.67; 95% CI=1.03-2.70; p=.038).
 Anxiety – Cumulative hazard functions did not differ significantly for patients with versus 
without an anxious partner (log-rank χ2=1.68; p=.20) (Figure 2). Partner anxiety was not associated 
with an increased risk for patient all-cause mortality during follow-up in unadjusted Cox regression 
analysis (HR=1.34; 95% CI=0.86-2.09; p=.20). Inclusion of the covariates did not change the results. 
 Repeating the results with continuous scores of partner emotional distress yielded similar 
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findings for both depression (unadjusted: HR=1.06; 95% CI=1.01-1.11; p=.037; adjusted: HR=1.05; 
95% CI=0.99-1.12; p=.11) and anxiety (unadjusted: HR=1.03; 95% CI=0.98-1.08; p=.27; adjusted: 
HR=1.02; 95% CI=0.97-1.08; p=.40).
Table 3. Results of the Cox regression analyses*
Partner depression
Block 1 HR 95% CI p
Depression partner 1.58 0.97-2.58 .066
Block 2 HR 95% CI p
Depression partner 1.63 1.00-2.67 .053
Indication for ICD 
implantation
1.45 0.90-2.34 .13
Use of amiodarone 1.60 0.99-2.61 .06
CCI 1.39 1.27-1.53 <.001
Shocks during follow-up 1.16 0.99-1.35 .07
Block 3 HR 95% CI p
Depression partner 1.43 0.86-2.38 .17
Indication for ICD 
implantation
1.50 0.92-2.42 .10
Use of amiodarone 1.49 0.90 -2.45 .12
CCI 1.38 1.25-1.52 <.001
Shocks during follow-up 1.16 0.99-1.35 .06
Depression patient 1.67 1.03-2.70 .038
Partner anxiety
Block 1 HR 95% CI p
Anxiety partner 1.31 0.84-2.05 .24
Block 2 HR 95% CI p
Anxiety partner 1.16 0.74-1.83 .52
Indication for ICD 
implantation
1.39 0.86-2.25 .18
Use of amiodarone 1.64 1.00-2.67 .049
CCI 1.39 1.26-1.52 <.001
Shocks during follow-up 1.16 0.99-1.36 .06
Block 3 HR 95% CI p
Anxiety partner 1.13 0.71-1.78 .61
Indication for ICD 
implantation
1.43 0.88-2.33 .15
Use of amiodarone 1.59 0.97-2.61 .06
CCI 1.39 1.27-1.53 <.001
Shocks during follow-up 1.16 1.00-1.36 .06
Anxiety patient 1.29 0.79-2.12 .31
* Bold p-values indicate statistical significance, bold and italic p-values indicate significance on a trend level. 
Abbreviations: CCI, Charlson Comorbidity Index; CI, confidence interval; HR, hazard ratio 
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Number of patients at risk
Baseline 1 year 2 years 3 years 4 years 5 years 6 years
No partner depression* 325 316 305 293 278 274 269
Partner depression* 93 88 80 78 74 70 67
Total # of patients 418 404 385 371 352 344 336
* A cut-off score of ≥8 on the HADS-D was used to define depression
Figure 1. Cumulative survival curve stratified by partners’ depression

















Number of patients at risk
Baseline 1 year 2 years 3 years 4 years 5 years 6 years
No partner anxiety* 238 233 224 213 203 199 196
Partner anxiety* 180 171 161 158 149 145 140
Total # of patients 418 404 385 371 352 344 336
* A cut-off score of ≥8 on the HADS-A was used to define anxiety
Figure 2. Cumulative survival curve stratified by partners’ anxiety
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DISCUSSION
To our knowledge, this is the first study in ICD patients to examine the relationship between 
partner emotional distress and patient risk of mortality, using a large cohort of ICD patients and 
their partners and a long term follow-up period. Knowledge on a possible contribution of partners’ 
psychological well-being to the patients’ mortality risk is important, as it can provide us with targets 
for risk management and psychological treatment. The primary aim of this study was to investigate 
whether emotional distress in partners would be associated with an increased risk of long-term 
all-cause mortality in patients with a first-time ICD implant. We found that partner depression was 
associated with increased risk of patient mortality, but only in unadjusted analyses. When entering 
patients’ own levels of emotional distress in the model, the relationship between emotional distress 
in partners and risk of mortality in patients became non-significant. We found no significant 
relationship between partner anxiety and patient risk of mortality. Clinical indicators of disease 
severity, including use of amiodarone and a higher CCI, were significant predictors of patient long-
term all-cause mortality risk. 
 To date, the association between partner emotional distress and prognosis of patients with 
heart disease remains understudied. However, in previous research investigating the relationship 
between partner distress and patient emotional outcomes, we found that partners’ emotional 
status was predictive of patients’ health status on several subdomains, beyond patients’ own own 
emotional status (Hoogwegt MT, Braeken J, Kupper N, Theuns DAMJ & Pedersen SS, unpublished 
data, 2013). The psychological status of partners is thus more likely to affect patients’ psychological 
well-being instead of patients’ physical status. 
 To our knowledge, no study has investigated the relationship between partner emotional 
distress and patient risk for morbidity and mortality in cardiovascular disease. Within the current 
literature though, several related concepts are frequently used in patient-partner research, including 
marital status, marital satisfaction or quality, and social support. Marital status refers to the question 
whether the patient has a partner or not, while marital quality is a marker of how satisfied patients 
and partners are about the relationship and the benefits that follow from that relationship. In both 
the general and cardiac population, marital status and marital quality have shown to be predictive 
of patient prognosis, with patients having a partner and being satisfied with this relationship 
displaying more favourable health outcomes than patients without a partner.13,14,20-23 Social support 
is associated with a better prognosis of cardiac patients as well,24 although there are also indications 
of this relationship being explained by lifestyle behaviors such as medication adherence and 
sedentary behaviour.25,26 However, besides these related concepts as predictors of patient prognosis, 
to our knowledge, no research to date has examined the relationship between partner distress and 
patient mortality, neither in the cardiac, nor in the non-cardiac population.
 We hypothesized that several mechanisms could explain a possible relationship between 
partner distress and patient mortality. First, partners with emotional distress are more likely to use 
inadequate coping strategies, such as avoidance and withdrawal.27 Coping styles are known to 
be similar within the dyad, which means that ineffective coping of partners could affect patients’ 
coping.28  Adequate coping is crucial when it comes to health behaviors, which are strongly predictive 
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of patient prognosis.29,30 With impaired coping resources in distressed partners, social support is also 
likely to be lower in these dyads, which again may increase the risk of poorer prognosis.24 In the light 
of our null-finding, these mechanisms may more likely explain the correlation between partner and 
patient emotional distress instead of a relationship between partner distress and patient prognosis. 
Future research should focus on the question whether persistent emotional distress in the partner 
(i.e. significant symptoms of depression and/or anxiety over a longer period of time) might have a 
stronger impact on patient prognosis than emotional distress around the time of implantation. In 
addition, it would be interesting to examine whether comorbid emotional distress within the dyad 
(i.e. in both patients and partners) might increase patient risk of morbidity and mortality more than 
if distress is present only in the partner or the patient. Unfortunately, we were not able to examine 
these two aspects in our study due to the relatively low number of events.
 The following limitations should be acknowledged. First, we have not been able to examine the 
association between partner emotional distress and cardiac-related mortality, because the cause 
of death was unclear from a considerable number of medical records. As a result, it is difficult to 
speculate about possible underlying mechanisms explaining the relationship between emotional 
distress and prognosis. Second, due to the limited number of patients who died during follow-up, we 
have not been able to include all factors that may impinge upon the relationship between partner 
distress and patient mortality. However, by including demographic and clinical covariates based on 
the literature, we have tried to incorporate as many relevant variables as possible. Furthermore, the 
design of the study permitted us to only use baseline measures of emotional distress in relation to 
patients’ risk of mortality. 
 An important strength of the current study is the relatively long mean follow-up period of 
4.9 years. This allowed us to study the long-term effect of partners’ emotional distress around 
implantation on patients’ risk of mortality. In addition, the partner sample size was particularly large, 
facilitating a reliable statistical evaluation. Third, the survival models were both performed with 
dichotomous and continuous measures of depression and anxiety. Finally, to our knowledge, no 
other study to date has examined the relationship between partner distress and patient prognosis 
in cardiovascular patients.
 To conclude, the current study among ICD patients found no association between partner 
emotional distress and patient risk of mortality over a mean follow-up of 6 years. The psychological 
status of partners turns out to be more likely to affect patients’ psychological well-being, instead 
of patients’ physical status. More research on this important topic is warranted and should focus 
on persistent emotional distress in the partner and the presence of comorbid emotional distress 
within the dyad. Nevertheless, given that partners of ICD patients play a major role in the adaptation 
process around and after ICD implantation, partners should be involved in order to facilitate as 
adequate adaptation to the challenging treatment of the ICD as possible.
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ABSTRACT
Background: Understanding the reasons for implantation with an implantable cardioverter-
defibrillator (ICD) and possible implications for daily life is crucial for patients’ adaptation. Few studies 
have examined the information ICD patients receive, their satisfaction, potential gaps in information 
provision, and patients’ needs and preferences. We examined (1) the information provided around 
ICD implantation; (2) patients’ satisfaction with the information; and (3) the association between 
information provision and satisfaction and emotional distress.
Methods: Patients (N=188) implanted with an ICD at two centers in the Netherlands completed a 
survey that included a purpose-designed vignette tapping into information provision and patient 
satisfaction, and standardized questionnaires on symptoms of depression and anxiety. The data 
were analyzed using descriptive statistics and linear regression analyses.
Results: The extent of adequate information provision differed per topic, with information on 
technical aspects of the ICD and patients’ underlying heart disease being communicated to 85-99% 
of patients. Information about potential ICD-related psychological, social and sexual consequences 
was provided to ±60% of patients. Approximately 33% of patients expressed a wish for more 
information. Importantly, lower satisfaction with information on  psychological consequences (β=-
0.31, p=.001), physical limitations (β=-0.25, p=.005) and driving limitations (β=-0.22, p=.012) was 
associated with increased levels of anxiety.
Conclusions: Health-care professionals may omit discussing certain topics when informing patients 
around the time of implantation, which may influence not only patient satisfaction but also their 
emotional well-being. Training of staff responsible for information provision could be one step 
towards improving information provision to patients around the time of ICD implantation.
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INTRODUCTION
The implantable cardioverter-defibrillator (ICD) is the best available treatment option for patients 
at risk of sudden cardiac death due to ventricular arrhythmias, both as primary and secondary 
prevention.1-3 The majority of ICD patients adapt well to living with an ICD, while about 1 in 4 
patients report significant levels of symptoms of anxiety and depression post implantation.4-6 This 
may not necessarily be attributable to the device itself, but also to the underlying heart disease,7 
symptomatic heart failure,8,9 and the patient’s pre implantation psychological profile.6,10
 Sufficient understanding of the reasons for ICD implantation, benefits and side effects of the ICD 
and its physical, mental and social implications for daily life play a major role in patients’ adaptation 
post implantation. Previous research has shown that adequate information provision and psycho-
education can help patients to adapt to life with an ICD and reduce emotional distress.11-14 As such, 
health-care professionals play a key role in discussing the issues surrounding ICD implantation with 
patients and their families in order to facilitate optimal understanding and adaptation. Paradoxically, 
recent surveys among ICD patients have indicated that many patients have insufficient knowledge 
of why they were implanted with an ICD, its possible side effects and benefits.15,16 In addition, 
involving the patient in the informed decision-making process around ICD implantation has shown 
to be a considerable challenge in clinical practice.17 
 Despite the importance of adequate patient education around ICD implantation, a paucity 
of studies have examined the actual amount of information patients receive, patients’ needs and 
preferences, and patients’ satisfaction with this information. In order to optimize the care and 
management patients with an ICD and their satisfaction with treatment, it is important to increase 
our knowledge of the information provision process in clinical practice. Therefore, the aims of the 
current study were to (1) map out the process of information provision around ICD implantation; (2) 
evaluate patients’ satisfaction with the information provided in terms of amount, content, timing, 
and understanding of the information; and (3) examine whether level of information provision and 
patient satisfaction with this information are associated with symptoms of depression and anxiety.
METHODS
Patients and study design
All patients implanted with an ICD or ICD with cardiac resynchronization therapy (CRT-D) based 
on the current guidelines between May 2012 and October 2013 in the Erasmus Medical Center, 
Rotterdam, and the TweeSteden Hospital, Tilburg, the Netherlands, aged ≥18 years, and sufficiently 
proficient in the Dutch language to complete the questionnaire, were approached for participation 
in the current study. Exclusion criteria included insufficient knowledge of the Dutch language 
and being unable or unwilling to provide written informed consent. In addition, patients already 
participating in a clinical trial with patient-reported outcomes (e.g. quality of life, anxiety or 
depression) as endpoints were ineligible for study participation.
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 Patients were identified via the institutional databases of the Erasmus Medical Center and the 
TweeSteden Hospital and approached via a letter sent to their home address. The letter included 
written information about the study, a written informed consent form, a questionnaire package 
comprised of a vignette, a set of standardized and validated questionnaires together with a self-
addressed, stamped envelope. If the questionnaire package was not returned within three weeks to 
the principal investigators at Tilburg University, a reminder letter and a new questionnaire package 
with a self-addressed, stamped envelope was sent. 
 The study protocol was approved by the Medical Ethics Committee of the Erasmus Medical 
Center, and the study was conducted according to the Helsinki Declaration. Written informed 
consent was obtained from all participating patients.
Measures
Demographic and clinical variables
Information on demographic characteristics (i.e. age, gender, marital status and educational 
level) was obtained via purpose-designed questions in the questionnaire. Information on clinical 
characteristics and patient’s medical history was captured from their medical records, including 
indication for ICD therapy (primary versus secondary prevention), type of ICD (i.e. single chamber, 
dual chamber, CRT-D or subcutaneous ICD), left ventricular ejection fraction (LVEF) ≤35%, QRS 
duration, the presence of CAD, symptomatic heart failure (defined as New York Heart Association 
(NYHA) functional class III+IV), atrial fibrillation, prior percutaneous coronary intervention (PCI) or 
coronary artery bypass grafting (CABG), and use of cardiac medication (i.e. beta-blockers, statins, 
amiodarone, diuretics, ACE-inhibitors, and digoxin). Information on the occurrence of appropriate 
and inappropriate shocks was obtained via device interrogation during follow-up. Furthermore, 
information to construct the Charlson Comorbidity Index (CCI)18 was gathered, including the 
presence of renal failure, previous myocardial infarction (MI), chronic heart failure, diabetes mellitus, 
peripheral arterial disease, cerebrovascular disease, chronic obstructive pulmonary disease and 
cancer. The sum score of this index was subsequently adjusted for age, with the addition of 1 extra 
point for each decade >50 years of age.19
Information provision and patient satisfaction
For the purpose of the current study, a vignette was designed, asking patients to recall the time 
around ICD implantation with respect to information received on specific topics (i.e. the patient’s 
underlying heart disease, how the ICD works, which therapies the ICD can provide, what to do in 
case of a shock, psychological, social and sexual consequences of having an ICD, physical limitations 
due to the ICD and driving limitations) and how satisfied they were with the information in terms 
of quantity, content, timing and their understanding of the information. The vignette is displayed 
in Figure 1.
 In order to collect additional data on information provision, we adapted the EORTC-INFO-25 
questionnaire to ICD patients. The EORTC-INFO-25 was originally developed to measure information 
disclosure to cancer patients and has shown to be a reliable and valid self-report instrument.20 
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Patients were asked to rate items on a 4-point Likert scale, with scores being linearly transformed via 
an algorhitm to a 0-100 scale. Four subscales can be derived from the EORTC-QLQ-INFO-25, including 
information about the disease (4 items), information about medical tests (3 items), information about 
treatment (6 items), and information about other services (i.e. out-of-hospital help, rehabilitation, 
dealing with the disease at home, psychological help, 4 items), as well as 8 single items which were 
not used in the current study.  
Emotional distress: symptoms of depression and anxiety
The Patient Health Questionnaire (PHQ-9) was used to assess symptoms of depression. Based 
on the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria of depression, this 
questionnaire consists of 9 items rated on a Likert scale from 0 to 3 (score range 0 to 27). The PHQ-9 
has shown to be a reliable and valid measure of depressive symptomatology, with a sensitivity and 
specificity of 88%.21
 Anxiety symptoms were assessed with the Generalized Anxiety Disorder (GAD-7) scale, a 7-item 
questionnaire measuring generalized anxiety with items being scored on a 4-point Likert scale from 
0 to 3 (score range 0 to 21).22 The psychometric properties of the GAD-7 are adequate.23
Statistical analyses
Baseline demographic and clinical variables for responders versus non-responders and for patients 
from the Erasmus Medical Center versus the TweeSteden Hospital were compared with the Chi-
square test (Fisher’s Exact test when appropriate) for nominal variables, and Student’s t-test for 
continuous variables. Frequency distributions and mean scores were computed in order to quantify 
self-reported information provision and patient satisfaction with information provision as collected 
with the vignette. The relationship between information provision and emotional distress was 
examined with unadjusted and adjusted linear regression analysis. Covariates were selected a priori 
based on the literature, with gender, the age-adjusted version of the CCI, center of implantation, and 
time since implantation being included as covariates in adjusted analyses using the Enter method. A 
p-value of <.05 (two-sided) was used to indicate statistical significance. PASW Statistics 20 statistical 
software was used to analyze the data (PASW IBM Corp., Armonk, NY, USA). 
RESULTS
Patient baseline characteristics
A questionnaire package was sent to 324 patients, of which 227 patients were implanted in the 
Erasmus Medical Center and 97 patients in the TweeSteden Hospital. Of these, 5 patients (1.5%; 
N=2 from the Erasmus Medical Center and N=3 from TweeSteden Hospital) had moved and their 
new home address was unknown, and 3 patients (0.9%; N=2 from the Erasmus Medical Center and 
N=1 from TweeSteden Hospital) refused to participate. Furthermore, 128 patients (39.5%) neither 
responded to the initial questionnaire nor to the reminder, resulting in a response rate of 58.0%. 
Patients who were not included in the analyses due to refusal, loss to follow-up or non-response 
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(N=136) were compared with patients who were included (N=188) on demographic and clinical 
characteristics. No systematic differences between the two groups were found (all p>.05). 
 Table 1 provides an overview of the baseline demographic and clinical characteristics of the 
total sample, stratified by implanting center. The mean age of patients was 61±13 years, and 127 
(68%) of the patients were male. A few systematic differences were found in demographic and 
clinical patient characteristics between the two hospitals. Patients from the Erasmus Medical Center 
were more likely to be younger (p<.001), to be male (p=.009) and to have undergone a previous 
PCI (p=.028), but less likely to suffer from symptomatic heart failure (p=.029) and to be prescribed 
diuretics (p=.002). No other systematic differences between patients from the two hospitals were 
found on baseline characteristics.









Mean age (±SD) 61.6 (13.3) 59.3 (14.6) 66.3 (8.6) <.001
Men 127 (67.6) 93 (73.8) 34 (54.8) .009
Clinical factors
Primary  prevention indication 143 (76.1) 94 (74.6) 49 (79.0) .50
LVEF ≤35% † 108 (68.8) 65 (67.0) 43 (71.7) .54
Mean QRS (ms ±SD) ‡ 127.9 (31.2) 126.1 (30.9) 133.6 (31.7) .19
CAD 99 (52.7) 65 (51.6) 34 (54.8) .68
Previous PCI 56 (29.8) 44 (34.9) 12 (19.4) .028
Previous CABG 27 (14.4) 17 (13.5) 10 (16.1) .63
Symptomatic heart failure § 30 (16.7) 16 (12.7) 14 (25.9) .029
Atrial fibrillation 45 (23.9) 33 (26.2) 12 (19.4) .30
Diabetes 41 (21.8) 24 (19.0) 17 (27.4) .19
Medication
Amiodarone 22 (11.7) 14 (11.1) 8 (12.9) .72
Beta-blockers 147 (78.2) 95 (75.4) 52 (83.9) .19
Diuretics 100 (53.2) 57 (45.2) 43 (69.4) .002
ACE-inhibitors 106 (56.4) 73 (57.9) 33 (53.2) .54
Statins 106 (56.4) 66 (52.4) 40 (64.5) .12
Digoxin 17 (9.0) 11 (8.7) 6 (9.7) .83
* Data are presented as N (%), unless otherwise indicated. † N=31 (16.5%) missing; ‡ N=22 (11.7%) missing; § N=8 
(4.3%) missing. Abbreviations: ACE, angiotensin-converting enzyme; CABG, coronary artery bypass grafting; CAD, 
coronary artery disease; EMC, Erasmus Medical Center; LVEF, left ventricular ejection fraction; N, number; PCI, 
percutaneous coronary intervention; QRS, QRS duration; SD, standard deviation; site 1, Erasmus Medical Center; 
site 2, TweeSteden Hospital
 Of all patients who completed the questionnaire package, 17-18% did not complete the vignette 
but did complete the other questionnaires. These patients were not included in the prevalence of 
information provision and mean satisfaction scores as shown in Table 2. This subset of patients was 
also excluded from the unadjusted and adjusted linear regression analyses as shown in Table 3.
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Information provision and patient satisfaction around implantation
When comparing information provision and patient satisfaction with information provision between 
the Erasmus Medical Center and the TweeSteden Hospital, patients from the TweeSteden Hospital 
received less information about which therapies the ICD can provide in case of an arrhythmia 
(p=.009) and about driving limitations (p=.024) as compared to patients from the Erasmus Medical 
Center. However, no differences were found with respect to patient satisfaction with the information 
provided by the two hospitals.  
 The results of the frequency of information provision and patient satisfaction with the provided 
information are shown in Table 2. Generally, information on more technical aspects related to the 
ICD and patients’ underlying heart disease was provided, with 85-99% of patients reporting to be 
informed about these topics. The majority of patients also reported that they were notified of what 
to do in case of an ICD shock. Interestingly, patients reported that information on psychological, social 
and sexual aspects of being implanted with an ICD was less frequently provided. Approximately 
60% of patients reported having received information on these topics. By contrast, information 
on physical limitations (81%) and driving limitations (88%) was more frequently provided. Not 
surprisingly, patient satisfaction with information provision was related to whether this information 
was provided. The highest satisfaction with amount, content, timing and understanding of 
information was found for information provision regarding the more technical aspects of the ICD 
and their underlying heart disease, whereas the lowest satisfaction was reported for information 
provision about psychological, social and sexual consequences of having an ICD. However, overall 
patient satisfaction on information provision was high as indicated by a mean satisfaction score of 
3.9 on a scale from 1 to 5.  
 In an open-ended question, patients were also asked to list which topics they would have liked 
to receive more information about around the time of implantation. The topics most frequently 
mentioned were information about the ICD itself (N=24, i.e. placement, risks, underlying heart 
disease, life span of the ICD and what to do after having received a shock), physical limitations as 
a result of the implantation (N=18; i.e. healing process, physical rehabilitation, exercise, driving 
limitations and weight of the subcutaneous ICD), psychological consequences (N=13; i.e. how to 
deal with feelings of anxiety, how to receive psychological treatment, psychological consequences 
for the family), social consequences (N=8; i.e. return to work, traveling, care at home) and the wish 
for more information in general (N=5). 
Association between information provision, satisfaction, and emotional distress
In order to examine the relationship between information provision and emotional distress, patients’ 
answers on the yes/no question ‘did you receive information on the following topics?’ were used for 
the topics psychological consequences, social consequences and sexual consequences of having 
an ICD, since these were the topics most likely not to have been addressed around the time of 
implantation. These results are presented in Table 3. No significant associations were found between 
information provision and emotional distress (i.e. depression and anxiety), neither in unadjusted 
analyses nor in adjusted analyses. 
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 In addition, for each topic, the mean satisfaction score from Table 2 was related to emotional 
distress. No significant associations between patient satisfaction and depression were found (all 
p>.05). However, lower patient satisfaction with the information provided about psychological 
consequences (β=-0.31, t=-3.37, p=.001), physical limitations (β=-0.25, t=-2.88, p=.005) and driving 
limitations (β=-0.22, t=-2.53, p=.012) was related to higher levels of anxiety. These relationships 
remained significant after adjusting for time since implantation, gender, the age-adjusted CCI and 
center of implantation.
Table 3. Association between information provision and symptoms of depression and anxiety (unadjusted and 
adjusted analyses)
Topic β t p
Unadjusted - depression
Psychological consequences of having an ICD 0.11 1.31 .19
Social  consequences of having an ICD 0.12 1.50 .14
Sexual  consequences of having an ICD 0.02 0.21 .83
Unadjusted - anxiety
Psychological consequences of having an ICD -0.09 -1.13 .26
Social  consequences of having an ICD -0.13 -.156 .12
Sexual  consequences of having an ICD -0.01 -0.09 .93
Adjusted - depression
Psychological consequences of having an ICD 0.12 1.47 .14
Social  consequences of having an ICD 0.12 1.48 .14
Sexual  consequences of having an ICD 0.02 0.27 .79
Adjusted - anxiety
Psychological consequences of having an ICD -0.11 -1.36 .18
Social  consequences of having an ICD -0.15 -1.82 .07
Sexual  consequences of having an ICD 0.002 0.02 .98
DISCUSSION
Given that adequate information provision around the time of ICD implantation can help patients 
to adjust to life with an ICD and reduce emotional distress,11-14 it is paradoxical that information 
provision and patient satisfaction with this information remains understudied.24-28 Available studies 
have used either a qualitative study design, examined a small sample of patients, or studied other 
cardiovascular populations than ICD patients.24-26 Hence, our knowledge of information provision 
and patient satisfaction with this information is limited in the general cardiac population, and is 
lacking in ICD patients with a need to identify gaps in patients’ potential needs and preferences. 
 To our knowledge, our study is one of the first in ICD patients to examine the process of information 
provision around the time of ICD implantation, patients’ satisfaction with this information, and to 
relate these aspects to emotional distress. Generally, information on a wide range of topics was well 
covered, with particularly information on technical aspects of the ICD and patients’ underlying heart 
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disease being conveyed to patients. Nevertheless, approximately 40% of the patients reported not 
having received information on potential psychological, social and sexual consequences of living 
with an ICD. Lower patient satisfaction with the information provided about these specific topics 
was related to higher levels of anxiety, also when adjusting for time since implantation, gender, the 
age-adjusted CCI and center of implantation.
 The results of our study from the patients’ perspective seem to largely correspond to health-
care professionals’ attitudes towards ICD therapy and issues that they discuss with patients.29 In 
a recent survey, physicians reported that they are more inclined to discuss clinical issues, such as 
device- and shock-related matters, and less frequently broach psychosocial issues, including the 
impact of the device on quality of life, sexual functioning and the family. This survey also revealed 
that health-care staff, such as nurses, was more likely to discuss psychosocial issues.29 It is possible 
that most physicians feel ill equipped to discuss these issues with patients, either due to time 
constraints, feelings of insecurity or other reasons. However, given that health-care staff other than 
physicians also do not always seem to cover the full range of topics that patients deem important, 
it is important to consider how this may be improved. One way would be to compile a checklist of 
topics that the physician or ICD nurse need to discuss with patients prior to implantation. Another 
way might be to add a psychologist to the multi-disciplinary team to support other health-care 
professionals, who may play an important role in training hospital staff how to communicate with 
patients and may be consulted for the diagnosis and treatment of psychological problems. Knowing 
that there is a mental health professional to refer to might alleviate the fears of some health care 
professionals of broaching particular topics.
 On the whole, patient satisfaction was high, with slightly lower satisfaction scores on the topics 
that were less frequently provided. Importantly, this indicates that patient education around the 
time of implantation is generally well taken care of in these two hospitals in the Netherlands, with 
few differences found between the centers. There is room for improvement though, with about 
one third of patients still reporting that they wish to receive more information about the ICD itself, 
physical limitations, and psychological and social consequences. The finding that lower patient 
satisfaction with information provision about potential psychological consequences, physical 
limitations and driving limitations was associated with increased levels of anxiety highlights not only 
the importance of information provision itself, but also that patients’ satisfaction with information 
provision may influence their emotional well-being. 
 The limitations of this study should be acknowledged. First, the response rate was somewhat 
low in comparison to other surveys.27,30 Second, as the number of missing answers to the vignette 
was relatively high, this suggests that the lay-out chosen for the vignette might have been too 
complicated for several patients. In addition, the study design was retrospective, which may have 
biased the results. However, time since implantation was included as a covariate in the analyses but 
had no influence.
 This study also has several strengths. Patients were included from two centers (one a university 
medical center and the other a peripheral teaching hospital), and few differences emerged between 
the centers. In addition, this is the first study with such a large sample size that has examined several 
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aspects of information provision and patients’ satisfaction, while also providing detailed information 
on ICD patients’ demographic and clinical profile. 
 In conclusion, we found that overall patients were well informed about a wide range of topics 
related to what to expect post ICD implantation. Information about technical aspects of the ICD 
and patients’ underlying heart disease was particularly well covered. However, information about 
potential psychological, social and sexual consequences of having an ICD was less frequently 
discussed, with approximately one third of patients expressing a wish for more information. 
Less information provision about these topics was reflected in lower patient satisfaction scores, 
and importantly, lower satisfaction scores were associated with increased levels of anxiety. The 
current study thus highlights the importance of not only information provision itself, but also 
patients’ satisfaction with the information provision process. Cardiologists, but also nurses and ICD 
technicians, have indicated that they might find it difficult to broach psychological, social and family 
matters with ICD patients,29 while patients in the current study indicated that these are just the 
issues they are the least satisfied with in terms of the extent of information provided. Accordingly, 
training of the staff responsible for information provision by for example a psychologist could be 
one step forward towards further improving the information provision process around the time of 
ICD implantation, patient satisfaction and patient well-being.
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ABSTRACT
Background: Twenty-five to 33% of patients with an implantable cardioverter-defibrillator (ICD) 
experience anxiety and depression, but it is not known whether their symptoms are adequately 
treated. We investigated (1) whether patients with clinically relevant symptoms of distress received 
appropriate treatment, and (2) whether patients not treated for their emotional distress reported 
poorer health status using a prospective study design.
Methods: A consecutive cohort of 448 first-time patients with an ICD (21% women; mean age, 
58±12 years) completed the Hospital Anxiety and Depression Scale (HADS) and the Short Form 
Health Survey 36 (SF-36). Information on psychological treatment was obtained via purpose-
designed questions.
Results: At baseline, 35.5% of patients were emotionally distressed, of which 70.2% received no 
psychological treatment. At 12 months post-implantation, 24.3% of all patients had clinically 
significant levels of distress, of which 58.3% received no treatment. Patients experiencing distress 
but without treatment reported a significantly poorer health status than patients without distress 
and treatment (all p<.001) and compared to patients without emotional distress who did receive 
treatment (p varying between p=.027 and p<.001 for 6 subscales). Health status was better on four 
subscales than for patients with emotional distress and treatment (p varying between p=.034 and 
p<.001).
Conclusions: There was a serious gap between the need for psychological treatment and the 
actual delivery of treatment, with consequences to patients’ health status. Detection and adequate 
treatment of distress in ICD patients remains an important target in this patient group in order to 
safeguard health status post-implantation.
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INTRODUCTION
The implantable cardioverter-defibrillator (ICD) is the therapy of first choice for patients at risk for 
life-threatening ventricular arrhythmias, with mortality reductions up to 23% in both primary and 
secondary prophylaxis patients.1-5 Although the majority of patients with an ICD reach acceptable 
levels of psychosocial functioning after ICD implantation,4,6 a subgroup of 25-33% reports significant 
levels of anxiety, depression and posttraumatic stress.7-11 In 50% of these patients, anxiety and 
depression remain at a clinically high level during the first year post implantation.8,9 Distress in 
patients with an ICD not only influences daily functioning but has also been associated with an 
increased risk of ventricular arrhythmias12,13 and mortality.7,14 
 The prevalence of emotional distress has been studied frequently over the last decade with 
distress receiving increasingly more attention in clinical cardiology practice,15,16 although it is far 
from optimal.16 However, identification of anxiety or depression does not automatically result in 
appropriate treatment, with a gap in the delivery of adequate care for patients with anxiety and 
depression. In epidemiological studies among the general population, with one-year prevalence 
rates of 8-17% and 5-11% for anxiety and mood disorders, respectively,17,18 prescription patterns 
reveal that two-thirds of patients do not receive pharmacological treatment for their mental 
disorder.17-19 An even smaller number of patients is treated by a mental health professional.17,18  In 
post myocardial infarction (MI) patients, increases in the prescription of antidepressants have been 
reported, but these were attributed to a general trend of increased prescription rates rather than 
raised attention to the mental health of patients.15 In patients with an ICD, a recent study found 
a considerable mismatch between patients with clinically significant levels of depression and 
pharmacological treatment, with only one out of 33 patients depressed at baseline and/or at 2 years 
post implantation receiving antidepressant therapy.20 
 To our knowledge, a paucity of studies in patients with an ICD have examined the level 
of emotional distress and whether patients with clinically significant levels receive adequate 
treatment.  Furthermore, it remains unclear if distress left untreated leads to impaired health status, 
with health status being an independent predictor of morbidity and mortality in patients with an 
ICD.21,22 Therefore, we examined (1) whether patients with clinically relevant symptoms of anxiety 
and depression received appropriate treatment (i.e. either psychotropic medication or treatment 
by a psychologist) and (2) whether patients not treated for their emotional distress report poorer 
health status. 
METHODS
Patients and study design
The study cohort consisted of consecutive patients (N=448) who were implanted with a first-time 
ICD between August 2003 and February 2010 in the Erasmus Medical Center, Rotterdam, the 
Netherlands, and who were enrolled in the prospective Mood and personality as precipitants of 
arrhythmia in patients with an Implantable cardioverter Defibrillator: A prospective Study (MIDAS). 
Exclusion criteria were a life-expectancy <1 year, being on the waiting list for heart transplantation, 
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history of psychiatric illness other than affective/anxiety disorders, or insufficient command of the 
Dutch language. Prior to ICD implantation, patients were approached by an ICD nurse, who provided 
written and oral information on the study, and asked patients to complete a set of standardized and 
validated questionnaires. Assessment took place at baseline (i.e. one day prior to implantation), and 
at 3, 6 and 12 months post implantation. The study protocol was approved by the Medical Ethics 
Committee of the Erasmus Medical Center, and the study was conducted according to the Helsinki 
Declaration. All patients provided written informed consent. 
Measures
Demographic and clinical variables
All demographic and clinical variables were collected at baseline and were obtained from patients’ 
medical records or from purpose-designed questions in the questionnaires. Information on 
demographic variables included age, gender, marital status and educational level. Information 
on clinical variables included indication for ICD therapy (primary versus secondary prevention), 
treatment with cardiac resynchronization therapy (CRT), left ventricular ejection fraction (LVEF) 
≤35%, QRS duration, the presence of coronary artery disease (CAD), symptomatic heart failure 
(defined as New York Heart Association (NYHA) functional class III+IV), atrial fibrillation, diabetes 
mellitus, prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), 
smoking, and use of cardiac medication (i.e. beta-blockers, amiodarone, diuretics, ACE-inhibitors, 
statins, and digoxin). The occurrence of ICD therapy for ventricular tachyarrhythmias, both anti 
tachycardiac pacing episodes and shocks (both appropriate and inappropriate) was prospectively 
registered in our institutional database.
Anxiety and depression
Symptoms of anxiety and depression were measured at baseline, and at 3, 6 and 12 months follow-
up using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-report questionnaire 
consisting of 7 items measuring symptoms of anxiety (HADS-A) and 7 items measuring symptoms 
of depression (HADS-D).23 All items are rated on a 4-point Likert scale, with scores ranging from 0 to 
3 (total score range of 0-21); higher scores reflect more symptoms.23 The psychometric properties 
of the HADS are good, with mean Cronbach’s alphas of 0.83 and 0.82 and a three-week test-retest 
reliability of 0.89 and 0.86 for the HADS-A and HADS-D subscales, respectively.24 The HADS is a 
valid instrument for screening for separate symptoms of anxiety and depression and was originally 
developed for assessment in non-psychiatric hospital settings.25 A cut-off score of ≥8 indicates 
an optimal balance between sensitivity and specificity,25 which we used in the current study to 
detect patients with clinically significant levels of anxiety and depression. Because of the high 
level of comorbidity between anxiety and depression and a large overlap in medication use for 
these conditions,17,26 anxiety and depression were combined into one variable reflecting emotional 
distress, defined as a score of ≥8 on the HADS-A or HADS-D, or both. 
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Health Status
The Short Form Health Survey 36 (SF-36) was used to assess patients’ health status at baseline, and 
at 3, 6 and 12 months post-implantation.27  The questionnaire consists of 36 items that contribute 
to eight subscales: physical functioning (10 items), role limitations - physical (4 items), bodily pain 
(2 items), social functioning (2 items), mental health (5 items), role limitations - emotional (3 items), 
vitality (4 items) and general health (5 items). Scores on the individual subscales range from 0 to 100, 
with higher scores indicating better health status.28 The SF-36 has adequate scale reliabilities, with 
Cronbach’s alphas ranging from 0.78 to 0.92 in the general population and 0.66 to 0.90 in a group of 
cancer patients, respectively.27
Psychological treatment for emotional distress
Information on the use of psychotropic medication (predominantly anxiolytic and antidepressant 
medication) and treatment for emotional distress (defined as treatment either by a psychologist or 
the use of psychotropic medication, or both) was obtained at baseline, and at 3, 6 and 12 months 
follow-up via purpose-designed questions in the questionnaires. Previous research has shown 
moderate to high concordance between written self-report measures of medication use and other 
measures of medication adherence, including plasma drug concentrations.29
Statistical analyses
Baseline characteristics were compared with the χ2 test (Fisher’s exact test when appropriate) for 
nominal variables and one-way analysis of variance (ANOVA) with post hoc Bonferroni correction in 
case of a significant main effect for continuous variables. In order to compare patients in the different 
treatment conditions, four groups were defined: (1) no emotional distress and no treatment; (2) no 
emotional distress and treatment; (3) emotional distress and treatment; and (4) emotional distress 
and no treatment. The last group was used as reference group when comparing the first three 
groups on health status during follow-up. Cross-tabulations were performed to obtain information 
on treatment trends in emotionally distressed versus non distressed patients. 
 In order to examine whether patients who are not treated for their emotional distress report 
poorer health status, repeated measures analysis of variance (RM ANOVA) using general linear mixed 
modelling analysis was performed, using an unstructured covariance structure. This technique is 
suitable for analysis of repeated measurements, as it reckons with the possibility of correlated data. 
In addition, in contrast to traditional repeated measures ANOVA, one missing measurement occasion 
does not automatically lead to exclusion of that patient from analysis, limiting bias and preserving 
statistical power. First, intraclass correlations (ICCs), a measure of score dependencies within the 
patients, were computed for each subscale. A priori based on the literature, we decided to adjust 
for the following covariates: gender, age, educational level, indication for ICD therapy, presence of 
CAD, symptomatic heart failure, atrial fibrillation, diabetes mellitus, the use of beta-blockers and 
the occurrence of shocks (combined appropriate and inappropriate) during the 12 month follow-
up period. All independent variables except group membership were set as fixed variables. Group 
membership was considered as time-varying, i.e. allowed to vary over time. The described effects 
in the results section are the effect of subgroup membership at any time point on the level of health 
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status over time, including all measurement occasions. Analyses were performed using SPSS 17.0 




From the 448 patients enrolled in the MIDAS study, 18 did not complete sufficient items on the 
HADS and/or the SF-36. In addition, 5 patients had missing data on treatment (either psychotropic 
or treatment by a psychologist) and were omitted. All remaining 425 patients (response rate 96.0%) 
provided sufficient data to be included in statistical analyses. Patients who were excluded from 
analyses were more likely to suffer from atrial fibrillation (p=.018). There were no other systematic 
differences on demographic and clinical baseline characteristics between study participants and 
non participants.
Baseline characteristics
Baseline characteristics of the remaining 425 patients are displayed in Table 1. The mean age was 
58±12 years and 337 (79.3%) of the patients were male. Overall, 151 patients (35.5%) had clinically 
significant levels of emotional distress. Divided into the 4 different patient groups, 237 (55.8%) 
had no emotional distress and were not receiving treatment, 37 (8.7%) had no emotional distress 
but received treatment, 45 (10.6%) had emotional distress and were treated, and 106 (24.9%) 
experienced emotional distress but received no treatment.  The various emotional distress and 
treatment groups did not differ significantly from each other on most variables. However, a few 
baseline differences were found. First, male patients were less likely to report emotional distress 
and to receive treatment for their distress than female patients. In addition, both distressed and non 
distressed single patients received more treatment (both p=.03). Patients having a lower educational 
level reported more emotional distress but did not receive treatment (p=.01). Finally, patients who 
smoked reported more emotional distress, both when treated and not treated (p=.04). 
Course of group membership during follow-up
Because the time-varying nature of the distress and treatment condition, we investigated whether 
patients stayed in the same group during follow-up. On average, 55% of the patients stayed in the 
same group between baseline and 12 months follow-up. When the subgroups were examined 
separately, patients with no distress and no treatment were found to stay in this group during 
follow-up in 85% of the cases. Patients with no distress who did receive treatment, and patients with 
distress who did receive treatment, both stayed in the same group in 49% of the cases. Importantly, 
39% of the patients in our reference group (distress but no treatment) remained untreated for their 
distress during the follow-up moments. In case of change, patients without distress and treatment 
were most likely to switch to the distress and no treatment group. Patients in the remaining 3 groups 
were all most likely to switch to the no distress and no treatment group.
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 As our main goal was to investigate the effect of distress and treatment group on health status, 
examining the effect of changing from distress and treatment group on health status is beyond the 
scope of this article. 
Psychological treatment of emotional distress in ICD patients at 12 months post 
implantation
During the 12-months follow-up, information on treatment was lacking in 96 patients. Mean 
scores on anxiety and depression at 12 months post implantation of the remaining 352 patients 
are displayed in Table 2, which differed significantly between the 4 groups (p<.001). At 12 months 
post implantation, 86 patients (24.3% of all patients) had clinically significant levels of distress, of 
which 41 (47.7%) had comorbid anxiety and depression. Divided into 4 groups, 225 (63.9%) had no 
emotional distress and received no treatment, 41 (11.6%) had no emotional distress but received 
treatment, 36 (10.2%) had emotional distress and received treatment, and 50 (14.2%) experienced 
emotional distress but received no treatment.
Course of health status over time
Mean health status scores for each subscale at all measurement occasions for the total patient 
population are displayed in Figure 1. A small improvement in health status was seen during the first 
3 months post implantation for each subscale (all p<.001). After this, scores tended to remain stable 
up to 12 months follow-up (all p>.05). Mean health status scores on the 4 measurement occasions 
for each subscale and stratified by group are shown in Figure 2.





















Figure 1. Mean scores on health status during the 12-month follow-up period 
Health status in patients treated and not treated for emotional distress
Intraclass correlations (ICCs), describing the correlations between the different measurement 
occasions within patients, were computed. ICCs ranged from 0.37 for role functioning - emotional 
to 0.73 for general health, indicating moderate to high correlations, as was expected in this repeated 
measures design. In Table 3, acquired estimates, t- and p-values are displayed. At any time point, 
patients experiencing emotional distress but not receiving psychological treatment reported 
significantly poorer health status on all subscales than patients without distress and treatment (all 
p<.001). 
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In addition, they reported inferior scores on physical functioning (p=.004), social functioning 
(p=0.001), mental health (p<.001), role functioning - emotional (p=.027), vitality (p<.001) and 
general health (p=.012) as compared to patients without emotional distress but receiving treatment. 
However, patients with emotional distress but without treatment experienced better health status 
with respect to bodily pain (p=.034), social functioning (p=.001), mental health and role functioning 
- emotional (both p<.001) than patients with emotional distress receiving treatment.
Interaction effects
Interaction effects between emotional distress and treatment on the one hand and time on the 
other hand were also examined for each subscale. In line with the main analysis, patients who 
suffered from emotional distress but who did not receive treatment were used as reference group. 
Interaction effects between time and subgroups were found on 2 subscales. With regard to bodily 
pain, patients without emotional distress and treatment improved significantly more during the first 
3 months than the reference group (p=.004). On the subscale vitality, patients with no emotional 
distress and no treatment showed significantly more improvement during the first 3 months than 
patients in the reference group (p<.001). The same applied to patients with emotional distress 
receiving treatment (p=.020). Finally, patients without emotional distress and with treatment 
reported more improvement on vitality than patients in the reference group (p=.004) between 6 
and 12 months follow-up.
DISCUSSION
In the current study, there was a serious gap between the prevalence of psychological distress 
and need for and the actual delivery of such treatment, with approximately two thirds of patients 
in need of treatment receiving none. In the subset of patients who were distressed and received 
treatment, the treatment response was poor, as reflected by these patients reporting the most 
impaired health status. Although patients treated for their distress reported poorer health status 
than patients with high levels of distress who were not treated, the latter group demonstrated 
significantly less improvement in health status at 12 months follow-up on the vitality subscale of 
the SF-36. As impaired health status has been found to be an independent predictor of morbidity 
and mortality in patients with an ICD,21,22 the need for adequate psychological treatment is evident. 
Highly distressed patients treated for their distress reported the poorest health status across all 
health status domains and at all follow-up occasions as compared to the other groups. At first 
sight, this finding may seem counterintuitive, but due to greater impairments in daily functioning, 
this subset of patients may be prone to consult their physician or mental health professional 
more rapidly. Alternatively, it is possible that the treatment offered to this subset of patients is not 
sufficient considering the specific needs of patients with an ICD. In terms of type of treatment, in 
our sample the majority of patients receiving treatment were prescribed psychotropic medication, 
while only a small part consulted a psychologist. Yet, emotional problems occurring in this patient 
group can be very complex and specific (i.e. excessive fear for ICD firing and the unpredictability and 
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uncontrollability of receiving shocks),30,31 such that being treated with psychotropic medication may 
not suffice and more specialized treatment by an experienced medical psychologist is warranted. 
This could explain the finding that distressed patients receiving treatment report the poorest health 
status in our sample. In addition, patients being treated for their emotional distress were more 
often single and women. Although the evidence is not conclusive, women with an ICD might be at 
heightened risk of psychological distress, in particular anxiety.32
 Approximately half of the patients stayed in the same subgroup during 12 months follow-up. 
When patients crossed over to another distress and treatment group during follow-up, they were 
all most likely to report low levels of distress and not to be treated. Thus, we can conclude that a 
substantial part of the patients remained free of distress or recovered from their distress during 
follow-up, which is supported by previous research in this patient population.33 However, a small 
subgroup of patients (approximately 8%) with no distress and receiving no treatment at inclusion 
is at risk for experiencing distress during follow-up, while not being treated for it. In addition, 
about 40% of untreated distressed patients remained in this condition during the 12 months of 
follow-up. This emphasizes the need for adequate monitoring and treatment, not solely around the 
implantation procedure but also during the first year(s) of follow-up.
 The findings of this study match the conclusions of previous studies investigating psychological 
treatment and psychopharmacological prescription rates in the general population, as well as 
in primary and secondary care. However, the current study also extends our knowledge of the 
prevalence of treatment for psychological distress in patients with an ICD, identifying a clear 
mismatch. Two studies among the general population highlight the discrepancy between the 
prevalence of mental health problems and receiving treatment.17,18 
 Several barriers exist that may prevent individuals from obtaining adequate mental health care. 
Not only underdiagnosis and lack of awareness on the part of the health care provider contribute 
to this problem, but also individual patient factors, including willingness to disclose problems and 
having negative stereotypes of psychological treatment, as well as systemic factors, such as access 
to medical care.18 Alonso and Lépine (2007) have indicated that only 36.8% of patients with a mood 
disorder and 20.6% of patients with anxiety seek help for these problems. Of these, still 20% received 
no psychological treatment, indicating that help seeking does not always result in adequate care.17 
In primary care patients, less than half of patients with any mood disorder receive any type of 
psychotropic drug.19 A substantial part of patients with a 12-month diagnosis of pure depression 
receive only anxiolytics, indicating inadequate treatment in addition to undertreatment.19 Several 
studies have reported that in particular patients with anxiety are at risk for undertreatment.17,18 
Although not specifically examined in this study, this is important to patients with an ICD, as anxiety 
is one of the most prevalent and disturbing symptoms among these patients, often with a chronic 
course.9,10,34
 One could argue that all patients with clinically significant levels of anxiety and depression 
should be treated with psychotropic drugs or be referred to a mental health professional. The 
importance of symptom reduction is evident, given the negative impact on quality of life, ventricular 
tachyarrhythmias and mortality.7,14,35 A recent meta-analysis indicates that selective serotonin 
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reuptake inhibitors (SSRIs) are safe to use in patients with depression and CAD.36 In addition, SSRIs 
have proven to favour clinical outcomes, including improvement in heart rate variability (HRV), 
decrease of ventricular extrasystoles and number of shocks, and patient-reported outcomes, 
including symptoms of depression, anxiety and quality of life in both non depressed and depressed 
patients with an ICD.37,38  The effectiveness of behavioral interventions in patients with an ICD has 
also been confirmed, as indicated by reduced symptoms of anxiety and depression and improved 
exercise capacity.39-41
 The current study has several strengths. These include the high response rate, the relatively 
large sample size and the prospective study design with several measurement occasions. In 
addition, the moderate to high intraclass correlations underline the importance of reckoning with 
correlated data, with the relatively new statistical approach used in the current study meeting this 
requirement. Furthermore, information on emotional distress and treatment were present during 
the entire follow-up period. 
 The limitations of the present study should also be acknowledged. First, the small number of 
patients treated by a psychologist made it necessary for us to combine the use of psychotropic 
medication with treatment by a psychologist into one treatment variable. In addition, information 
on pharmacotherapy and treatment by a psychologist was based on self-report, which could lead to 
an underestimation of actual treatment rates. Third, we had no information on the type of specific 
psychotropic agents used at the different measurement occasions. However, Lecrubier (2007) has 
demonstrated that we still do not know what constitutes optimal psychopharmacological therapy 
for specific psychological symptoms.19 
 In conclusion, the current study indicates that there is serious gap between the prevalence of 
psychological distress and need for treatment, and the actual delivery of such treatment in patients 
with an ICD. Importantly, emotional distress that is untreated may have a detrimental influence on 
health status, which in turn may increase the risk of morbidity and mortality in this subset of patients. 
Closing the gap between the common symptoms of emotional distress and access to effective 
pharmacological and psychological treatment remains an important target in both primary and 
secondary prevention in this patient group. This could be accomplished by enhancing awareness 
in both physicians and patients, incorporating standard screening of psychosocial functioning 
in clinical practice, paying more attention to cross-talk between the responsible physician and 
mental health care provider in patients’ medical records, and implementing specific psychological 
treatment programs targeting the specific issues and needs of patients with an ICD. 
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The implantable cardioverter-defibrillator (ICD) is the treatment of first choice for the primary and 
secondary prevention of sudden cardiac death (SCD) in patients at high risk of life-threatening 
ventricular arrhythmias, with mortality risk reductions of 37% for all-cause mortality and 57% for 
sudden cardiac death when compared to antiarrhythmic drugs.1-3 Expansion of the indications for 
ICD implantation throughout the years owing to encouraging results of primary prevention trials 
has led to an increasing number of patients living with an ICD.4 Despite the unequivocal medical 
benefits of the ICD, a subset of ICD patients experiences emotional distress, including symptoms of 
depression, anxiety, and posttraumatic stress, as well as reduced quality of life.5-7 
 Due to cumulative evidence that the patient’s psychological profile and level of distress are 
associated with risk of morbidity and mortality8 and affect compliance,9 recent European Guidelines 
on cardiovascular disease prevention in clinical practice emphasize the need to manage patients’ 
distress.10 According to these guidelines, adequate management of these factors via individual 
or group counselling has proven to have additional beneficial effects on biomedical risk factors 
and emotional distress, beyond cardiac rehabilitation. The sole focus on the management of the 
underlying somatic condition has thus shifted towards treating the patient as a whole, with the 
recognition that biological, psychological and social factors all interact to contribute to the patient’s 
well-being and survival. 
 Although attention to more diverse risk stratification in ICD patients clearly has increased and 
models using multiple clinical risk markers have shown promising results regarding prediction of 
SCD risk,11 there still remains a need for more optimal identification of vulnerable patients within 
the ICD population, in which there might also be a role for psychological factors. 
 The main objectives of this thesis were therefore to (1) expand the knowledge on clinical 
associates of emotional distress; (2) investigate autonomic nervous system (ANS) functioning as a 
potential associate of psychological and clinical outcomes; (3) further elucidate the influence of the 
partner on psychological and clinical outcomes of the patient; and (4) explore which information 
and psychological care are available to ICD patients in standard clinical practice and the needs and 
preferences of patients with this respect.
Emotional distress in patients with complications and more complex disease
Despite the unequivocal benefits of ICD therapy in terms of survival, research has also pinpointed 
the possible ‘side effects’ of ICD therapy in terms of a potentially negative impact on patient well-
being.12 Complications, including procedure- (e.g. lead dislodgement, infection) and device-
related (inadequate sensing, inappropriate shocks) issues, may affect psychological adaption post 
implantation. Since it is known that the patient’s emotional distress level tends to be at its highest 
within the first months post implantation, Chapter 2 examined the association of procedure- and 
device related complications with emotional distress. We found that the occurrence of procedure- 
and device-related complications around and post implantation was associated with increased 
symptoms of anxiety and ICD-related concerns, while no relationship was found with depressive 
symptoms. The association of complications with general and ICD-specific anxiety instead of 
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depression seems logical, since complications may more likely infringe on patients’ confidence in 
the ICD as a ‘life-saver’, which in turn may induce anxiety and insecurity. The observation that one 
in six patients experienced a complication throughout the first year emphasizes the importance of 
careful clinical and psychological monitoring of patients around and post implantation. 
 Comorbidities, including myocardial infarction (MI), chronic heart failure (CHF), renal failure 
and diabetes, are highly prevalent among ICD patients,13 with multiple comorbidities often 
hampering patients’ daily living and functioning. Chapter 3 investigated the relationship between 
comorbidities assessed with an age-adjusted version of the Charlson Comorbidity Index (CCI) 
and emotional distress. In contrast to the findings in Chapter 2, where procedure- and device-
related complications were associated with increased anxiety, we found that comorbidity burden 
was associated with depressive symptomatology and impaired physical health status. Since 
comorbidities may impinge on patients’ activity levels, sleeping pattern, and social life, and thus 
overall lead to impaired physical functioning, this likely induces depressed mood and feelings of 
hopelessness rather than anxiety. Due to overlap in for example somatic symptoms of depression 
(i.e. sleep disturbance, loss of energy and weight changes) and clinical conditions such as CHF or 
renal failure, it may be a challenge in clinical practice to accurately signal psychological symptoms 
and not only interpret them as a ‘normal’ reaction to or part of impaired physical functioning.  Both 
Chapters 2 and 3 extend our knowledge of the relation between somatic conditions, comorbidities 
and psychological distress by confirming a link between physical and psychological symptoms. 
This underlines the importance of attention to a holistic approach to patient care including both 
clinical and psychological factors. Notwithstanding, the question whether a clinical high-risk profile 
leads to impaired psychological well-being, or the other way around, remains unsolved. Instead of 
focusing on separate risk factors, future research should seek to identify the most optimal ‘package’ 
of risk factors to detect vulnerable patients in order to optimize the care of patients with an ICD and 
enhance their well-being, quality of life, and survival.  
Association of beta-blocker and statin use with psychological well-being in 
ICD patients
Beta-blockers are commonly prescribed to patients with an ICD due to their anti ischemic, anti 
arrhythmic and anti hypertensive properties, and their beneficial effects on ejection fraction and 
prognosis.14 For years, concerns have been raised about a possible association between beta-blocker 
use and depression, which might play a role in the underutilization of beta-blockers in ICD patients.14 
Several central and peripheral pathways are proposed that could underlie this relationship, involving 
among others central binding to beta-adrenergic and beta-serotonergic receptors, interfering 
with noradrenergic and serotonergic signal flow, as well as peripherally mediated mechanisms 
in which beta-blockers alter autonomic activity in the periphery, which feeds back to the central 
nervous system (CNS) potentially inducing depressed mood.15 The cardiovascular literature so far 
is inconclusive with respect to potential psychological side effects of beta-blockers. Moreover, 
the majority of studies have focused on a link between beta-blockers and depression, while little 
attention has been given to symptoms of anxiety. The relation between beta-blocker use and 
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anxiety may work differently than the relation with depression, with beta-blockers possibly reducing 
anxiety symptoms due to their arousal-lowering effect. In Chapter 4, we examined the relationship 
between beta-blocker use, including type and dosage, and symptoms of depression, anxiety and 
ICD concerns prior to implantation. We found no indication that beta-blockers are associated with 
emotional distress, which is consistent with a number of recent studies on the association between 
beta-blocker use and depression in general cardiac populations (for reviews see15,16). Although a 
recent cross-sectional study in percutaneous coronary intervention (PCI) patients revealed less 
depressive symptoms 12 months post intervention in patients using beta-blockers, at 1 month post 
PCI no significant association was present. Besides, these latter findings were contradicted in a large 
prospective study among post MI patients.17 In conclusion, the majority of evidence so far suggests 
that beta-blocker use is not associated with impaired psychological well-being, which we confirmed 
in ICD patients in Chapter 4. Studies demonstrating an association between beta-blocker use and 
depression tend to be dated and based on small sample sizes. Physicians should not be restrained 
to prescribe beta-blockers to ICD patients, since they have proven benefits in terms of prognosis. 
 Statin therapy is prescribed in the majority of ICD patients as well, but the relation between statin 
therapy and psychological well-being remains unexplored and was therefore assessed in Chapter 
5. Several mechanisms may be involved in the association between statin use and psychological 
well-being. Possible actions that could plead for a positive relation are protective effects on 
cerebrovascular processes (i.e. decreasing endothelial dysfunction and oxidative stress, and anti-
inflammatory effects),18,19 prevention of physical disabilities20 and increased health conscientiousness 
and adherence in statin users.20 On the other hand, statin use may have unfavourable effects. Low 
membrane cholesterol has been associated with depressive symptoms by disrupting the serotonin 
system21 and statin use has been associated with side-effects, including headache, gastrointestinal 
complaints and dizziness, which might influence patients’ health status.22 In general, statin use 
was associated with poorer health status with respect to dimensions of physical and emotional 
role limitations, and social functioning. No significant relationship with depression and anxiety 
was found. Recently two reviews21,23 on the association between statin use and depression were 
published, with mixed evidence. Importantly, these reviews both have methodological limitations 
(i.e. absence of a systematic review of the literature21, focus on effects of low cholesterol instead of 
statin use on mood,21 absence of thorough randomized controlled trials (RCTs)23, and exclusion of 
post hoc analyses from trials23). Moreover, evidence mainly focused on non cardiac patients, while 
inflammatory and oxidative mechanisms that could underlie a possible relation between statin 
use and impaired psychological well-being may differ between cardiac and non cardiac patients. 
Recapitulating the evidence, there seems no strong indication for statin use being associated with 
depression. The relation with health status has been understudied, and our finding of statin use 
being associated with impaired health status, particularly reflected on the domains of physical and 
emotional role limitations and social functioning, implies that possible side-effects of statin use on 
health status should be discussed with the patient in order to prevent non compliance.
 In summary, we found no strong indications for cardiovascular medication use to be associated 
with impaired psychological functioning. Physicians should not hesitate to prescribe beta-blockers 
and statins if indicated in ICD patients, since the evidence on negative effects of cardiovascular 
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drugs on psychological functioning is rather dated and of less robust methodology. Nevertheless, 
physicians should always be aware of possible interactions between medications, since ICD patients 
are often prescribed a complex multi-drug treatment regimen and for example, interactions 
between antidepressant use and beta-blockers have been reported.24,25 Importantly, attention to 
side-effects obviously still remains a target in clinical practice.
In search of a psychophysiological link between emotional distress and 
clinical outcomes: The autonomic nervous system
Emotional distress is known to be associated with impaired clinical outcomes in ICD patients, 
including increased risk of ventricular arrhythmias and mortality.8 Knowledge of the mechanisms 
explaining this link is important, as they can point towards treatment targets in clinical practice 
that may not only improve mood, but also improve cardiovascular prognosis. Of particular 
importance to the pathophysiology of ICD patients, the autonomic nervous system (ANS) has an 
important share in the development of ventricular arrhythmias, with a shift towards sympathetically 
dominated cardiac control.26 Chapter 6 examined the relationship between emotional distress (i.e. 
depression, ICD concerns and Type D personality) and heart rate variability (HRV), a measure of 
autonomic regulation of the heart. Although the sample size was small, there was an indication for 
lower overall autonomic control over 24 hours and lower parasympathetic control during rest in 
emotionally distressed patients. 
 The concepts of allostasis and allostatic load may provide us with insight into the way that 
(emotional) stress may lead to progression of heart disease. Allostasis is the process whereby 
an organism maintains physiological stability by changing parameters of its internal milieu by 
matching them appropriately to environmental demands.27 Allostatic responses continuously occur 
throughout daily life, and allostatic load refers to the wear and tear that the body experiences when 
repeated allostatic responses are activated during stressful situations.28 Chronic stress increases 
allostatic load and results in alterations in bodily systems functioning, including over-activation of 
the neuronal and hormonal sympathetic axes, as well as the HPA-axis (see also the level II response 
of the psychophysiological stress reactivity model by Lovallo and Gerin29). This is related to changes 
in cellular function and ultimately, due to an ever-shifting allostatic setpoint, leads to allostatic 
overload. Allostatic overload increases the risk of physiological dysfunction, disease and mortality.30 
Emotional distress, including depression, anxiety and more stable traits like Type D personality, 
can act as long-lasting stressors. The reduced overall HRV in distressed Type D patients (Chapter 
6) may be a reflection of an inadequate response30 in which the ANS is in a hypoactive state, while 
the reduced parasympathetic control in Type D and depressed patients during rest may indicate 
a prolonged stress response.30 This inadequate stress response and increase in allostatic load may 
explain the increased risk of ventricular arrhythmias and prognosis that is observed in emotionally 
distressed ICD patients. 
 In Chapter 7, the associations of respectively heart rate and QRS duration with mortality 
were investigated. In accordance with existing literature in other cardiac populations, in our ICD 
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population a heart rate of ≥80 bpm conferred an increased mortality risk, while the relation between 
QRS duration (both when using a cut-off of >120 ms and a continuous measure of QRS duration) 
and mortality risk was non significant and mainly explained by the presence of comorbidities. 
Interestingly, emotional distress did not seem to affect the relationship between heart rate 
and mortality (i.e. act as confounder), as indicated by the relatively unaffected hazard ratio and 
confidence interval when including depression and anxiety as covariates in the analyses. 
 A number of potential mechanisms have been proposed to explain the relationship between 
increased heart rate and mortality, including increased oxidative stress, decreased restoration 
of endothelial function and arterial stiffness, hampering of angiogenesis, increased likelihood 
of plaque disruption and decreased myocardial blood flow.31 More specifically looking at the 
autonomic nervous system, tachycardia may have various causes. Lower overall autonomic control, 
which we demonstrated to be associated with emotional distress (Chapter 6), speeds up heart rate 
towards the intrinsic automaticity level (or spontaneous pacemaker rhythm). On the other hand, 
sympathetic cardiac dominance facilitates automaticity, thereby increasing heart rate as well as the 
chance of ventricular arrhythmias.32 The increased mortality risk associated with increased heart 
rate, which we confirmed in Chapter 7, may be a consequence of a sympatho-vagal imbalance 
which is characterized by sympathetic dominance and reduction of vagal control.
 Chapters 6 and 7 give important impressions of the interrelationships between emotional 
distress, autonomic functioning and mortality, although the question whether the ANS may act 
as a pathophysiological pathway between emotional distress and clinical outcomes remains 
unanswered. Therefore, we performed additional analyses examining whether heart rate acts as a 
mediator in the relation between emotional distress and mortality. The results of the analyses are 
included as an addendum to this dissertation. In order for heart rate to be considered as a mediator, 
(1) the relationship between emotional distress and mortality should be statistically significant; (2) 
the relationship between emotional distress and heart rate should be statistically significant; (3) 
heart rate should be related to mortality, and (4) the relation between depression and mortality 
should become smaller or ideally non significant after adjusting for heart rate.33 More extensively 
shown in the Addendum, the mortality risk associated with depression was not mediated via heart 
rate. This finding is also supported by previous research within this patient cohort, demonstrating 
an absence of a relationship between depression and the risk of ventricular tachyarrhythmias.34 The 
pathway explaining the relation between depression and all-cause mortality risk is more likely to be 
multifactorial, with a combination of ANS functioning, stress hormones, inflammation, endothelial 
dysfunction, comorbidities and behavioral factors playing a role,35 while the relation between 
heart rate and mortality may more easily be explained by ANS functioning and physical effects on 
the vasculature and myocardium (i.e. plaque damage and diminished perfusion). Future research 
should further elucidate which biobehavioral pathophysiological pathways may explain the heart 
rate-mortality and depression-mortality links. One major prerequisite in these future studies would 
be to also better differentiate between causes of death, because the link with all-cause mortality 
gives no directions towards specific mechanisms involved. 
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Risk stratification in ICD patients
This dissertation has revealed important predictors of prognosis in ICD patients. In Chapter 7, we 
found that heart rate was a significant predictor of long-term mortality, independent of several other 
clinical and psychological risk factors, just as the age-adjusted version of the Charlson Comorbidity 
Index (CCI), the occurrence of shocks during follow-up, the use of amiodarone and the presence 
of depressive symptoms. Inclusion of variables that are easy to assess and accurately predict risk 
enhances the chances of successful implementation of risk stratification models in clinical practice. 
Heart rate and the CCI may be examples of such variables. Since emotional distress has been shown 
to predict prognosis in ICD patients as well, inclusion of the patient’s psychological profile in future 
algorithms used for risk stratification may be warranted. 
The importance of the partner for patient well-being and prognosis 
To date, research has mainly focused on the patient’s psychological well-being, while recently 
attention has been called to the partner’s emotional state. Partners of ICD patients may be 
confronted with a wide range of challenges, including caring for the patient, feelings of helplessness 
and uncertainty about the ICD giving a shock, changes in role patterns, fear of sexual activities, 
overprotective behavior and, more practical, driving restrictions to the patient.36 Any of these 
challenges may be similar for patients and partners, with research indicating that emotional distress 
levels are equally high in patients and partners,37 and also that the type of distress corresponds 
within the dyad.38 
 The knowledge on the influence of the partner’s emotional state on the patient’s well-being has 
been expanded in the current dissertation, as demonstrated in Chapter 8. We confirmed that patient 
and partner distress patterns during the first year post implantation are largely similar. However, 
we also demonstrated that although the patients’ health status was largely predicted by their own 
levels of emotional distress, partner distress predicted baseline health status and course of health 
status during follow-up beyond patients’ emotional functioning. Thus, patients experienced poorer 
baseline health status and poorer health status recovery during follow-up if their partners were 
emotionally distressed. These findings are supported by several theories, including dyadic coping 
theories, which assume that the process of stress-coping is perceived as a dyadic exchange of action 
(i.e. stress signals of one partner), reaction (dyadic coping of the other partner), and common dyadic 
coping efforts, with the patient and partner thus mutually influencing each other.39 Within this 
context, the social baseline theory assumes that social proximity and interaction decrease physical 
and mental costs of environmental demands.  Absence of social proximity may lead to impaired 
control of emotions due to reduced mesolimbic functioning and the release of stress hormones, 
which explains why having a partner may be supportive for both psychological and physical 
functioning.40
 In addition to partner distress having an influence on patients’ distress levels and health status, 
preliminary research in heart failure patients has shown that distress in partners may affect the 
course of heart failure symptoms during follow-up, independently of the level of the patient’s own 
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distress level.41 In continuation of this finding, the impact of partner distress on patient mortality risk 
was examined in Chapter 9, controlling for relevant clinical patient characteristics and the patients’ 
own distress level. We found that the relationship between partner distress and patient mortality 
risk was non significant, mainly due to the patient’s own level of distress explaining the majority 
of variance in mortality. Although the literature is scarce when it comes to the impact of partner 
distress on patient prognosis, several related concepts, including marital status, marital satisfaction 
or quality, and social support, have been investigated in relation to patient mortality risk, indicating 
a protective effect of the presence of a partner and/or a relationship of good quality.42,43 A reason for 
the non significant results in Chapter 9 could be the timing of assessment, with emotional distress 
in patients and partners being measured at baseline (i.e. one day prior to implantation). It is well-
known that distress levels of both patients and partners decline during the first three months post 
implantation, and the group of partners with high distress levels at baseline may consist for a large 
part of partners who successfully adapt to ICD implantation on the short-term and thus constitute 
a low-risk group regarding prognosis. Future research should explore whether persistent distress in 
partners and comorbid distress within the patient-partner dyad may lead to more disadvantageous 
outcomes for both patients and partners.
 Importantly, although so far the patient’s mortality risk mainly seems to depend on the patient’s 
own level of distress and clinical risk profile, the importance of the partner as a supportive anchor 
for the patient has been demonstrated in Chapter 8. To summarize, the partner thus seems more 
important for the psychological well-being of the patient than for the patients’ physical state and 
prognosis. Due to equally high distress levels in partners and in patients, the partner should be 
involved in the treatment process in order to increase the chance of optimal adaptation for both 
patient and partner. 
Screening patients for emotional distress in clinical practice
There is sufficient evidence showing that emotional distress is associated with a wide range of 
negative physical and psychological outcomes in cardiac patients, including reductions in quality 
of life,44 decreased adherence45 and participation in cardiac rehabilitation46 and increased risk of 
morbidity and mortality.34,47,48 This led the American Heart Association (AHA) to publish an advisory 
in 2008 calling for systematic screening for depression in patients with coronary heart disease 
(CHD) using a 2-step approach, with initial administration of the 2-item version of the Patient Health 
Questionnaire (PHQ), and immediate administration of the full PHQ-9 in patients scoring ≥1 at the 
PHQ-2 as a second screening step.49 However, criticism rose shortly after publication of the advisory. 
The accuracy of depression screening instruments, the effect of screening on depression and cardiac 
outcomes and the effect of depression treatment on depression in patients in cardiovascular care 
settings were challenged in a subsequent review,50 and inappropriate labeling, premature exposure 
of patients to antidepressant medications and increasing risk of stigma were raised as additional 
concerns.51 Several recent, large-scale studies have investigated the feasibility of implementation 
of the AHA screening protocol in clinical cardiology practice. These studies also raised important 
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limitations, but ultimately point towards a more positive evaluation of the advisory. Having adopted 
a similar depression screening protocol in post MI patients, Smolderen et al. (2011) demonstrated 
that approximately 75% of eligible patients were screened, with 90% of those patients who 
underwent the routine depression screening protocol and who suffered from depression having 
their depression recognized after which further action was being taken.52 A second study using the 
2-step PHQ screening approach to identify depression among 4783 cardiac patients, with nurses 
performing the depression screening, revealed similar results.53 
 Screening should ideally take place in the inpatient hospital setting shortly after admission, 
which has shown to lead to better screening results in patients with cardiac illness when compared 
to screening afterwards the primary care setting.53,54 Standard cardiac units seem to be the most 
suitable screening setting, since patients in the coronary intensive care unit are more likely to be 
confused, sedated or in poor physical state.53 Ideal timing may differ across ICD patients, as primary 
indication patients often stay in the hospital for a very short period of time around implantation 
(which may be a suitable timing for screening), while secondary indication patients may be brought 
to the hospital in a life-threatening, urgent condition and are thus more likely to end up in an 
intensive care setting (in which case later screening may be more appropriate). Clinical practice 
should be aware of barriers that hamper the implementation of psychological screening, including 
money and time constraints and screening protocols with too many steps. Facilitation of staff 
education, short and uncomplicated referral pathways and improving visibility of the screening 
protocol in the workplace likely increase the chances of successful implementation of psychological 
screening in the cardiac setting. Female patients and patients with comorbid disorders should be 
extra carefully monitored, since these patients are at higher risk of not being screened.52
 Although to date there is no evidence that screening for emotional distress leads to better 
prognosis, conquering these implementation barriers may lead to improved recognition of 
emotional distress. For effective continuation of care, in-hospital screening for emotional distress 
should be continued with follow-up screening since the course of distress can fluctuate over 
time,55,56 and psychological treatment should be delivered if necessary.52,57 
 Future research should further investigate the efficacy, safety and cost-effectiveness of screening 
for emotional distress,58 examine which instruments are the most sensitive and specific,50 and 
investigate which professionals could best perform and evaluate the screening and what the most 
suitable timing for distress assessment would be. In particular, specific attention should be paid 
to screening for other psychological constructs than depression, since the psychological screening 
debate has only touched upon depression screening so far. Needless to say screening does not 
resolve patient’s distress but only identifies those who are afflicted. Hence, screening should be 
combined with appropriate treatment in the subset of patients who need it, which will be discussed 
in detail in the following section.
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Psychological treatment of ICD patients
In Chapter 11, we have shown that approximately two thirds of patients in need of psychological 
treatment around the time of implantation did not receive help. Moreover, approximately 40% 
of patients were persistently distressed throughout the first year post implantation, but were not 
treated for their distress during that period.59 Chapter 11 also showed that when treated, this 
treatment mainly consisted of prescription of psychotropic medication, while only a few patients 
were referred to a specialized mental health care professional such as a clinical psychologist. 
Probably partly for this reason, treatment was not entirely effective, as patients who did receive 
treatment, still reported the highest levels of emotional distress.59 
 Although missed by a considerable number of ICD patients, treatment of emotional distress 
has shown to improve several important aspects of daily functioning. The effect of cognitive 
behavioral therapy (CBT) has most frequently been investigated. The core principle of CBT explains 
that irrational, dysfunctional thoughts (i.e. ‘my device prevents me to safely go out with friends’) are 
leading to dysfunctional behavior (i.e. avoidance of public places). During CBT, automatic negative 
patterns of thinking are challenged and replaced by more functional thoughts and behaviors 
during individual or group sessions.60 CBT interventions have shown significant effects on anxiety, 
depression, ICD concerns and quality of life.61 CBT is often combined with an exercise program 
within the cardiac rehabilitation setting. Resuming healthy activity levels is particularly challenging 
for ICD patients, because patients may be uncertain about the level of activity that is safe to perform 
without being shocked by the ICD.61 While exercise training alone has shown to be effective in 
improving psychological functioning in ICD patients,61 a combined approach of CBT and exercise 
training seems to provide additional benefits.62,63   
 The cardiac rehabilitation setting also provides scope for a more detailed psycho-educational 
program targeted to ICD patients. While it is known that adequate information provision and psycho-
education can reduce emotional distress,64,65 knowledge of the actual information that patients 
receive and their satisfaction with this information is lacking. Chapter 10 adds to this knowledge by 
showing that information about more technical aspects of the ICD and its therapies was adequately 
communicated to patients, while information about possible ICD-related psychological, social and 
sexual consequences was less frequently provided. Although in general patient satisfaction was 
high, about 1 in 3 patients expressed a wish for more information around the time of implantation. 
Importantly, lower patient satisfaction with information provision was associated with increased 
symptoms of anxiety. Thus, providing information to patients that suit their needs may increase 
their satisfaction with treatment and their ICD and reduce anxiety. Obviously, this remains an 
important target in clinical practice. Given that partners have also expressed their wish for more 
information66,67 and that we showed that partners’ distress levels influence patients’ health status, 
involving the partner in the treatment process may be appropriate during cardiac rehabilitation, as 
this provides a unique setting to combine educational, physical, mental and social aspects of ICD 
treatment. Future research should focus in more detail on information provision wishes of partners 
of ICD patients, on the most appropriate timing and frequency of information provision, and on the 
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question how continuity of care, for example via a follow-up phone call, can ideally be facilitated. 
CBT is also frequently combined with psychopharmacological treatment. Since tricyclic 
antidepressants (TCAs) may exert toxic effects on the heart by provoking conductance disorders,68 
SSRIs seem to be the psychopharmacological drugs of first choice in ICD patients. Further advantage 
of SSRIs is that they have both antidepressant and anxiolytic effects.69 Although meta-analyses and 
reviews on the effectiveness of SSRIs to treat depression in patients with CHD have shown clear 
beneficial effects on depression,70,71 large-scale trials have also reported non-significant results.72 
Besides, recent animal research has shown that long-term intake of fluoxetine, a SSRI, may reduce 
the responsiveness to autonomic control of the heart rhythm.73 This is pertinent with respect 
to the psychological treatment of ICD patients, since autonomic cardiac control may already be 
deregulated in these patients.74 Evidence on the safety and effectiveness of pharmacological 
treatment in ICD patients is scarce, and more research is warranted. 
 A small subset of ICD patients suffers from post-traumatic stress disorder (PTSD) (symptoms),75 
which may be treated with eye movement desensitization and reprocessing (EMDR). During 
treatment, the patient’s attention is drawn to an external stimulus via eye movements, auditory 
tones or hand taps, while simultaneously focusing on the source of the trauma in order to process 
the trauma in an accelerated way.76 The effectiveness of EMDR in reducing PTSD symptoms has 
been demonstrated in the general population,77 while research in cardiac patients in general and 
ICD patients in particular is lacking. Extra caution and consultation of a cardiologist’s expertise is 
warranted here, because mentally activating the traumatic event could lead to sudden increases in 
stress and autonomic arousal, which may be harmful to the ICD patient. 
 In Chapter 6, we found support for lower autonomic control in patients with increased levels 
of emotional distress.78 Biofeedback training may be an effective treatment option in ICD patients, 
with several studies among cardiac patients having found encouraging effects of parasympathetic 
drive stimulating biofeedback on depressive symptoms79 and on HRV.80 Although these results 
are promising, they should be interpreted with prudence, since study samples are generally small, 
long-term effects on both psychological and medical outcomes are yet unclear and non significant 
results have also been published.81
 Recent research has also revealed some interesting initial results on mindfulness and yoga on 
(bio)psychological functioning in ICD patients. Meditation practices, an important component of 
mindfulness therapy, have been associated with reductions in adrenergic arousal, with decreases in 
premature ventricular contractions in patients with ischemic heart disease.82 Mindfulness training 
has previously shown to improve depression and clinical outcomes in heart failure patients,83 and 
a recent study has revealed that a phone-delivered mindfulness training was effective in reducing 
anxiety and improve mindfulness skills in ICD patients.84 Yoga, another arousal-reducing training, 
appears to be associated with reductions in anxiety as well, next to reductions in device-treated 
ventricular events.85 
 Even though the evidence of psychological interventions being effective in reducing emotional 
distress and improving quality of life is accumulating, it is not known yet whether and how these 
effects can translate into effects on clinical outcomes, such as morbidity and mortality. To date, the 
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majority of studies have failed to detect effects of psychological treatment on clinical outcomes. 
This may partly be explained by methodological limitations of current psychosocial intervention 
studies, including small samples, heterogeneous interventions, lack of randomization, a relatively 
high mean age, a wide range of timespan between implantation and start of intervention, lack of 
information on treatment adherence and lack of screening for patients at risk of emotional distress.86 
Furthermore, an a priori fixed length of treatment without distinguishing effective treatment 
strategies for subgroups is common in clinical trials, while this may not connect to the patients’ 
needs.87 However, effects of psychological treatment on patients’ well-being have been established, 
which should be sufficient to justify the value of incorporating psychological treatment in clinical 
cardiology practice.
Future considerations with respect to psychological treatment
Several other factors that may impact on the success of psychological intervention (studies) in ICD 
patients should receive attention in future research. First, it is important to consider the patient’s 
needs and preferences for treatment, as positive outcomes of psychological interventions strongly 
depend on whether the patient is willing to receive help and actually has a question for help. Second, 
the most optimal timing of treatment start should be examined. Emotional distress of ICD patients 
tends to decline particularly during the first 3 months post implantation.88 Linden and colleagues 
have shown that psychological treatment in cardiac patients may be more effective when started 
at least 2 months post event, probably due to the natural decline in distress during this initial post 
event phase.87 Other factors in relation to treatment accessibility and success, such as resources 
(i.e. travel distance, health insurance), differences between subgroups of patients and psychological 
factors other than depression and anxiety, should be topics for further investigation.
Methodological considerations 
The results presented in this dissertation should be interpreted with the following limitations in 
mind. Initial distress was measured only one day prior to implantation, and we have no knowledge 
of the distress pattern in the period prior to implantation. However, the nature of cardiac disease 
leading to an indication for ICD implantation makes it impossible to assess distress earlier in at 
least 35% of patients, who received an ICD due to secondary prevention prophylaxis, which is 
often suddenly indicated. Furthermore, we only focused on all-cause mortality as an endpoint, as 
information on cause of death was lacking. Knowledge on cause of death is vital in order to explore 
which psychobiological mechanisms account for the found relationship, as this could provide us 
with targets for prevention and treatment. Future research should thus include cause of death. In 
addition, our results were based on self-report measures of emotional distress and not on clinical 
diagnoses based on the Diagnostic and Statistical Manual of Mental Disorders (DSM). However, we 
expect that in general, the relationships that we found would have been stronger in case of clinical 
diagnoses of emotional distress as compared to self-reported symptoms of anxiety and depression. 
Furthermore, even minimal symptoms of emotional distress are found to be predictive of prognosis 
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in cardiac patients and thus to be important.89 Finally, the results of the current dissertation may 
not be fully generalizable to all ICD patients. Since our sample predominantly consisted of male 
patients with a mean age of around 60 years, outcomes may differ for example in younger patients 
and female patients. 
 The studies presented in this dissertation also have several strengths. For all chapters except 
Chapter 6, a relatively large sample of ICD patients (N=448) was used, which promotes the likelihood 
of sufficient power to detect significant relationships if present. Moreover, the number of partners 
included simultaneously in this study exceeds that of many other studies investigating the well-
being of partners of ICD patients, and the response rate ranging from 96% at baseline to 81% at 
12 months follow-up is rather high.38,90 The availability of an extensive demographic and clinical 
patient profile in the current study enabled us to control for important potential confounders on 
top of it. Finally, we used a longitudinal study design, with one distress measurement one day prior 
to ICD implantation, and four follow-up occasions throughout the first year post implantation. This 
enabled us to describe how ICD patients and their partners adapt to the implantation throughout 
the first year post implant. 
Box 1. What the current dissertation adds
· ICD patients experiencing complications around and post implantation and patients suffering 
from comorbid diseases report more emotional distress and poorer physical health status than 
patients without complications or comorbidities. These patients may require additional cardiac and 
psychological monitoring and care.
· Cardiac medication use is not associated with symptoms of anxiety and depression and only with 
some subdomains of health status in ICD patients.
· ICD patients with emotional distress and Type D personality show impaired functioning of the 
autonomic nervous system. 
· Increased heart rate, a marker of autonomic functioning, is associated with poorer prognosis and could 
be added as an easy-to-measure risk marker in clinical practice.
· Partners of ICD patients experience a similar pattern of emotional distress around and post implantation. 
Partner emotional distress is related to patient distress, and partner distress partly determines patients’ 
evaluation of their own health status. Involvement of the partner in the adaptation process thus seems 
to have additional benefits for both patients and partners.
· Information on psychological, social and sexual consequences post implantation is not adequately 
provided, which is associated with impaired patient satisfaction. This in turn is associated with 
increased levels of anxiety.
· A substantial number (25%) of ICD patients report emotional distress during the first year post 
implantation, but paradoxically the majority of these patients are not treated for their distress with 
potential consequences to health status, morbidity, and mortality.
Concluding remarks
The current dissertation adds to our knowledge of factors that may contribute to the well-being 
and prognosis of patients with an ICD, which is the current state-of-the-art and first line treatment 
for the prevention of sudden cardiac death due to life-threatening arrhythmias both as primary 
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and secondary prophylaxis. Complications around and post implantation and the presence of a 
higher comorbidity burden increased the risk of emotional distress. Further, we demonstrated that 
the use of beta-blockers and statins did not contribute substantially to psychological distress in 
patients. This is important, since underuse of cardiac medication still exists, which could impede 
the recovery of patients. Furthermore, ANS components, including heart rate variability and heart 
rate, were shown to be associated with emotional distress and to contribute to poor prognosis. To 
broaden the scope from the patient as an individual to the patient as part of a dyad, the correlation 
between patient and partner distress, and the impact of partner distress on patient health status, 
were also investigated. Distress patterns between patients and partners were largely similar, and 
partners’ distress exerted an effect on patient health status beyond patients’ own distress. Future 
consideration should be given to involving the partner in the treatment process. Finally, as a 
transition to psychology practice, the relation between delivery of information about the ICD and 
its possible consequences, patient satisfaction and emotional distress was investigated. Information 
around the time of implantation was generally well-provided, but information on potential 
psychological, social and sexual issues post implant were less often discussed. Importantly, 
decreased patient satisfaction with the provided information was associated with increased anxiety, 
which underlines the importance of adequate psycho-education around the time of implantation. 
Unfortunately, our results also demonstrated undertreatment for psychological distress in the ICD 
population, with a negative association with health status. The implementation of screening for 
psychological functioning in ICD patients in clinical practice followed by patient-tailored treatment 
should be given due consideration, in order to identify the subgroup of patients at risk for decreased 
psychological functioning and optimize the clinical care and management of ICD patients and their 
partners.
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ADDENDUM: Mediation model depression, heart rate and mortality
In secondary analyses, heart rate was formally tested as a mediator of the relationship between 
depression and mortality. In order for heart rate to be considered as a mediator, (1) depression should 
be significantly related to mortality; (2) depression should be significantly related to the proposed 
mediator heart rate; (3) heart rate should be related to mortality, and (4) the relation between 
depression and mortality should become non-significant after adjusting for heart rate.1 Anxiety was 
left out of consideration, as the association between anxiety and mortality was non significant in 
the current sample. The association between depression and mortality risk was examined with Cox 
regression analysis, just as the primary analyses on the relation between heart rate and mortality 
risk as described in Chapter 7. The association between depression and heart rate was assessed 
with linear regression. For both depression and heart rate, continuous values were used, because 
depressive symptom levels were equally distributed across the heart rate range. In Cox regression, 
the relationship between emotional distress and mortality turned out to be significant (HR=1.11, 
95% CI=1.06-1.17, p<.001), which has previously been demonstrated in the current sample.2 
Furthermore, the association between depression and heart rate was also significant (β=0.12, t=2.33, 
p=.020). Subsequently, the relationship between heart rate and mortality was assessed, indicating 
that heart rate was significantly associated with mortality risk (HR=1.02, 95% CI=1.01-1.03, p=.040). 
When heart rate was added as a predictor of mortality next to depression, the relation between 
depression and mortality was unaltered, and remained significant (HR=1.11, 95% CI=1.05 -1.16, 
p<.001), while continuous heart rate became a non-significant predictor of mortality (HR=1.01, 95% 
CI=0.99-1.03, p=.07). This leads us to conclude that heart rate does not act as a mediator in the 
relationship between depression and mortality risk in the current sample.
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SUMMARY IN DUTCH / NEDERLANDSE SAMENVATTING
Plotse hartdood komt voor bij ongeveer 1:1000 tot 1:2000 mensen in de algemene populatie, terwijl 
individuen met een bestaande coronaire hartziekte ongeveer 50% kans lopen om te overlijden aan 
plotse hartdood. Een van de oorzaken van plotse hartdood is het optreden van ritmestoornissen 
van de hartkamers (ventrikels). Deze ventriculaire ritmestoornissen kunnen leiden tot een snel en 
chaotisch samentrekken van de hartkamers, waardoor de vitale organen te weinig bloed ontvangen 
wat uiteindelijk kan resulteren in overlijden. De implanteerbare cardioverter-defibrillator (ICD) 
wordt gezien als de belangrijkste en meest succesvolle vorm van behandeling bij patiënten die 
een verhoogd risico hebben op plotse hartdood. De ICD wordt net onder de huid in de borst 
geïmplanteerd en registreert via een of meerdere elektronische draden continue het hartritme. 
Wanneer een levensbedreigende ventriculaire ritmestoornis optreedt, kan de ICD deze verhelpen 
door het leveren van antitachycardie pacing of door een elektrische shock. Daarnaast bestaan er 
ook biventriculaire pacemakers die zorgen voor een gelijktijdig samentrekken van de hartkamers bij 
patiënten met hartfalen (cardiale resynchronisatie therapie (CRT)) en die eveneens shocks kunnen 
afgeven bij ventriculaire ritmestoornissen. De ICD werd oorspronkelijk alleen geïmplanteerd bij 
patiënten die eerder een plotse hartstilstand hebben overleefd (secundaire preventie indicatie). 
Tegenwoordig zijn de indicatiecriteria echter verruimd en wordt de ICD ook geïmplanteerd bij 
patiënten die een hoog risico lopen op plotse hartdood, maar nog niet eerder een hartstilstand of 
ventriculaire ritmestoornissen hebben ervaren (primaire preventie indicatie). 
Patiënten met een ICD worden rondom en na de implantatie geconfronteerd met medische en 
psychologische uitdagingen. Medische uitdagingen zijn onder andere complicaties ten gevolge 
van de implantatie, en het onderliggend lijden van de patiënt zoals hartfalen en andere gelijktijdige 
medische aandoeningen, zoals nierfalen, diabetes, perifeer vaatlijden of een aandoening aan de 
luchtwegen. Daarnaast rapporteert ongeveer 25% van de ICD-patiënten psychologische klachten, 
waaronder symptomen van depressie, angst, post-traumatische stress en aanpassingsproblemen 
in het sociale leven. Een aantal factoren dat geassocieerd is met het optreden van psychologische 
klachten is bekend, waaronder het optreden van shocks en het onderliggend hartlijden. De relatie 
tussen andere medische factoren enerzijds, zoals medicatiegebruik en de aanwezigheid van andere, 
gelijktijdige aandoeningen, en psychologisch functioneren anderzijds, was tot op heden echter niet 
eenduidig. 
In dit proefschrift wordt daarom aandacht besteed aan de relatie tussen de medische behandeling 
en medische patiënt-gerelateerde factoren enerzijds, en het psychologisch functioneren anderzijds. 
Allereerst werd onderzocht of het optreden van procedure- en ICD-gerelateerde complicaties in de 
periode van vlak voor implantatie tot 12 maanden erna geassocieerd was met slechter psychologisch 
welbevinden. In totaal kreeg 17% van de patiënten te maken met een complicatie, waarvan het 
merendeel ICD-gerelateerd was. Er werd een significante relatie gevonden tussen het optreden van 
complicaties en symptomen van angst en zorgen om de ICD gedurende de eerste 12 maanden na 
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implantatie, terwijl er geen relatie werd gevonden tussen complicaties en depressie (Hoofdstuk 
2). Daarnaast werd gedurende dezelfde periode eveneens onderzocht of er een relatie bestaat 
tussen de aanwezigheid van andere medische aandoeningen en het psychologisch functioneren 
(symptomen van depressie en angst en patiënt-gerapporteerde gezondheidstoestand). Hierbij 
werd gebruikt gemaakt van een aangepaste versie van de Charlson Comorbidity Index (CCI), een 
samenvattingsmaat voor het aantal andere aanwezige medische aandoeningen die ook rekening 
houdt met de ernst van de aandoeningen en waarin leeftijd ook als risicofactor werd meegenomen. 
In tegenstelling tot complicaties, die geassocieerd waren met meer angst, was de aanwezigheid 
van andere medische aandoeningen geassocieerd met meer depressie en een verslechtering in 
fysieke gezondheidstoestand. De aanwezigheid van chronisch hartfalen, chronisch obstructieve 
longziekten, cerebrovasculaire aandoeningen en nierfalen waren de belangrijkste voorspellers 
van depressie en een verslechterde gezondheidstoestand (Hoofdstuk 3). Uit dit hoofdstuk 
bleek eveneens dat de prevalentie van gelijktijdig voorkomende medische aandoeningen bij 
ICD-patiënten hoog is. Om deze aandoeningen te behandelen, gebruikt het grootste deel van 
de ICD patiënten meerdere cardiale en niet-cardiale medicijnen. De mogelijke relatie tussen dit 
medicijngebruik en de psychologische toestand van de patiënt heeft in het verleden veel stof doen 
opwaaien. In dit proefschrift werd daarom onderzocht of het gebruik van bètablokkers en statinen 
geassocieerd was met het psychologisch functioneren van de ICD-patiënt, waarbij rekening werd 
gehouden met het type bètablokker en statine. Er werd geen significante relatie gevonden tussen 
het gebruik van bèta-blokkers en symptomen van depressie, angst en ICD-gerelateerde zorgen 
(Hoofdstuk 4). Dit is in overeenstemming met een groot deel van de bestaande recente literatuur. 
Daarentegen rapporteerden patiënten die statinen gebruikten een slechtere gezondheidstoestand 
dan patiënten die geen statinen gebruikten, vooral op het gebied van fysieke en emotionele 
rolbeperkingen en sociaal functioneren. Er werd geen relatie gevonden tussen het gebruik van 
statinen en symptomen van depressie en angst (Hoofdstuk 5). Het uitbreiden van kennis over de 
relatie tussen medische factoren die te maken hebben met de implantatie en bijkomende (hart)
aandoeningen, en het psychologisch functioneren van de patiënt is belangrijk, omdat op deze 
manier de patiënten die een hoog risico lopen op het ontwikkelen van psychologische problemen 
gemakkelijker herkend kunnen worden.
In het tweede deel van dit proefschrift is het functioneren van het autonome zenuwstelsel van ICD-
patiënten onderzocht. Het autonome zenuwstelsel heeft een belangrijke regulerende functie in het 
lichaam en stuurt organen aan, waaronder het hart.  Sympathische en parasympathische (vagale) 
zenuwtakken verbinden het centrale gedeelte van het autonome zenuwstelsel met het hart, 
waarmee geleiding, hartslag, en het samentrekken van het hart worden gereguleerd. Het autonome 
zenuwstelsel heeft een belangrijk aandeel in de ontwikkeling van ritmestoornissen, waarbij een 
verschuiving wordt gezien van de sympatho-vagale aansturing naar sympathisch gedomineerde 
aansturing. Goed functioneren van het autonome zenuwstelsel is dus een belangrijke voorspeller 
voor de prognose van de patiënt. 
        
Nederlandse samenvatting   |   209
 Hartslagvariabiliteit (HRV) is de schommeling in het tijdsinterval tussen twee opeenvolgende 
hartslagen en wordt veelvuldig gebruikt als maat van autonome controle. In dit proefschrift werd 
HRV gemeten met behulp van 24-uurs Holter monitoring. Psychologische klachten, zoals symptomen 
van depressie, angst en post-traumatische stress, zijn in eerder onderzoek in verband gebracht 
met HRV binnen de algemene en de cardiale populatie, waarbij een relatie werd gevonden tussen 
depressie en angst en een verlaagde HRV. Omdat autonoom functioneren van groot belang is bij 
de ontwikkeling van ritmestoornissen, werd deze relatie verder onderzocht. Bij ICD-patiënten met 
een Type D persoonlijkheid werd een lagere autonome sturing over het hele etmaal, en een lagere 
parasympathische sturing tijdens periodes van rust gevonden. Daarnaast werden bij patiënten 
met verhoogde depressiescores ook indicaties gevonden voor verstoorde hartregulatie door het 
parasympathische zenuwstelsel tijdens rust en slaap (Hoofdstuk 6). De gevonden verhoogde 
sympathische en verlaagde parasympathische sturing bij ICD-patiënten met meer psychologische 
klachten zou de ontwikkeling van ventriculaire ritmestoornissen kunnen bevorderen. Gezien de 
kleine steekproef die in dit onderzoek gebruikt werd, is meer onderzoek onder een groter aantal 
ICD-patiënten nodig om deze relaties te repliceren en goed onderbouwde conclusies te kunnen 
trekken. 
 Het belang van een goed functionerend autonoom zenuwstelsel voor de prognose van ICD-
patiënten lijkt dus evident. In deze patiëntenpopulatie is hier echter nog weinig onderzoek naar 
verricht. In dit proefschrift werd daarom onderzocht of er een relatie bestaat tussen de hartslag en de 
QRS-duur (de depolarisatiefase van de hartkamers) enerzijds, en het risico op overlijden anderzijds. 
Een hogere hartslag, zowel bij een grenswaarde van ≥80 slagen per minuut, als continue gemeten, 
bleek geassocieerd te zijn met een slechtere prognose, onafhankelijk van een aantal belangrijke 
medische en psychologische factoren. De relatie tussen QRS-duur en het risico op overlijden 
bleek verklaard te worden door de aanwezigheid van gelijktijdig voorkomende andere medische 
aandoeningen. Deel 2 van dit proefschrift laat dus zien dat psychologische klachten gerelateerd 
zijn aan een minder goed werkend autonoom zenuwstelsel, en dat een minder goed functionerend 
autonoom zenuwstelsel een hoger overlijdensrisico met zich meebrengt.
Wetenschappelijk onderzoek heeft zich tot op heden voornamelijk gericht op de patiënt, terwijl 
de partner eventuele ICD-therapieën of een hartstilstand ook van dichtbij meemaakt. Uit eerder 
onderzoek is bekend dat partners evenveel of zelfs meer psychologische klachten rapporteren dan 
de patiënt zelf, waarbij met name angst een belangrijke rol lijkt te spelen bij de partner. Aandacht voor 
het psychologisch functioneren van de partner is belangrijk, omdat psychologische problematiek 
bijvoorbeeld kan leiden tot overbeschermend gedrag richting de patiënt. De relatie tussen het 
psychologisch functioneren van de patiënt en de partner werd daarom gedurende 12 maanden 
na ICD implantatie onderzocht, evenals de impact van psychologische klachten bij de partner op 
de subjectieve gezondheidstoestand van de patiënt. Het psychologische klachtenpatroon bleek 
overeen te komen tussen patiënten en hun partners, zowel rond implantatie als gedurende de 
12 maanden erna. De gezondheidstoestand van de patiënten rond implantatie en gedurende 
de 12 maanden erna bleek voornamelijk bepaald te worden door hun eigen psychologische 
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klachtenpatroon, al waren symptomen van depressie en angst bij de partner daarbovenop ook 
voorspellend voor de subjectieve gezondheidstoestand van de patiënt (Hoofdstuk 8). Dit geeft aan 
dat de partner een belangrijke toegevoegde rol vervult in het aanpassingsproces van de patiënt. Het 
belang van het betrekken van de partner bij de begeleiding van de patiënt rond en na implantatie is 
hiermee onderstreept, evenals het feit dat psychologische klachten ook bij partners voorkomen en 
professionele aandacht verdienen.
 Naast een aandeel van de partner in het psychologische functioneren van de patiënt, zou 
de partner ook van invloed kunnen zijn op medische uitkomsten. Het wel of niet getrouwd zijn 
en psychologische klachten bij de patiënt zelf zijn bekende risicofactoren voor overlijden van de 
patiënt, maar over de aanwezigheid van psychologische klachten bij de partner als voorspeller 
van overlijdensrisico is weinig bekend. In dit proefschrift is daarom onderzocht of psychologische 
klachten van de partner het overlijdensrisico van de patiënt konden voorspellen, bovenop de 
psychologische klachten die de patiënt zelf rapporteerde. Psychologische klachten van de partner 
leken de kans op overlijden van de patiënt te voorspellen, maar dit effect werd niet-significant 
wanneer de psychologische klachten van de patiënt werden meegenomen. Psychologische klachten 
van de partner bleken dus geen toegevoegde voorspellende waarde te hebben met betrekking 
tot het overlijdensrisico van de patiënt (Hoofdstuk 9). Desondanks hebben de resultaten van 
Hoofdstuk 8 aangetoond dat het belangrijk blijft de partner te betrekken bij de behandeling van 
de ICD-patiënt. Hierdoor is de kans op een optimaal psychologisch herstel van zowel patiënt als 
partner en een hernieuwde, evenwichtige relatie tussen patiënt en partner groter.
 Voor het aanpassingsproces van de patiënt zijn begrip van de redenen voor ICD implantatie, 
het onderliggende medische probleem en de mogelijke medische, psychologische en sociale 
implicaties voor het dagelijks leven belangrijk. Eerder onderzoek heeft uitgewezen dat adequate 
informatievoorziening en psycho-educatie het bestaan van psychologische klachten bij ICD 
patiënten kunnen verminderen. Er is echter nauwelijks onderzoek verricht naar de mate van 
informatievoorziening rondom implantatie, en wat de behoeften van de patiënt hierin zijn. Dit 
werd onderzocht in dit proefschrift. Naar voren kwam dat informatie over de meer technische 
aspecten van de ICD en de medische oorzaak voor implantatie, evenals informatie over fysieke 
beperkingen en beperkingen in het autorijden frequent met patiënten besproken werd (in zo’n 
80-99% van de gevallen). Informatie over psychologische, sociale en seksuele gevolgen van ICD 
implantatie werd echter met slechts 57-64% van de patiënten besproken. Ongeveer een derde van 
de patiënten wenste rondom implantatie meer informatie over al deze onderwerpen te ontvangen. 
Daarnaast werd duidelijk dat patiënten die minder tevreden zijn over de informatievoorziening, 
meer angst ervaren. Een goede informatievoorziening rondom implantatie kan dus bijdragen aan 
een beter begrip van de noodzaak en eventuele gevolgen van de ICD-implantatie bij de patiënt, 
evenals een betere aanpassing aan het leven met een ICD. De klinisch psycholoog zou hierin een 
belangrijke rol kunnen spelen, omdat is aangetoond dat artsen, maar ook verpleegkundigen en 
ander zorgpersoneel, moeite kunnen hebben met het ter sprake brengen van dit soort voor de 
patiënt belangrijke onderwerpen.
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 Hoewel een aanzienlijk deel van de ICD-patiënten aangeeft last te hebben van depressie, angst of 
andere klachten die het dagelijks functioneren kunnen belemmeren, betekent dit niet automatisch 
dat deze patiënten op een adequate manier psychologisch worden begeleid. In dit proefschrift 
werd daarom onderzocht of de patiënten met verhoogde niveaus van depressie en angst in de 
praktijk psychologisch werden behandeld, en of het niet behandelen van deze kwetsbare groep zou 
samengaan met een slechtere subjectieve gezondheidstoestand. Een belangrijke bevinding van dit 
proefschrift was dat ongeveer twee derde van de patiënten met verhoogde niveaus van depressie 
en angst geen psychologische behandeling in de vorm van psychotrope medicatie of behandeling 
door een psycholoog onderging. Dit leek bovendien een negatieve weerslag te hebben op de 
gezondheidstoestand van deze patiënten. Daarnaast leek de behandeling die patiënten wel 
kregen, niet altijd aan te sluiten bij de behoeften van de patiënt, wat gereflecteerd werd door de 
laagste subjectieve gezondheidstoestand van patiënten die psychologische problemen hadden en 
hier wél voor werden behandeld (Hoofdstuk 11). Het feit dat psychologische behandeling bij de 
meeste patiënten werd gegeven in de vorm van psychotrope medicatie en niet in de vorm van 
gesprekstherapie bij een psycholoog, zou hiervoor een verklaring kunnen zijn. Het is dus van groot 
belang dat het signaleren van psychologische klachten in een vroeg stadium plaatsvindt, en de 
gekozen psychologische behandeling aansluit bij de behoeften van de patiënt en diens eventuele 
partner.
 Dit proefschrift heeft bijgedragen aan de kennis op het gebied van factoren die een rol 
spelen bij het welzijn en de prognose van patiënten met een ICD. Complicaties rondom en na de 
implantatie en de aanwezigheid van andere medische aandoeningen zijn gerelateerd aan een 
verslechterd psychologisch functioneren van de patiënt. Het gebruik van twee belangrijke soorten 
cardiale medicatie, namelijk bètablokkers en statinen, bleek nauwelijks geassocieerd te zijn met het 
psychologisch functioneren van ICD-patiënten. Dit is een belangrijke bevinding, omdat er helaas 
nog steeds sprake is van ondergebruik van cardiale medicatie en dit een belangrijke beperking kan 
zijn voor zowel fysiek als mentaal herstel van de patiënt. Verder werd in dit proefschrift aangetoond 
dat HRV en hartslag, beide indicatoren van het functioneren van het autonome zenuwstelsel, 
gerelateerd waren aan psychologisch functioneren en prognose. In dit proefschrift werd ook getracht 
de samenhang tussen het psychologisch functioneren van patiënt en partner in kaart te brengen, 
en werd onderzocht of een slechter psychologisch functioneren van de partner van invloed was op 
de subjectieve gezondheidstoestand van de patiënt. Het psychologisch functioneren van patiënt 
en partner bleek voor een belangrijk deel samen te hangen, en psychologische problemen bij de 
partner bleken een negatieve weerslag te hebben op de gezondheidstoestand van de patiënt. In de 
toekomst zal onderzocht moeten worden hoe de partner het beste bij het begeleidingsproces na 
ICD-implantatie kan worden betrokken en zelf ook psychologische hulp zou kunnen krijgen, mocht 
dat nodig zijn . 
 Informatievoorziening is een belangrijk middel om het aanpassingsproces van de patiënt aan 
het leven met de ICD te vergemakkelijken. Met name informatie over psychologische, sociale en 
seksuele gevolgen van ICD implantatie bleek met een aanzienlijk deel van de patiënten niet te zijn 
besproken, met een lagere patiënttevredenheid als gevolg. Deze lagere patiënttevredenheid was 
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geassocieerd met meer angstklachten, wat aangeeft hoe belangrijk een goede informatievoorziening 
rondom implantatie is. Ten slotte werd in dit proefschrift aangetoond dat een groot deel van de 
patiënten met psychologische problemen geen adequate psychologische behandeling kreeg. Het 
implementeren van psychologische screening is dan ook een belangrijk doel voor de klinische 
praktijk, waarbij het ziekenhuis een geschikte plaats lijkt om deze screening uit te voeren. 
Wanneer deze screening gecombineerd wordt met een psychologische behandeling op maat die 
aansluit bij de wensen en behoeften van de patiënt, waarbij gedacht kan worden aan cognitieve 
gedragstherapie, psychotrope medicatie, eye movement desensitization and reprocessing (EMDR) 
therapie, een multidisciplinair hartrevalidatieprogramma, biofeedback of mindfulness, zou de zorg 
voor de ICD-patiënt en diens partner verbeterd kunnen worden.
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het verbeteren van de patiëntenzorg, en zonder hen zou dit nooit mogelijk zijn. 
 Mijn promotor, prof. dr. Susanne Pedersen, wil ik hartelijk danken voor de begeleiding en 
betrokkenheid bij het werken aan dit proefschrift. Beste Susanne, het enthousiasme waarmee 
jij binnen de wetenschap werkt, is inspirerend. Ik heb veel bewondering voor je nooit aflatende 
werklust en voor de dappere keuze die je het afgelopen jaar hebt gemaakt door terug naar 
Denemarken te verhuizen. Ik hoop dat je gaat genieten van het Deense leven, zowel binnen als 
buiten de wetenschap.
 Nina, jouw betrokkenheid als copromotor heeft me enorm geholpen! Ik waardeer je tomeloze 
inzet en het feit dat je deur altijd open stond voor advies, oppeppers of een gezellig praatje. Ik heb 
ook mooie herinneringen aan ons gezamenlijke congresbezoek in Miami! Daarnaast heb ik erg veel 
geleerd van jouw gewoonte om altijd na te denken over het ‘waarom’ en het ‘hoe’, iets wat ik zeker 
meeneem in mijn werk als psycholoog in het ziekenhuis. Het lijkt me leuk in de toekomst te blijven 
samenwerken!
 Dominic, het was fijn ook een copromotor te hebben die werkzaam is in het ziekenhuis en 
dagelijks te maken krijgt met patiënten. Je kennis over de elektrofysiologie kwam regelmatig goed 
van pas. Daarnaast hebben de vele practical jokes die je als onderdeel van het DOPE (Dominic-
Petter) team met mij en anderen hebt uitgehaald, zeker bijgedragen aan het vergroten van mijn 
dagelijkse werkplezier. 
 De leden van de promotiecommissie, dr. Krista van den Broek, prof. dr. Johan Denollet, prof. 
dr. Eco de Geus, dr. Erwin Hartong, dr. Sanne Hoeks en prof. dr. Joep Smeets, wil ik hartelijk 
danken voor het lezen en beoordelen van mijn proefschrift. Prof. dr. Denollet, beste Johan, ik ben 
je zeer erkentelijk dat je de afgelopen jaren met me hebt meegedacht over goede toekomstige 
carrièrestappen. Dr. Hoeks, beste Sanne, als ik mijn masterscriptie niet bij jou had geschreven, was 
de kans dat ik een promotietraject was gestart significant kleiner geweest! Bedankt dat je mij hebt 
geënthousiasmeerd voor de wetenschap, en bedankt voor de leuke tijd samen in het Erasmus MC. 
 Mijn collega’s in het Erasmus MC, en dan met name Agnes Muskens-Heemskerk en Petter Janse, 
wil ik hartelijk danken voor de samenwerking en vooral voor de gezellige, soms ietwat jolige sfeer 
in het Erasmus MC. Als je je zelf al te serieus neemt, wordt daar korte metten mee gemaakt zodra je 
D-305 binnenstapt en dat is een goede zaak!
 De collega’s van Tilburg University ben ik dankbaar voor de samenwerking en de gezellige 
momenten tijdens en buiten werktijd. In het bijzonder wil ik Anke, Dounya, Floortje, Hester, Loes, 
Lotje, Marleen Pullens, Marleen van Son, Mirjam, Paula, Pauline en Wobbe bedanken voor de 
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gezellige lunches, borrels en etentjes. ‘Psychobabes’ Corline, Henneke, Krista, Mirela en Nikki: ik heb 
mooie herinneringen aan onze gezamenlijke congresbezoeken en de vele hapjes en drankjes die 
daarbij hoorden. Dat onze promotor vervolgens ging denken dat we chardonnay-verslaafd zijn, is 
helemaal niet erg 
 Marjan, Dionne en Maria, als paranimfen wil ik jullie voor veel meer bedanken dan voor het achter 
mij staan op 12 september. Marjan, ik ben blij dat we roomies zijn geworden en elkaar beter hebben 
leren kennen. Jouw snoepvoorraad, luisterend oor, vreugdedansjes, kennis van jaren ’90 hip-hop en 
niet te vergeten het dagelijkse gezamenlijke genot van het foute uur hebben het promoveren een 
stuk gemakkelijker, leuker en enerverender gemaakt. Dionne, paranimf en ceremoniemeester in één 
jaar, het moet niet gekker worden (en ook niet drukker)  Ik vind het heel fijn dat ik je altijd om raad 
kan vragen, en dat we samen zoveel lol kunnen trappen. Het maakt niet uit hoe ver we uit elkaar 
wonen, en dat is een goed gevoel. Maria, ik heb mooie herinneringen aan ons eerste gezamenlijke 
jaar Geneeskunde, en bewonder jouw drive en enthousiasme voor je vak. Het is bijzonder dat we in 
2014 allebei trouwen en promoveren, maar de meer alledaagse geneugten van onze vriendschap, 
waaronder de etentjes samen met Haasje, zijn voor mij net zo waardevol.
 Mijn vriendinnetjes van Il Lustra, en vooral Lieke, Marjolein en Suzanne, bedankt voor de mooie 
jaren in Leiden en het feit dat we nu nog steeds goed bevriend zijn. Afleiding is een noodzakelijk goed 
wanneer je een proefschrift schrijft, en de klaverjasavonden, Wie-is-de-Mol-poules, shopmiddagen 
in The Ritzz en weekendjes Parijs/Brussel hebben daar zeker aan bijgedragen. Ik ben heel blij met 
jullie!
 Toen ik wegging uit Leiden, lukte het gelukkig snel vriendinnetjes in het Brabantse land te 
maken. Angela en Marion (en natuurlijk Dionne, maar die heeft een dubbelrol in dit dankwoord), 
het plezier dat we hebben gehad in de collegebanken en daarbuiten hebben de tijd in Tilburg 
warm en gezellig gemaakt. Ik vind het erg bijzonder hoe snel we zo’n goede vriendschap hebben 
opgebouwd.
 Lieve homies van de Hogewoerd 111 (en dan vooral Fenna, Haasje, Ines, Joyce, Junior, Maria, Petra, 
Simone en Yvanka), jullie hebben mijn studententijd tot een groot feest gemaakt! Jullie vormden 
mijn tweede familie, en dit voelt nog steeds zo als ik jullie zie. Ik ben enorm blij dat we elkaar nog 
regelmatig zien, en dat we alle mooie gebeurtenissen van de afgelopen jaren (promoveren, huizen 
kopen, leuke mannen vinden en hiermee trouwen, kinderen krijgen) met elkaar hebben mogen 
delen. 
 Lieve familie Buijs, lieve Jos en Marijke, Jesper en Marieke, Merijn en Loes, bedankt voor de 
gezellige momenten aan tafel in Renkum en in de Europese steden die we met elkaar hebben 
mogen bezoeken. Ik voel me thuis bij jullie en hoop dat onze band de komende jaren blijft groeien, 
of jullie nu in het buitenland wonen of om de hoek.
 Lieve oma Hoogwegt, jouw motto ‘leef met de dag’ is een goede levensles voor iedereen en ik 
kijk met bewondering naar jouw doorzettings- en relativeringsvermogen. Opa Hoogwegt heb ik 
altijd enorm bewonderd om zijn leergierigheid. Ik weet dan ook zeker dat hij trots zou zijn geweest 
op dit proefschrift en vind het erg jammer dat hij dit niet kan meemaken, net als opa en oma Van 
Steen.
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 Dan nu wat welverdiende woorden voor ‘de boys’  Als olijk drietal bezorgen jullie mij een hoop 
plezier en geluk, waarbij ik vooral glimlachend (of hardop lachend) terugdenk aan onze vakanties 
samen in Bolsena, de etentjes in Den Haag waarbij het stillen van jullie eetlust een eeuwige uitdaging 
blijft en de ‘schaft’ tijdens de verbouwing van de Eikenbocht waar alle opvoedkundige prestaties van 
pappa en mamma teniet werden gedaan. Maar ook als individuen mogen jullie er zijn. Bas, we zijn 
maatjes van kleins af aan. Ik denk met plezier terug aan de stiekeme sigaretjes en lange gesprekken 
tijdens onze puberteit, maar ook aan de gezelligheid, lekkere etentjes en wijntjes tijdens mijn jaar in 
Knegsel. Ik ben enorm trots op je prestaties van de afgelopen jaren en weet zeker dat er een mooie 
weg voor je open ligt! Wouter, je imitaties van Neerlands’ voltallige cabaretcrew zijn onnavolgbaar 
en roepen blije herinneringen op. Met je bezoek aan Milaan en het scoren van een topbaan bij PWC 
laat je zien dat je lef hebt en bent uitgegroeid tot een volwassen vent die weet wat hij wil. Jouw 
levensmotto ‘succes is een keuze’ (met een knipoog) zou velen moeten inspireren! Daan, ook jij bent 
inmiddels niet klein meer! We hebben vroeger heerlijk geknuffeld, maar nu kunnen we praten over 
het leven, anderen en onszelf, heel fijn. Maak gretig gebruik deze mooie eigenschap! Daarnaast ben 
ik blij dat er ten minste één andere persoon bestaat met een voorliefde voor hele, hele, hele flauwe 
grappen (en Osbourne Cox) 
 Lieve pappa en mamma, jullie zijn de beste ouders die me kan wensen. De warmte van het gezin 
blijft voelbaar lang nadat iedereen zijn eigen plekje heeft gevonden. Jullie hebben ieder van ons de 
kans gegeven zich op zijn eigen manier te ontwikkelen en het beste uit zichzelf naar boven te halen. 
Dit proefschrift is daar ook een resultaat van! Pap, ik ben trots dat ik me net als jij voor het mooie 
vak van de ziekenhuispsycholoog mag inzetten. Je adviezen met betrekking tot mijn carrière, maar 
vooral op persoonlijk vlak, hebben me enorm op weg geholpen en ik hoop dat ik nog vaak op je 
mag terugvallen. Mam, wat ben jij een stoere doorzetter! Van moeder naar leerkracht naar directrice 
van een grote basisschool. Ik ben enorm trots op je. 
 Lieve Geert, jij bent niet alleen mijn trouwste maatje en grote liefde, maar ook een dagelijkse 
bron van inspiratie. Ik bewonder je om je wil jezelf te blijven ontwikkelen, zowel in je loopbaan als 
op persoonlijk vlak. Ik ben je dankbaar voor alle rust en veiligheid die je me geeft, en net zoveel voor 
de lol die we samen altijd hebben. Ik koester de herinneringen aan onze prachtige reizen samen en 
kijk uit naar alle nieuwe dingen in het leven die we samen nog mogen gaan ontdekken.
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